


**CUMULATIVE  
SUPPLEMENT 3  
MARCH 2017**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2017**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37<sup>th</sup> EDITION**

**Cumulative Supplement 3  
March 2017**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content .....	vi
1.3 Applicant Name Changes .....	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition .....	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS**  
**with**  
**THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 3**  
**March 2017**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

mail to: FDA/CDER Orange Book Staff  
Office of Generic Drugs  
7620 Standish Place  
Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
JAI PHARMA LTD (JAI PHARMA LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)

### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.



## New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2016</u>	<u>MAR 2017</u>	<u>JUN 2017</u>	<u>SEP 2017</u>	<u>DEC 2017</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	18130 2646 (14.6%)	18391 2688 (14.6%)			
MULTISOURCE	15484 (85.4%)	15703 (85.4%)			
THERAPEUTICALLY EQUIVALENT	15335 (84.7%)	15581 (84.7%)			
NOT THERAPEUTICALLY EQUIVALENT	129 (0.7%)	122 (0.7%)			
EXCEPTIONS <sup>1</sup>	73 (0.4%)	73 (0.4%)			
NEW MOLECULAR ENTITIES APPROVED	7	14			
NUMBER OF APPLICANTS	1051	1053			

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >D>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**\*\*Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

>A>	AB	AUROBINDO PHARMA LTD	EQ 600MG BASE;300MG	A206151	001	Mar 28, 2017	Mar	NEWA
>A>	AB	CIPLA LTD	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Mar	NEWA
>A>	AB	LUPIN LTD	EQ 600MG BASE;300MG	A204990	001	Mar 28, 2017	Mar	NEWA

ACETAMINOPHEN

SOLUTION;IV (INFUSION)

ACETAMINOPHEN

AP		CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jan	CAHN
----	--	----------------	---------------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>D>	AA	MALLINCKRODT	325MG;50MG;40MG	A087804	001	Jan 24, 1985	Mar	CAHN
>A>	AA	MALLINCKRODT INC	325MG;50MG;40MG	A087804	001	Jan 24, 1985	Mar	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>	AA	MALLINCKRODT INC	300MG;5MG	A206718	001	Mar 31, 2017	Mar	NEWA
>A>	AA		300MG;7.5MG	A206718	002	Mar 31, 2017	Mar	NEWA
>A>	AA		300MG;10MG	A206718	003	Mar 31, 2017	Mar	NEWA
>A>	AA	UPSHER-SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017	Mar	NEWA
>A>	AA		325MG;7.5MG	A206484	002	Mar 24, 2017	Mar	NEWA
>A>	AA		325MG;10MG	A206484	003	Mar 24, 2017	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

>A>	AA	ASCENT PHARMS INC	325MG;2.5MG	A207419	001	Mar 22, 2017	Mar	NEWA
>A>	AA		325MG;5MG	A207419	002	Mar 22, 2017	Mar	NEWA
>A>	AA		325MG;7.5MG	A207419	003	Mar 22, 2017	Mar	NEWA
>A>	AA		325MG;10MG	A207419	004	Mar 22, 2017	Mar	NEWA
	AA	NOVEL LABS INC	325MG;2.5MG	A204407	001	Feb 24, 2017	Feb	NEWA
	AA		325MG;5MG	A204407	002	Feb 24, 2017	Feb	NEWA
	AA		325MG;7.5MG	A204407	003	Feb 24, 2017	Feb	NEWA
	AA		325MG;10MG	A204407	004	Feb 24, 2017	Feb	NEWA
		PERCOCET						
	AA	! VINTAGE PHARMS LLC	325MG;7.5MG	A040330	003	Nov 23, 2001	Jan	CMS1
	AA	!	325MG;10MG	A040330	004	Nov 23, 2001	Jan	CMS1

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>A>	AB	AUROBINDO PHARMA LTD	325MG;37.5MG	A207152	001	Mar 22, 2017	Mar	NEWA
-----	----	----------------------	--------------	---------	-----	--------------	-----	------

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT		ICU MEDCL	250MG/100ML	N017656	001		Feb	CAHN
----	--	-----------	-------------	---------	-----	--	-----	------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

@ CHARTWELL MOLECULES 200MG

A074872 001 Apr 22, 1997 Jan CAHN

ZOVIRAX

AB	+!	MYLAN PHARMS INC	200MG	N018828	001	Jan 25, 1985	Jan	CAHN
----	----	------------------	-------	---------	-----	--------------	-----	------

SUSPENSION;ORAL

ZOVIRAX

AB	+!	MYLAN PHARMS INC	200MG/5ML	N019909	001	Dec 22, 1989	Jan	CAHN
----	----	------------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

ACYCLOVIR

@ CHARTWELL MOLECULES 400MG

A074834 001 Apr 24, 1997 Jan CAHN

@ 800MG

A074834 002 Apr 24, 1997 Jan CAHN

>D>	AB	MYLAN	400MG	A075211	001	Sep 28, 1998	Mar	CAHN
-----	----	-------	-------	---------	-----	--------------	-----	------

>D>	AB		800MG	A075211	002	Sep 28, 1998	Mar	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

>A>	AB	MYLAN PHARMS INC	400MG	A075211	001	Sep 28, 1998	Mar	CAHN
-----	----	------------------	-------	---------	-----	--------------	-----	------

>A>	AB		800MG	A075211	002	Sep 28, 1998	Mar	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

## TABLET; ORAL

	ZOVIRAX								
AB	+	MYLAN PHARMS INC	400MG	N020089	001	Apr 30, 1991	Jan	CAHN	
AB	+	!	800MG	N020089	002	Apr 30, 1991	Jan	CAHN	

ACYCLOVIR SODIUM

## INJECTABLE; INJECTION

## ACYCLOVIR SODIUM

>D>	@	AMPHASTAR PHARMS INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar	CAHN	
>D>	@		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar	CAHN	
>A>	@	ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar	CAHN	
>A>	@		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar	CAHN	
>D>	!	HIKMA PHARMS LLC	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Mar	CTEC	
>A>	AP	!	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Mar	CTEC	
>A>	AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017	Mar	NEWA	
>A>	AP		EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Mar	NEWA	

ADENOSINE

## INJECTABLE; INJECTION

## ADENOSINE

AP		WEST-WARD PHARMS INT	3MG/ML	A076404	001	Jun 16, 2004	Jan	CAHN	
AP			3MG/ML	A076500	001	Jun 16, 2004	Jan	CAHN	
	@		3MG/ML	A076501	001	Jun 16, 2004	Jan	CAHN	

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

## SOLUTION; INHALATION

## ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN		WATSON LABS TEVA	EQ 0.083% BASE;0.017%	A077063	001	Dec 31, 2007	Feb	CAHN	
----	--	------------------	-----------------------	---------	-----	--------------	-----	------	--

ALPRAZOLAM

## TABLET, EXTENDED RELEASE; ORAL

## ALPRAZOLAM

AB		AUROBINDO PHARMA LTD	0.5MG	A090871	001	Jun 07, 2011	Jan	CAHN	
AB			1MG	A090871	002	Jun 07, 2011	Jan	CAHN	
AB			2MG	A090871	003	Jun 07, 2011	Jan	CAHN	
AB			3MG	A090871	004	Jun 07, 2011	Jan	CAHN	
	@	IMPAX LABS INC	0.5MG	A077996	001	Jan 31, 2007	Feb	CAHN	
	@		1MG	A077996	002	Jan 31, 2007	Feb	CAHN	
	@		2MG	A077996	003	Jan 31, 2007	Feb	CAHN	
	@		3MG	A077996	004	Jan 31, 2007	Feb	CAHN	

ALPROSTADIL

## SUPPOSITORY; URETHRAL

## MUSE

>D>	+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Mar	CAHN	
>D>	+		0.25MG	N020700	002	Nov 19, 1996	Mar	CAHN	
>D>	+		0.5MG	N020700	003	Nov 19, 1996	Mar	CAHN	
>D>	+		1MG	N020700	004	Nov 19, 1996	Mar	CAHN	
>A>	+	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Mar	CAHN	
>A>	+		0.25MG	N020700	002	Nov 19, 1996	Mar	CAHN	
>A>	+		0.5MG	N020700	003	Nov 19, 1996	Mar	CAHN	
>A>	+		1MG	N020700	004	Nov 19, 1996	Mar	CAHN	

AMANTADINE HYDROCHLORIDE

## SYRUP; ORAL

## SYMMETREL

+	@	ENDO PHARMS	50MG/5ML	N016023	002		Jan	CRLD	
---	---	-------------	----------	---------	-----	--	-----	------	--

## TABLET; ORAL

## AMANTADINE HYDROCHLORIDE

AB		NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan	NEWA	
----	--	-------------------	-------	---------	-----	--------------	-----	------	--

AMINO ACIDS

## INJECTABLE; INJECTION

## AMINOSYN 10%

		ICU MEDCL	10% (10GM/100ML)	N017673	003		Feb	CAHN	
--	--	-----------	------------------	---------	-----	--	-----	------	--

## AMINOSYN 10% (PH6)

		ICU MEDCL	10% (10GM/100ML)	N017673	008	Nov 18, 1985	Feb	CAHN	
--	--	-----------	------------------	---------	-----	--------------	-----	------	--

## AMINOSYN 3.5%

		ICU MEDCL	3.5% (3.5GM/100ML)	N017789	004		Feb	CAHN	
--	--	-----------	--------------------	---------	-----	--	-----	------	--

## AMINOSYN 5%

		ICU MEDCL	5% (5GM/100ML)	N017673	001		Feb	CAHN	
--	--	-----------	----------------	---------	-----	--	-----	------	--

## INJECTABLE; INJECTION

AMINOSYN 7%							
ICU MEDCL	7% (7GM/100ML)	N017673	002			Feb	CAHN
AMINOSYN 7% (PH6)							
ICU MEDCL	7% (7GM/100ML)	N017673	006	Nov 18, 1985		Feb	CAHN
AMINOSYN 8.5%							
ICU MEDCL	8.5% (8.5GM/100ML)	N017673	004			Feb	CAHN
AMINOSYN 8.5% (PH6)							
ICU MEDCL	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985		Feb	CAHN
AMINOSYN II 10%							
ICU MEDCL	10% (10GM/100ML)	N019438	005	Apr 03, 1986		Feb	CAHN
AMINOSYN II 10% IN PLASTIC CONTAINER							
ICU MEDCL	10% (10GM/100ML)	N020015	001	Dec 19, 1991		Feb	CAHN
AMINOSYN II 15% IN PLASTIC CONTAINER							
ICU MEDCL	15% (15GM/100ML)	N020041	001	Dec 19, 1991		Feb	CAHN
AMINOSYN II 3.5%							
@ ICU MEDCL	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986		Feb	CAHN
AMINOSYN II 5%							
@ ICU MEDCL	5% (5GM/100ML)	N019438	002	Apr 03, 1986		Feb	CAHN
AMINOSYN II 7%							
ICU MEDCL	7% (7GM/100ML)	N019438	003	Apr 03, 1986		Feb	CAHN
AMINOSYN II 8.5%							
ICU MEDCL	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986		Feb	CAHN
AMINOSYN-HBC 7%							
ICU MEDCL	7% (7GM/100ML)	N019374	001	Jul 12, 1985		Feb	CAHN
AMINOSYN-PF 10%							
ICU MEDCL	10% (10GM/100ML)	N019492	002	Oct 17, 1986		Feb	CAHN
AMINOSYN-PF 7%							
ICU MEDCL	7% (7GM/100ML)	N019398	001	Sep 06, 1985		Feb	CAHN

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 3.5% M							
ICU MEDCL	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N017789	003			Feb	CAHN

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 3.5% M							
@ ICU MEDCL	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789	005			Feb	CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES							
ICU MEDCL	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789	002			Feb	CAHN
AMINOSYN 8.5% W/ ELECTROLYTES							
ICU MEDCL	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005			Feb	CAHN

AMIODARONE HYDROCHLORIDE

## TABLET; ORAL

## AMIODARONE HYDROCHLORIDE

AB	MAYNE PHARMA INC	200MG	A075389	001	Jan 25, 2001	Jan	CAHN
>D>	AB	MYLAN	200MG	A075188	001	Feb 24, 1999	Mar DISC
>A>	@	200MG	A075188	001	Feb 24, 1999	Mar	DISC
>D>	AB	SANDOZ	200MG	A075315	001	Dec 23, 1998	Mar CHRS
>A>	AB	!	200MG	A075315	001	Dec 23, 1998	Mar CHRS
>D>	AB	TARO	100MG	A075424	002	Dec 18, 2002	Mar CAHN
>D>	AB		200MG	A075424	001	Mar 30, 2001	Mar CAHN
>D>			300MG	A076362	002	Dec 02, 2003	Mar CAHN
>D>	AB		400MG	A076362	001	Nov 29, 2002	Mar CAHN
>A>	AB	TARO PHARM	100MG	A075424	002	Dec 18, 2002	Mar CAHN
>A>	AB		200MG	A075424	001	Mar 30, 2001	Mar CAHN
>A>			300MG	A076362	002	Dec 02, 2003	Mar CAHN
>A>	AB		400MG	A076362	001	Nov 29, 2002	Mar CAHN
	CORDARONE						
+	@ WYETH PHARMS INC	200MG	N018972	001	Dec 24, 1985	Jan	DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

ELAVIL

>D>	@	ASTRAZENECA	10MG	N012703	001		Mar	CRLD
>A>	+	@	10MG	N012703	001		Mar	CRLD
>D>	@		25MG	N012703	003		Mar	CRLD
>A>	+	@	25MG	N012703	003		Mar	CRLD
>D>	@		50MG	N012703	004		Mar	CRLD
>A>	+	@	50MG	N012703	004		Mar	CRLD
>D>	@		75MG	N012703	005		Mar	CRLD
>A>	+	@	75MG	N012703	005		Mar	CRLD
>D>	@		100MG	N012703	006		Mar	CRLD
>A>	+	@	100MG	N012703	006		Mar	CRLD
>D>	@		150MG	N012703	007		Mar	CRLD
>A>	+	@	150MG	N012703	007		Mar	CRLD

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>D>	AB	MYLAN	EQ 2.5MG BASE	A076418	001	Oct 03, 2005	Mar	CAHN
>D>	AB		EQ 5MG BASE	A076418	002	Oct 03, 2005	Mar	CAHN
>D>	AB		EQ 10MG BASE	A076418	003	Oct 03, 2005	Mar	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A076418	001	Oct 03, 2005	Mar	CAHN
>A>	AB		EQ 5MG BASE	A076418	002	Oct 03, 2005	Mar	CAHN
>A>	AB		EQ 10MG BASE	A076418	003	Oct 03, 2005	Mar	CAHN

AMMONIUM LACTATE

LOTION; TOPICAL

LAC-HYDRIN

+	@	RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Jan	CRLD
---	---	---------	-------------	---------	-----	--------------	-----	------

AMOXAPINE

TABLET; ORAL

AMOXAPINE

@ WATSON PHARMS TEVA

@

@

@

A072418	001	May 11, 1989	Feb	CAHN
A072419	001	May 11, 1989	Feb	CAHN
A072420	001	May 11, 1989	Feb	CAHN
A072421	001	May 11, 1989	Feb	CAHN

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXIL

@ DR REDDYS LABS INC

@

N050760	001	Apr 15, 1999	Feb	DISC
N050760	002	Apr 15, 1999	Feb	DISC

TABLET; ORAL

AMOXIL

>D>	AB	DR REDDYS LABS INC	500MG	N050754	002	Jul 10, 1998	Mar	DISC
>A>	+	@	500MG	N050754	002	Jul 10, 1998	Mar	DISC
>D>	AB		875MG	N050754	001	Jul 10, 1998	Mar	DISC
>A>	+	@	875MG	N050754	001	Jul 10, 1998	Mar	DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

TEVA

!

AMOXIL

A064013	002	Sep 11, 1995	Feb	CTEC
A064013	001	Dec 22, 1992	Feb	CTEC
N050542	002		Feb	DISC
N050542	001		Feb	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '200'

+	@	DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	Feb	DISC
+	@	DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	Feb	DISC
+	@	DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Feb	DISC

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	!	SANDOZ	250MG;EQ 125MG BASE	A065189	001	Aug 23, 2005	Feb	CHRS
AB	!	SANDOZ INC	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002	Feb	CHRS

## TABLET;ORAL

AUGMENTIN '250'

+ @ DR REDDYS LABS INC 250MG;EQ 125MG BASE N050564 001 Aug 06, 1984 Feb DISC

AUGMENTIN '500'

+ @ DR REDDYS LABS INC 500MG;EQ 125MG BASE N050564 002 Aug 06, 1984 Feb DISC

## TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

TEVA

200MG;EQ 28.5MG BASE

A065205 001 Feb 09, 2005 Feb CTEC

!

400MG;EQ 57MG BASE

A065205 002 Feb 09, 2005 Feb CTEC

AUGMENTIN '200'

+ @ DR REDDYS LABS INC 200MG;EQ 28.5MG BASE N050726 001 May 31, 1996 Feb DISC

AUGMENTIN '400'

+ @ DR REDDYS LABS INC 400MG;EQ 57MG BASE N050726 002 May 31, 1996 Feb DISC

AMPICILLIN SODIUM

## INJECTABLE;INJECTION

AMPICILLIN SODIUM

@ WEST-WARD PHARMS INT

EQ 125MG BASE/VIAL

A062692 001 Jun 24, 1986 Jan CAHN

@

EQ 250MG BASE/VIAL

A062692 002 Jun 24, 1986 Jan CAHN

@

EQ 500MG BASE/VIAL

A062692 003 Jun 24, 1986 Jan CAHN

@

EQ 1GM BASE/VIAL

A062692 004 Jun 24, 1986 Jan CAHN

@

EQ 2GM BASE/VIAL

A062692 005 Jun 24, 1986 Jan CAHN

@

EQ 10GM BASE/VIAL

A062692 006 Jun 24, 1986 Jan CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

## INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP WEST-WARD PHARMS INT

EQ 1GM BASE/VIAL;EQ 500MG

A065074 001 Mar 19, 2002 Jan CAHN

BASE/VIAL

AP

EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL

A065074 002 Mar 19, 2002 Jan CAHN

AP

EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL

A065076 001 Mar 19, 2002 Jan CAHN

ANAGRELIDE HYDROCHLORIDE

## CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE

&gt;D&gt; AB

MYLAN

EQ 0.5MG BASE

A076811 001 Apr 18, 2005 Mar CAHN

&gt;D&gt; AB

MYLAN

EQ 1MG BASE

A076811 002 Apr 18, 2005 Mar CAHN

&gt;A&gt; AB

MYLAN PHARMS INC

EQ 0.5MG BASE

A076811 001 Apr 18, 2005 Mar CAHN

&gt;A&gt; AB

MYLAN

EQ 1MG BASE

A076811 002 Apr 18, 2005 Mar CAHN

ARGATROBAN

## INJECTABLE;INJECTION

ARGATROBAN

+! HIKMA PHARM CO LTD 50MG/50ML (1MG/ML) N203049 002 Sep 30, 2016 Feb NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

## TABLET;ORAL

FIORINAL

+ @ ALLERGAN SALES LLC 325MG;50MG;40MG N017534 003 Apr 16, 1986 Jan CRLD

ASPIRIN; DIPYRIDAMOLE

## CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB IMPAX LABS INC

25MG;200MG

A206964 001 Jan 18, 2017 Jan NEWA

AB PAR PHARM INC

25MG;200MG

A207944 001 Jan 18, 2017 Jan NEWA

AB SANDOZ INC

25MG;200MG

A206739 001 Jan 18, 2017 Jan NEWA

ATORVASTATIN CALCIUM

## TABLET;ORAL

ATORVASTATIN CALCIUM

&gt;A&gt; AB

TEVA PHARMS USA

EQ 10MG BASE

A205300 001 Mar 27, 2017 Mar NEWA

&gt;A&gt; AB

TEVA

EQ 20MG BASE

A205300 002 Mar 27, 2017 Mar NEWA

&gt;A&gt; AB

TEVA

EQ 40MG BASE

A205300 003 Mar 27, 2017 Mar NEWA

&gt;A&gt; AB

TEVA

EQ 80MG BASE

A205300 004 Mar 27, 2017 Mar NEWA

ATRACURIUM BESYLATE

## INJECTABLE;INJECTION

ATRACURIUM BESYLATE

@ WATSON PHARMS TEVA

10MG/ML

A074945 001 Jul 28, 1998 Feb CAHN

ATRACURIUM BESYLATE PRESERVATIVE FREE

&gt;A&gt; AP

MYLAN LABS LTD

10MG/ML

A206001 001 Apr 07, 2017 Mar NEWA

AZACITIDINE

>D>	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS							
>D>	AZACITIDINE							
>D> AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Mar	CDFR	
>D> AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Mar	CDFR	
>D> AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Mar	CDFR	
>D>	VIDAZA							
>D> AP	+! CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Mar	CDFR	
	POWDER;IV (INFUSION), SUBCUTANEOUS							
	AZACITIDINE							
>D>	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Mar	CTEC	
>A> AP		100MG/VIAL	N208216	001	Apr 29, 2016	Mar	CTEC	
>A> AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Mar	CDFR	
>A> AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Mar	CDFR	
>A> AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Mar	CDFR	
>A>	VIDAZA							
>A> AP	+! CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Mar	CDFR	

AZELASTINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC							
	AZELASTINE HYDROCHLORIDE							
AT	SANDOZ INC	0.05%	A202305	001	May 31, 2012	Feb	CAHN	
	OPTIVAR							
>D> AT	+! MEDA PHARMS	0.05%	N021127	001	May 22, 2000	Mar	CAHN	
>A> AT	+! MYLAN SPECIALITY LP	0.05%	N021127	001	May 22, 2000	Mar	CAHN	
	SPRAY, METERED;NASAL							
	ASTELIN							
>D> AB	+! MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Mar	CAHN	
>A> AB	+! MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Mar	CAHN	
	ASTEPRO							
>D>	@ MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Mar	CAHN	
>D> AB	+!	EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009	Mar	CAHN	
>A>	@ MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Mar	CAHN	
>A> AB	+!	EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009	Mar	CAHN	
	AZELASTINE HYDROCHLORIDE							
AB	BRECKENRIDGE PHARM	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Feb	CAHN	
>A> AB	UPSHER-SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Mar	NEWA	

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

	SPRAY, METERED;NASAL							
	DYMISTA							
>D>	+! MEDA PHARMS	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Mar	CAHN	
>A>	+! MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Mar	CAHN	

AZITHROMYCIN

	INJECTABLE;INJECTION							
	AZITHROMYCIN							
AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204732	001	Jan 26, 2017	Jan	NEWA	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

	OINTMENT;TOPICAL							
	CORTISPORIN							
	+! MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984	Feb	CAHN	

BACLOFEN

	INJECTABLE;INTRATHECAL							
	BACLOFEN							
>A> AP	EMERALD INTL LTD	0.05MG/ML	A091193	001	May 03, 2016	Mar	CAHN	
>A> AP		0.5MG/ML	A091193	002	May 03, 2016	Mar	CAHN	
>A> AP		2MG/ML	A091193	003	May 03, 2016	Mar	CAHN	
>D> AP	SINETICA SA	0.05MG/ML	A091193	001	May 03, 2016	Mar	CAHN	
>D> AP		0.5MG/ML	A091193	002	May 03, 2016	Mar	CAHN	
>D> AP		2MG/ML	A091193	003	May 03, 2016	Mar	CAHN	
	GABLOFEN							
>D>	MALLINCKRODT INC	1MG/ML	N022462	004	Jun 22, 2012	Mar	CRLD	
>A>	+!	1MG/ML	N022462	004	Jun 22, 2012	Mar	CRLD	



BARIUM SULFATE

SUSPENSION;ORAL

>A>		LIQUID E-Z-PAQUE							
>A>	+!	BRACCO	60% (213GM/355ML)	N208143	003	Mar 01, 2017	Mar	NEWA	

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

CORZIDE

>D>	AB	+	KING PHARMS	5MG;40MG	N018647	001	May 25, 1983	Mar	CAHN
>D>	AB	+!		5MG;80MG	N018647	002	May 25, 1983	Mar	CAHN
>A>	AB	+	KING PHARMS LLC	5MG;40MG	N018647	001	May 25, 1983	Mar	CAHN
>A>	AB	+!		5MG;80MG	N018647	002	May 25, 1983	Mar	CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

>D>	AA		PADDOCK	50MG	A040578	001	Apr 17, 2006	Mar	CAHN
>A>	AA		TWI PHARMS INC	50MG	A040578	001	Apr 17, 2006	Mar	CAHN

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA	!		UPSHER-SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Feb	CAHN
AA	!			1MG	A040103	002	Dec 12, 1996	Feb	CAHN
AA	!			2MG	A040103	003	Dec 12, 1996	Feb	CAHN

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	!		FOUGERA PHARMS INC	EQ 0.05% BASE	A070275	001	Aug 12, 1985	Jan	CAHN
			DIPROSONE						
			+ @ SCHERING	EQ 0.05% BASE	N017781	001		Jan	CRLD

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

LUXIQ

AB	+!		MYLAN PHARMS INC	0.12%	N020934	001	Feb 28, 1999	Jan	CAHN
----	----	--	------------------	-------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

@ IMPAX LABS

@

@

			IMPAX LABS	5MG	A040721	001	Nov 01, 2006	Jan	CMS1
				10MG	A040721	002	Nov 01, 2006	Jan	CMS1
				25MG	A040721	003	Nov 01, 2016	Jan	CMS1

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

>D>	AT		ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Mar	CAHN
>A>	AT		SANDOZ INC	0.03%	A202565	001	May 05, 2015	Mar	CAHN

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB			ORIT LABS LLC	5MG	A204891	001	Jan 11, 2017	Jan	NEWA
AB				10MG	A204891	002	Jan 11, 2017	Jan	NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ZIAC

AB	+		TEVA BRANDED PHARM	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Jan	CAHN
AB	+			5MG;6.25MG	N020186	001	Mar 26, 1993	Jan	CAHN
AB	+!			10MG;6.25MG	N020186	002	Mar 26, 1993	Jan	CAHN

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

@ WEST-WARD PHARMS INT

			WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986	Jan	CAHN
--	--	--	----------------------	---------	---------	-----	--------------	-----	------

BRIMONIDINE TARTRATESOLUTION/DROPS;OPHTHALMIC  
BRIMONIDINE TARTRATE

>D>	AT	SANDOZ	0.2%	A078075	001	Jan 30, 2008	Mar	CAHN
	AT	SANDOZ INC	0.2%	A076254	001	Sep 16, 2003	Feb	CAHN
>A>	AT		0.2%	A078075	001	Jan 30, 2008	Mar	CAHN
		QOLIANA						
>D>	AT	ALCON PHARMS LTD	0.15%	N021764	001	May 22, 2006	Mar	CAHN
>A>	AT	SANDOZ INC	0.15%	N021764	001	May 22, 2006	Mar	CAHN

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC  
BROMFENAC SODIUM

>A>	AT1	AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Mar	CAHN
	AT1	! APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Feb	CHRS
		@ COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Feb	DISC
>D>	AT2	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Mar	CHRS
>A>	AT2	!	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Mar	CHRS
>D>	AT1	LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Mar	CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		TARO PHARM	2MG/5ML;10MG/5ML;30MG/5ML	A205112	001	Feb 27, 2017	Feb	NEWA
----	--	------------	---------------------------	---------	-----	--------------	-----	------

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

>A>	AB	APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Mar	NEWA
-----	----	------------------	-----	---------	-----	--------------	-----	------

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

>D>	AP	! AMPHASTAR PHARMS INC	0.25MG/ML	A074441	001	Jan 27, 1995	Mar	CAHN
>A>	AP	! ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Mar	CAHN
	AP	WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Jan	CAHN

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan	CAHN
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan	CAHN
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan	CAHN
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan	CAHN
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan	CAHN
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan	CAHN
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan	CAHN

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

>A>	AB	RHODES PHARMS	EQ 2MG BASE	A207276	001	Mar 27, 2017	Mar	NEWA
>A>	AB		EQ 8MG BASE	A207276	002	Mar 27, 2017	Mar	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

ZUBSOLV

+	OREXO US INC	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jan	CHRS
+	!	EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jan	CHRS

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

>A>	AB3	LUPIN LTD	150MG	A090693	001	Apr 06, 2017	Mar	NEWA
>A>	AB3		300MG	A090693	002	Apr 06, 2017	Mar	NEWA
>A>	AB3	SCIEGEN PHARMS INC	150MG	A207479	001	Apr 12, 2017	Mar	NEWA
>A>	AB3		300MG	A207479	002	Apr 12, 2017	Mar	NEWA
		FORFIVO XL						
	+	! ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan	CAHN

BUSULFANINJECTABLE; INJECTION  
BUSULFAN

>A>	AP	PHARMASCIENCE INC	6MG/ML	A207050	001	Mar 24, 2017	Mar	NEWA
-----	----	-------------------	--------	---------	-----	--------------	-----	------

BUTABARBITAL SODIUMTABLET; ORAL  
BUTISOL SODIUM

>D>		@ MEDA PHARMS	15MG	N000793	002		Mar	CAHN
>D>		+!	30MG	N000793	004		Mar	CAHN
>D>		@	50MG	N000793	003		Mar	CAHN
>D>		@	100MG	N000793	005		Mar	CAHN
>A>		@ MYLAN SPECIALITY LP	15MG	N000793	002		Mar	CAHN
>A>		+!	30MG	N000793	004		Mar	CAHN
>A>		@	50MG	N000793	003		Mar	CAHN
>A>		@	100MG	N000793	005		Mar	CAHN

BUTORPHANOL TARTRATEINJECTABLE; INJECTION  
BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP		WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan	CAHN
AP			2MG/ML	A075045	002	Aug 12, 1998	Jan	CAHN

CALCIPOTRIENEAEROSOL, FOAM; TOPICAL  
SORILUX

+!	MAYNE PHARMA	0.005%		N022563	001	Oct 06, 2010	Jan	CAHN
----	--------------	--------	--	---------	-----	--------------	-----	------

CALCIUM ACETATECAPSULE; ORAL  
CALCIUM ACETATE

>A>	AB	CHARTWELL RX	667MG	A091312	001	Jun 01, 2012	Mar	CAHN
>D>	AB	PADDOCK LLC	667MG	A091312	001	Jun 01, 2012	Mar	CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATEINJECTABLE; INJECTION  
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		ICU MEDCL	20MG/100ML; 5GM/100ML; 30MG/100ML; 60 0MG/100ML; 310MG/100ML	N017608	001		Feb	CAHN
		@ ICU MEDCL	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER 20MG/100ML; 5GM/100ML; 104MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	005	Oct 17, 1988	Feb	CAHN
		@	20MG/100ML; 5GM/100ML; 179MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	006	Oct 17, 1988	Feb	CAHN
		@ ICU MEDCL	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER 20MG/100ML; 5GM/100ML; 254MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	007	Oct 17, 1988	Feb	CAHN
AP		ICU MEDCL	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER 20MG/100ML; 5GM/100ML; 179MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	002	Oct 17, 1988	Feb	CAHN
AP			20MG/100ML; 5GM/100ML; 328MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	008	Oct 17, 1988	Feb	CAHN
		@ ICU MEDCL	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER 20MG/100ML; 5GM/100ML; 254MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	003	Oct 17, 1988	Feb	CAHN
AP		ICU MEDCL	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER 20MG/100ML; 5GM/100ML; 328MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	004	Oct 17, 1988	Feb	CAHN
		@ ICU MEDCL	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER 20MG/100ML; 5GM/100ML; 104MG/100ML; 6 00MG/100ML; 310MG/100ML	N019685	001	Oct 17, 1988	Feb	CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION  
RINGER'S IN PLASTIC CONTAINER

AP		ICU MEDCL	33MG/100ML; 30MG/100ML; 860MG/100ML	N018251	001		Feb	CAHN
AT		ICU MEDCL	SOLUTION; IRRIGATION RINGER'S IN PLASTIC CONTAINER 33MG/100ML; 30MG/100ML; 860MG/100ML	N017635	001		Feb	CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ICU MEDCL	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N017641	001		Feb	CAHN
----	-----------	---------------------------------------------------	---------	-----	--	-----	------

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+! ICU MEDCL	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N019416	001	Jan 17, 1986	Feb	CAHN
----	--------------	---------------------------------------------------	---------	-----	--------------	-----	------

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017	Feb	NEWA
AB		500MG	A204741	002	Feb 28, 2017	Feb	NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

>D>	AB	MYLAN	12.5MG	A074434	001	Feb 13, 1996	Mar	CAHN
>D>	AB		25MG	A074434	002	Feb 13, 1996	Mar	CAHN
>D>	AB		50MG	A074434	003	Feb 13, 1996	Mar	CAHN
>D>	AB	!	100MG	A074434	004	Feb 13, 1996	Mar	CAHN
>A>	AB	MYLAN PHARMS INC	12.5MG	A074434	001	Feb 13, 1996	Mar	CAHN
>A>	AB		25MG	A074434	002	Feb 13, 1996	Mar	CAHN
>A>	AB		50MG	A074434	003	Feb 13, 1996	Mar	CAHN
>A>	AB	!	100MG	A074434	004	Feb 13, 1996	Mar	CAHN

CARBAMAZEPINE

SOLUTION;IV (INFUSION)

CARNEKXIV

+! LUNDBECK PHARMS LLC 200MG/20ML (10MG/ML)

N206030 001 Oct 07, 2016 Jan CAHN

SUSPENSION;ORAL

TERIL

>D>	AB	TARO	100MG/5ML	A076729	001	Sep 20, 2004	Mar	CAHN
>A>	AB	TARO PHARM	100MG/5ML	A076729	001	Sep 20, 2004	Mar	CAHN

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	Jan	NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	Jan	NEWA

CARISOPRODOL

CAPSULE;ORAL

SOMA

>D>		@ MEDA PHARMS	250MG	N011792	003		Mar	CAHN
>A>		@ MYLAN SPECIALITY LP	250MG	N011792	003		Mar	CAHN

TABLET;ORAL

SOMA

>D>	AB	+! MEDA PHARMS	250MG	N011792	004	Sep 13, 2007	Mar	CAHN
>D>	AA	+	350MG	N011792	001		Mar	CAHN
>A>	AB	+! MYLAN SPECIALITY LP	250MG	N011792	004	Sep 13, 2007	Mar	CAHN
>A>	AA	+	350MG	N011792	001		Mar	CAHN

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

>D>	AT	ALCON	1%	A075476	001	Jan 03, 2000	Mar	CAHN
>A>	AT	SANDOZ INC	1%	A075476	001	Jan 03, 2000	Mar	CAHN

CASPOFUNGIN ACETATE

>D>	INJECTABLE; IV (INFUSION)							
>D>	CANCIDAS							
>D>	+! MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	Mar	CDFR	
>D>	+!	70MG/VIAL	N021227	002	Jan 26, 2001	Mar	CDFR	
>A>	POWDER; IV (INFUSION)							
>A>	CANCIDAS							
>A>	AP +! MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	Mar	CDFR	
>A>	AP +!	70MG/VIAL	N021227	002	Jan 26, 2001	Mar	CDFR	

CEFDINIR

CAPSULE; ORAL

OMNICEF

+ @	ABBVIE	300MG	N050739	001	Dec 04, 1997	Jan	CRLD	
-----	--------	-------	---------	-----	--------------	-----	------	--

FOR SUSPENSION; ORAL

OMNICEF

+ @	ABBVIE	125MG/5ML	N050749	001	Dec 04, 1997	Jan	CRLD	
-----	--------	-----------	---------	-----	--------------	-----	------	--

+ @		250MG/5ML	N050749	002	Jul 29, 2004	Jan	CRLD	
-----	--	-----------	---------	-----	--------------	-----	------	--

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

AB	BELCHER PHARMS LLC	100MG/5ML	A206938	001	Feb 06, 2017	Jan	NEWA	
----	--------------------	-----------	---------	-----	--------------	-----	------	--

AB		200MG/5ML	A206938	002	Feb 06, 2017	Jan	NEWA	
----	--	-----------	---------	-----	--------------	-----	------	--

AB		500MG/5ML	A206939	001	Feb 06, 2017	Jan	NEWA	
----	--	-----------	---------	-----	--------------	-----	------	--

SUPRAX

AB	+! LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Jan	CFTG	
----	--------------	-----------	---------	-----	--------------	-----	------	--

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Jan	CAHN	
----	----------------------	------------------	---------	-----	--------------	-----	------	--

AP		EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Jan	CAHN	
----	--	------------------	---------	-----	--------------	-----	------	--

AP		EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Jan	CAHN	
----	--	-------------------	---------	-----	--------------	-----	------	--

CEFPODOXIME PROXETIL

TABLET; ORAL

VANTIN

>D>	@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674	001	Aug 07, 1992	Mar	CRLD	
-----	------------------------	---------------	---------	-----	--------------	-----	------	--

>A>	+ @	EQ 100MG BASE	N050674	001	Aug 07, 1992	Mar	CRLD	
-----	-----	---------------	---------	-----	--------------	-----	------	--

>D>	@	EQ 200MG BASE	N050674	002	Aug 07, 1992	Mar	CRLD	
-----	---	---------------	---------	-----	--------------	-----	------	--

>A>	+ @	EQ 200MG BASE	N050674	002	Aug 07, 1992	Mar	CRLD	
-----	-----	---------------	---------	-----	--------------	-----	------	--

CEFPROZIL

TABLET; ORAL

CEFPROZIL

AB	AUROBINDO PHARMA LTD	250MG	A065340	001	May 24, 2007	Jan	CAHN	
----	----------------------	-------	---------	-----	--------------	-----	------	--

AB		500MG	A065340	002	May 24, 2007	Jan	CAHN	
----	--	-------	---------	-----	--------------	-----	------	--

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

CEFTRIAZONE SODIUM

AP	SAGENT PHARMS	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Jan	NEWA	
----	---------------	-------------------	---------	-----	--------------	-----	------	--

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

+ @	HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan	CRLD	
-----	-------------------	-----------------	---------	-----	--------------	-----	------	--

+ @		EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan	CRLD	
-----	--	-----------------	---------	-----	--------------	-----	------	--

+ @		EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan	CRLD	
-----	--	-----------------	---------	-----	--------------	-----	------	--

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan	CAHN	
----	----------------------	---------------	---------	-----	--------------	-----	------	--

AB		EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan	CAHN	
----	--	---------------	---------	-----	--------------	-----	------	--

AB		EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan	CAHN	
----	--	---------------	---------	-----	--------------	-----	------	--

CELECOXIBCAPSULE;ORAL  
CELECOXIB

>A>	AB	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Mar	NEWA
>A>	AB		100MG	A207061	002	Apr 04, 2017	Mar	NEWA
>A>	AB		200MG	A207061	003	Apr 04, 2017	Mar	NEWA
>A>	AB		400MG	A207061	004	Apr 04, 2017	Mar	NEWA

CEPHALEXINCAPSULE;ORAL  
CEPHALEXIN

AB		AUROBINDO PHARMA LTD	EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan	CAHN
AB			EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan	CAHN

CEPHAPIRIN SODIUMINJECTABLE;INJECTION  
CEPHAPIRIN SODIUM

	@	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987	Jan	CAHN
	@		EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987	Jan	CAHN
	@		EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987	Jan	CAHN
	@		EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987	Jan	CAHN

CHENODIOLTABLET;ORAL  
CHENIX

	+	@	LEADIANT BIOSCI INC	250MG	N018513	002	Jul 28, 1983	Feb	CAHN
--	---	---	---------------------	-------	---------	-----	--------------	-----	------

CHLORAMPHENICOL SODIUM SUCCINATEINJECTABLE;INJECTION  
CHLOROMYCETIN

>D>		@	PARKEDALE	EQ 1GM BASE/VIAL	N050155	001		Mar	CRLD
>A>		+	@	EQ 1GM BASE/VIAL	N050155	001		Mar	CRLD

CHLORPHENESIN CARBAMATETABLET;ORAL  
MAOLATE

>A>		@	PAMLAB LLC	400MG	N014217	002		Mar	CAHN
>D>		@	PHARMACIA AND UPJOHN	400MG	N014217	002		Mar	CAHN

CHLORPROPAMIDETABLET;ORAL  
CHLORPROPAMIDE

	@	ANI PHARMS INC	250MG	A087353	001		Jan	CAHN
--	---	----------------	-------	---------	-----	--	-----	------

CHLORTHALIDONETABLET;ORAL  
CHLORTHALIDONE

>A>	AB	RICONPHARMA LLC	25MG	A206904	001	Mar 30, 2017	Mar	NEWA
>A>	AB		50MG	A206904	002	Mar 30, 2017	Mar	NEWA

CILOSTAZOLTABLET;ORAL  
CILOSTAZOL

>D>	AB	MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004	Mar	DISC		
>A>		@	50MG	A077019	001	Nov 23, 2004	Mar	DISC		
>D>	AB		100MG	A077019	002	Nov 23, 2004	Mar	DISC		
>A>		@	100MG	A077019	002	Nov 23, 2004	Mar	DISC		
>D>	AB	PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007	Mar	DISC		
>A>		@	50MG	A077898	001	Oct 29, 2007	Mar	DISC		
>D>	AB		100MG	A077898	002	Oct 29, 2007	Mar	DISC		
>A>		@	100MG	A077898	002	Oct 29, 2007	Mar	DISC		
			PLETAL							
		+	@	OTSUKA	50MG	N020863	001	Jan 15, 1999	Jan	CRLD
		+	@		100MG	N020863	002	Jan 15, 1999	Jan	CRLD

CIMETIDINETABLET;ORAL  
CIMETIDINE

	@	CHARTWELL MOLECULES	200MG	A074281	001	May 17, 1994	Jan	CAHN
	@		300MG	A074281	002	May 17, 1994	Jan	CAHN
	@		400MG	A074281	003	May 17, 1994	Jan	CAHN

TABLET;ORAL

## CIMETIDINE

	@	800MG	A074329	001	May 17, 1994	Jan CAHN
>D>	@ LEK PHARMS	200MG	A074250	001	Jun 29, 1995	Mar CAHN
>D>	@	300MG	A074250	002	Jun 29, 1995	Mar CAHN
>D>	@	400MG	A074250	003	Jun 29, 1995	Mar CAHN
>D>	@	800MG	A074250	004	Jun 29, 1995	Mar CAHN
>A>	@ SANDOZ INC	200MG	A074250	001	Jun 29, 1995	Mar CAHN
>A>	@	300MG	A074250	002	Jun 29, 1995	Mar CAHN
>A>	@	400MG	A074250	003	Jun 29, 1995	Mar CAHN
>A>	@	800MG	A074250	004	Jun 29, 1995	Mar CAHN

CIPROFLOXACIN

## INJECTABLE; INJECTION

## CIPRO

	+ @	BAYER HLTHCARE	400MG/40ML (10MG/ML)	N019847	001	Dec 26, 1990	Feb DISC
	+ @		200MG/20ML (10MG/ML)	N019847	002	Dec 26, 1990	Feb DISC
		CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER					
	+ @	BAYER HLTHCARE	200MG/100ML	N019857	001	Dec 26, 1990	Feb DISC
	+ @		400MG/200ML	N019857	002	Dec 26, 1990	Feb DISC
		CIPROFLOXACIN					
AP	!	CLARIS	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Feb CHRS
AP	!		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Feb CHRS
		CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	!	HOSPIRA	200MG/100ML	A077753	001	Mar 18, 2008	Feb CHRS
AP	!		400MG/200ML	A077753	002	Mar 18, 2008	Feb CHRS

CIPROFLOXACIN HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## CIPROFLOXACIN HYDROCHLORIDE

>A>	AT	AMRING PHARMS	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Mar CAHN
>D>	AT	PHARMAFORCE	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Mar CAHN

## TABLET;ORAL

## CIPROFLOXACIN HYDROCHLORIDE

>D>	AB	TARO	EQ 100MG BASE	A076912	001	Feb 18, 2005	Mar CAHN
>D>	AB		EQ 250MG BASE	A076912	002	Oct 06, 2004	Mar CAHN
>D>	AB		EQ 500MG BASE	A076912	003	Oct 06, 2004	Mar CAHN
>D>	AB		EQ 750MG BASE	A076912	004	Oct 06, 2004	Mar CAHN
>A>	AB	TARO PHARM	EQ 100MG BASE	A076912	001	Feb 18, 2005	Mar CAHN
>A>	AB		EQ 250MG BASE	A076912	002	Oct 06, 2004	Mar CAHN
>A>	AB		EQ 500MG BASE	A076912	003	Oct 06, 2004	Mar CAHN
>A>	AB		EQ 750MG BASE	A076912	004	Oct 06, 2004	Mar CAHN

CISATRACURIUM BESYLATE

## INJECTABLE; INJECTION

## CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP		JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Jan NEWA
----	--	---------------------	----------------	---------	-----	--------------	----------

CISPLATIN

## INJECTABLE; INJECTION

## CISPLATIN

>A>	AP	GLAND PHARMA LTD	1MG/ML	A207323	001	Mar 17, 2017	Mar NEWA
>D>	AP	HQ SPCLT PHARMA	1MG/ML	N018057	004	Nov 08, 1988	Mar CRLD
>A>	AP	+	1MG/ML	N018057	004	Nov 08, 1988	Mar CRLD
		PLATINOL					
>D>		@ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Mar CRLD
>A>		+ @	10MG/VIAL	N018057	001		Mar CRLD
>D>		@	50MG/VIAL	N018057	002		Mar CRLD
>A>		+ @	50MG/VIAL	N018057	002		Mar CRLD
		PLATINOL-AQ					
>D>		@ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Mar CRLD
>A>		+ @	0.5MG/ML	N018057	003	Jul 18, 1984	Mar CRLD

CITALOPRAM HYDROBROMIDE

>D>		CAPSULE; ORAL					
>D>		CITALOPRAM HYDROBROMIDE					
>D>		MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007	Mar DISC
>A>		@	EQ 10MG BASE	A077668	001	Feb 28, 2007	Mar DISC
>D>			EQ 20MG BASE	A077668	002	Feb 28, 2007	Mar DISC
>A>		@	EQ 20MG BASE	A077668	002	Feb 28, 2007	Mar DISC
>D>		!	EQ 40MG BASE	A077668	003	Feb 28, 2007	Mar DISC
>A>		@	EQ 40MG BASE	A077668	003	Feb 28, 2007	Mar DISC

	SOLUTION;ORAL							
	CITALOPRAM HYDROBROMIDE							
AA	AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006	Jan	CAHN	
	<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE</u>							
	FOR SOLUTION;ORAL							
	PREPOPIK							
>D>	+!	FERRING PHARMS AS	12GM/PACKET;3.5GM/PACKET;10MG/PACK	N202535	001	Jul 16, 2012	Mar	CAHN
			ET					
>A>	+!	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACK	N202535	001	Jul 16, 2012	Mar	CAHN
			ET					
	<u>CLEMASTINE FUMARATE</u>							
	TABLET;ORAL							
	CLEMASTINE FUMARATE							
	@	SANDOZ	2.68MG	A073459	001	Oct 31, 1993	Feb	DISC
	!	TEVA	2.68MG	A073283	001	Jan 31, 1992	Feb	CTEC
	<u>CLINDAMYCIN PHOSPHATE</u>							
	AEROSOL, FOAM;TOPICAL							
	EVOCLIN							
AT	+!	MYLAN PHARMS INC	1%	N050801	001	Oct 22, 2004	Jan	CAHN
	INJECTABLE;INJECTION							
	CLINDAMYCIN PHOSPHATE							
AP		WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Jan	CAHN
	SOLUTION;TOPICAL							
	CLINDAMYCIN PHOSPHATE							
AT		FOUGERA PHARMS INC	EQ 1% BASE	A064159	001	Jun 05, 1997	Jan	CAHN
	<u>CLOBAZAM</u>							
	SUSPENSION;ORAL							
	ONFI							
	+!	LUNDBECK PHARMS LLC	2.5MG/ML	N203993	001	Dec 14, 2012	Jan	CAHN
	TABLET;ORAL							
	ONFI							
	@	LUNDBECK PHARMS LLC	5MG	N202067	001	Oct 21, 2011	Jan	CAHN
	+		10MG	N202067	002	Oct 21, 2011	Jan	CAHN
	+!		20MG	N202067	003	Oct 21, 2011	Jan	CAHN
	<u>CLOBETASOL PROPIONATE</u>							
	AEROSOL, FOAM;TOPICAL							
	OLUX							
AB1	+!	MYLAN PHARMS INC	0.05%	N021142	001	May 26, 2000	Jan	CAHN
	OLUX E							
AB2	+!	MYLAN PHARMS INC	0.05%	N022013	001	Jan 12, 2007	Jan	CAHN
	CREAM;TOPICAL							
	CLOBETASOL PROPIONATE							
AB1		FOUGERA PHARMS INC	0.05%	A074392	001	Sep 30, 1996	Jan	CAHN
	@	MYLAN PHARMS INC	0.05%	A075338	001	Feb 09, 2001	Jan	CAHN
	GEL;TOPICAL							
	CLOBETASOL PROPIONATE							
AB		TELIGENT PHARMA INC	0.05%	A208881	001	Mar 06, 2017	Feb	NEWA
	OINTMENT;TOPICAL							
	CLOBETASOL PROPIONATE							
>A> AB		GLENMARK PHARMS	0.05%	A208933	001	Mar 20, 2017	Mar	NEWA
	@	MYLAN PHARMS INC	0.05%	A075057	001	Aug 12, 1998	Jan	CAHN
	TEMOVATE							
	+	@ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan	CRLD
	SPRAY;TOPICAL							
	CLOBETASOL PROPIONATE							
AT		ZYDUS PHARMS USA INC	0.05%	A206378	001	Feb 16, 2017	Feb	NEWA
	<u>CLOMIPRAMINE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	CLOMIPRAMINE HYDROCHLORIDE							
AB		SANDOZ	25MG	A074953	001	Jun 25, 1997	Feb	CMFD
AB			50MG	A074953	002	Jun 25, 1997	Feb	CMFD
AB			75MG	A074953	003	Jun 25, 1997	Feb	CMFD



CLONAZEPAM

TABLET; ORAL  
CLONAZEPAM

>D>	AB	MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Mar	DISC
>A>		@	0.5MG	A074940	001	Oct 30, 1997	Mar	DISC
>D>	AB		1MG	A074940	002	Oct 30, 1997	Mar	DISC
>A>		@	1MG	A074940	002	Oct 30, 1997	Mar	DISC
>D>	AB		2MG	A074940	003	Oct 30, 1997	Mar	DISC
>A>		@	2MG	A074940	003	Oct 30, 1997	Mar	DISC
	AB	PRINSTON INC	0.5MG	A077856	001	Jun 28, 2006	Feb	CAHN
	AB		1MG	A077856	002	Jun 28, 2006	Feb	CAHN
	AB		2MG	A077856	003	Jun 28, 2006	Feb	CAHN

CLONIDINE HYDROCHLORIDE

TABLET; ORAL  
CLONIDINE HYDROCHLORIDE

		@	CHARTWELL MOLECULES	0.1MG	A071783	001	Apr 05, 1988	Feb	CAHN
		@		0.3MG	A071785	001	Apr 05, 1988	Feb	CAHN
	AB		PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007	Feb	CAHN
	AB			0.2MG	A077901	002	Mar 09, 2007	Feb	CAHN
	AB			0.3MG	A077901	003	Mar 09, 2007	Feb	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL  
CLOPIDOGREL BISULFATE

>A>	AB	ALLIED PHARMA INC	EQ 75MG BASE	A078004	001	May 17, 2012	Mar	CAHN
	AB	CSPC OUYI PHARM CO	EQ 75MG BASE	A204359	001	Feb 02, 2017	Jan	NEWA
>D>	AB	ROXANE	EQ 75MG BASE	A078004	001	May 17, 2012	Mar	CAHN

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL  
CLORAZEPATE DIPOTASSIUM

>D>	AB	TARO	3.75MG	A075731	003	Apr 27, 2000	Mar	CAHN
>D>	AB		7.5MG	A075731	002	Apr 27, 2000	Mar	CAHN
>D>	AB		15MG	A075731	001	Apr 27, 2000	Mar	CAHN
>A>	AB	TARO PHARM	3.75MG	A075731	003	Apr 27, 2000	Mar	CAHN
>A>	AB		7.5MG	A075731	002	Apr 27, 2000	Mar	CAHN
>A>	AB		15MG	A075731	001	Apr 27, 2000	Mar	CAHN

CODEINE SULFATE

SOLUTION; ORAL  
CODEINE SULFATE

		@	WEST-WARD PHARMS INT	30MG/5ML	N202245	001	Jun 30, 2011	Jan	CAHN
--	--	---	----------------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL  
CODEINE SULFATE

	AB	+	WEST-WARD PHARMS INT	15MG	N022402	001	Jul 16, 2009	Jan	CAHN
	AB	+		30MG	N022402	002	Jul 16, 2009	Jan	CAHN
	AB	+	!	60MG	N022402	003	Jul 16, 2009	Jan	CAHN

CORTISONE ACETATE

TABLET; ORAL  
CORTONE

>D>		@	MERCK	25MG	N007750	003		Mar	CRLD
>A>		+	@	25MG	N007750	003		Mar	CRLD

CROMOLYN SODIUM

CONCENTRATE; ORAL  
GASTROCROM

>D>	AA	+	MEDA PHARMS	100MG/5ML	N020479	001	Feb 29, 1996	Mar	CAHN
>A>	AA	+	MYLAN SPECIALITY LP	100MG/5ML	N020479	001	Feb 29, 1996	Mar	CAHN

SOLUTION; INHALATION  
CROMOLYN SODIUM

	AN		BAUSCH AND LOMB	10MG/ML	A075585	001	Dec 21, 2000	Feb	CAHN
--	----	--	-----------------	---------	---------	-----	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL  
CYCLOBENZAPRINE HYDROCHLORIDE

	AB		PRINSTON INC	5MG	A077797	001	Feb 28, 2007	Feb	CAHN
	AB			10MG	A077797	002	Feb 28, 2007	Feb	CAHN

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

+ @ WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Jan	CAHN
+ !	50MG	N203856	002	Sep 16, 2013	Jan	CAHN

INJECTABLE; INJECTION

CYTOXAN (LYOPHILIZED)

+ @ BAXTER HLTHCARE	500MG/VIAL	N012142	003		Feb	CRLD
+ @	1GM/VIAL	N012142	004	Aug 30, 1982	Feb	CRLD
+ @	2GM/VIAL	N012142	005	Aug 30, 1982	Feb	CRLD

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

PERIACTIN

+ @ MERCK	2MG/5ML	N013220	002		Jan	CRLD
-----------	---------	---------	-----	--	-----	------

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Jan	NEWA
AA	IMPAX LABS INC	4MG	A040537	001	Sep 30, 2003	Feb	CAHN

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

>A>	+ HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013	Mar	CAHN
>A>	+ !	EQ 75MG BASE	N203389	002	Apr 30, 2013	Mar	CAHN
>D>	+ RAPTOR INC	EQ 25MG BASE	N203389	001	Apr 30, 2013	Mar	CAHN
>D>	+ !	EQ 75MG BASE	N203389	002	Apr 30, 2013	Mar	CAHN

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYSTARAN

+ ! LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Feb	CAHN
-------------------------	---------------	---------	-----	--------------	-----	------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

>A>	AP	MYLAN LABS LTD	20MG/ML	A200915	001	Dec 13, 2011	Mar	CAHN
>D>	AP	MYLAN PHARMS INC	20MG/ML	A200915	001	Dec 13, 2011	Mar	CAHN
>D>	AP	WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Mar	CTEC
>A>			100MG/VIAL	A071471	001	Aug 02, 1989	Mar	CTEC
>D>	AP		500MG/VIAL	A071472	001	Aug 02, 1989	Mar	CHRS
>A>	!		500MG/VIAL	A071472	001	Aug 02, 1989	Mar	CHRS
>D>	AP		1GM/VIAL	A074245	001	Aug 31, 1994	Mar	CHRS
>A>	!		1GM/VIAL	A074245	001	Aug 31, 1994	Mar	CHRS
>D>	AP		2GM/VIAL	A074245	002	Aug 31, 1994	Mar	CHRS
>A>	!		2GM/VIAL	A074245	002	Aug 31, 1994	Mar	CHRS
>D>		CYTOSAR-U						
>D>	AP	TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998	Mar	DISC
>A>	@		100MG/VIAL	A075206	001	Dec 30, 1998	Mar	DISC
>D>	AP	!	500MG/VIAL	A075206	002	Dec 30, 1998	Mar	DISC
>A>	@		500MG/VIAL	A075206	002	Dec 30, 1998	Mar	DISC
>D>	AP	!	1GM/VIAL	A075206	004	Dec 30, 1998	Mar	DISC
>A>	@		1GM/VIAL	A075206	004	Dec 30, 1998	Mar	DISC
>D>	AP	!	2GM/VIAL	A075206	003	Dec 30, 1998	Mar	DISC
>A>	@		2GM/VIAL	A075206	003	Dec 30, 1998	Mar	DISC

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

AP	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999	Feb	CHRS
AP	!		200MG/VIAL	A075371	002	Aug 27, 1999	Feb	CHRS

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

AB	+ !	ACORDA	10MG	N022250	001	Jan 22, 2010	Jan	CFTG
		DALFAMPRIDINE						
AB		ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan	NEWA
AB		AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan	NEWA

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

QTERN

+! ASTRAZENECA AB EQ 10MG BASE;EQ 5MG BASE N209091 001 Feb 27, 2017 Feb NEWA

DAPSONE

TABLET;ORAL

DAPSONE

&gt;A&gt; AB ACTAVIS LLC 25MG A204380 001 Mar 23, 2017 Mar NEWA

&gt;A&gt; AB 100MG A204380 002 Mar 23, 2017 Mar NEWA

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

AP ACCORD HLTHCARE 50MG/VIAL A203475 001 Feb 27, 2017 Feb NEWA

DEFLAZACORT

SUSPENSION;ORAL

EMFLAZA

+! MARATHON PHARMS LLC 22.75MG/ML N208685 001 Feb 09, 2017 Feb NEWA

TABLET;ORAL

EMFLAZA

+ MARATHON PHARMS LLC 6MG N208684 001 Feb 09, 2017 Feb NEWA

+ 18MG N208684 002 Feb 09, 2017 Feb NEWA

+ 30MG N208684 003 Feb 09, 2017 Feb NEWA

+! 36MG N208684 004 Feb 09, 2017 Feb NEWA

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB IMPAX LABS INC 10MG A205153 001 Oct 28, 2016 Feb CAHN

AB 25MG A205153 002 Oct 28, 2016 Feb CAHN

AB 50MG A205153 003 Oct 28, 2016 Feb CAHN

AB 75MG A205153 004 Oct 28, 2016 Feb CAHN

AB 100MG A205153 005 Oct 28, 2016 Feb CAHN

AB 150MG A205153 006 Oct 28, 2016 Feb CAHN

DESMETHYL PIROXICAM

CAPSULE;ORAL

PIROXICAM

&gt;A&gt; SUN PHARM INDS 10MG A073536 002 Jan 23, 2008 Mar CMS1

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL

NOCTIVA

&gt;A&gt; + SERENITY PHARMS LLC 0.00083MG/SPRAY N201656 001 Mar 03, 2017 Mar NEWA

&gt;A&gt; +! 0.00166MG/SPRAY N201656 002 Mar 03, 2017 Mar NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

&gt;A&gt; AB AUROBINDO PHARMA LTD 0.15MG,N/A;0.02MG,0.01MG A206853 001 Mar 22, 2017 Mar NEWA

DESONIDE

OINTMENT;TOPICAL

DESONIDE

&gt;A&gt; AB HI-TECH PHARMACAL 0.05% A208836 001 Mar 27, 2017 Mar NEWA

DESOXIMETASONE

GEL;TOPICAL

TOPICORT

+ @ TARO PHARMS NORTH 0.05% N018586 001 Mar 29, 1982 Jan CRLD

SPRAY;TOPICAL

DESOXIMETASONE

AT PERRIGO ISRAEL 0.25% A206441 001 Jan 20, 2017 Jan NEWA

TOPICORT

AT +! TARO 0.25% N204141 001 Apr 11, 2013 Jan CFTG

DEXAMETHASONE SODIUM PHOSPHATESOLUTION/DROPS;OPHTHALMIC, OTIC  
DEXAMETHASONE SODIUM PHOSPHATE

AT ! SANDOZ INC EQ 0.1% PHOSPHATE A088771 001 Jan 16, 1985 Feb CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS;OPHTHALMIC  
MAXITROL

AT SANDOZ INC 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062341 001 May 22, 1984 Feb CAHN

DEXMEDETOMIDINE HYDROCHLORIDEINJECTABLE;INJECTION  
DEXMEDETOMIDINE HYDROCHLORIDE

&gt;A&gt; AP ACCORD HLTHCARE EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A204023 001 Feb 09, 2016 Mar CAHN

&gt;D&gt; AP ACCORD HLTHCARE INC EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A204023 001 Feb 09, 2016 Mar CAHN

DEXTROSEINJECTABLE;INJECTION  
DEXTROSE 10% IN PLASTIC CONTAINER

AP +! ICU MEDCL 10GM/100ML N018080 001 Feb CAHN

DEXTROSE 20% IN PLASTIC CONTAINER

AP +! ICU MEDCL 20GM/100ML N018564 001 Mar 23, 1982 Feb CAHN

DEXTROSE 30% IN PLASTIC CONTAINER

AP +! ICU MEDCL 30GM/100ML N019345 001 Jan 26, 1985 Feb CAHN

DEXTROSE 5% IN PLASTIC CONTAINER

AP +! ICU MEDCL 50MG/ML N016367 002 Feb CAHN

DEXTROSE 50% IN PLASTIC CONTAINER

AP +! ICU MEDCL 50GM/100ML N018563 001 Mar 23, 1982 Feb CAHN

DEXTROSE 70% IN PLASTIC CONTAINER

AP +! ICU MEDCL 70GM/100ML N019893 001 Dec 26, 1989 Feb CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDEINJECTABLE;INJECTION  
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINERICU MEDCL 5GM/100ML;21MG/100ML;128MG/100ML;2 N017610 001 Feb CAHN  
34MG/100MLDEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUSINJECTABLE;INJECTION  
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINERICU MEDCL 5GM/100ML;30MG/100ML;141MG/100ML;1 N019513 001 May 08, 1986 Feb CAHN  
5MG/100ML;260MG/100ML;25MG/100MLDEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATEINJECTABLE;INJECTION  
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINERICU MEDCL 5GM/100ML;30MG/100ML;37MG/100ML;22 N017609 001 Feb CAHN  
2MG/100ML;526MG/100ML;502MG/100MLDEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE;INJECTION  
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ICU MEDCL 5GM/100ML;74.5MG/100ML;225MG/100ML N018365 002 Jul 05, 1983 Feb CAHN

5GM/100ML;149MG/100ML;225MG/100ML N018365 006 Mar 28, 1988 Feb CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ICU MEDCL 5GM/100ML;74.5MG/100ML;450MG/100ML N018362 005 Mar 28, 1988 Feb CAHN

AP 5GM/100ML;74.5MG/100ML;450MG/100ML N018362 009 Jul 05, 1983 Feb CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ICU MEDCL 5GM/100ML;224MG/100ML;225MG/100ML N018365 008 Mar 28, 1988 Feb CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ICU MEDCL 5GM/100ML;224MG/100ML;450MG/100ML N018362 006 Mar 28, 1988 Feb CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ICU MEDCL 5GM/100ML;149MG/100ML;225MG/100ML N018365 001 Feb CAHN

5GM/100ML;298MG/100ML;225MG/100ML N018365 009 Mar 28, 1988 Feb CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ICU MEDCL 5GM/100ML;149MG/100ML;450MG/100ML N018362 010 Jul 05, 1983 Feb CAHN

AP 5GM/100ML;298MG/100ML;450MG/100ML N018362 007 Mar 28, 1988 Feb CAHN

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDCL	5GM/100ML;224MG/100ML;225MG/100ML	N018365	003	Jul 05, 1983	Feb CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDCL	5GM/100ML;224MG/100ML;450MG/100ML	N018362	002		Feb CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDCL	5GM/100ML;298MG/100ML;225MG/100ML	N018365	004	Jul 05, 1983	Feb CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDCL	5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Feb CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDCL	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	005	Mar 28, 1988	Feb CAHN
		5GM/100ML;149MG/100ML;225MG/100ML	N018365	007	Mar 28, 1988	Feb CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDCL	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Feb CAHN
AP		5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Feb CAHN

DEXTROSE; SODIUM CHLORIDEINJECTABLE; INJECTION

	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	+! ICU MEDCL	5GM/100ML;225MG/100ML	N017606	001		Feb CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	+! ICU MEDCL	5GM/100ML;300MG/100ML	N017799	001		Feb CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDCL	5GM/100ML;450MG/100ML	N017607	001		Feb CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDCL	5GM/100ML;900MG/100ML	N017585	001		Feb CAHN

DIAZEPAMTABLET; ORALDIAZEPAM

	@ VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986	Feb CAHN
	@	5MG	A070463	001	Feb 25, 1986	Feb CAHN
	@	10MG	A070464	001	Feb 25, 1986	Feb CAHN

DICLOFENAC SODIUMSOLUTION; TOPICALDICLOFENAC SODIUM

>D>	AT	PADDOCK LLC	1.5%	A202393	001	Nov 24, 2014	Mar CAHN
>A>	AT	TWI PHARMS INC	1.5%	A202393	001	Nov 24, 2014	Mar CAHN
		PENNSAID					
		+ @ NUVO RES INC	1.5%	N020947	001	Nov 04, 2009	Feb DISC
		SOLUTION/DROPS; OPHTHALMIC					
		DICLOFENAC SODIUM					
AT		SANDOZ INC	0.1%	A078031	001	Feb 06, 2008	Feb CAHN

DICLOFENAC SODIUM; MISOPROSTOLTABLET, DELAYED RELEASE; ORALDICLOFENAC SODIUM AND MISOPROSTOL

>D>	AB	EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
	AB		50MG;0.2MG	A200540	001	Mar 14, 2014	Jan CAHN
>D>	AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar CAHN
	AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Jan CAHN
>A>	AB	EXELA HOLDINGS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
>A>	AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar CAHN

DICYCLOMINE HYDROCHLORIDEINJECTABLE; INJECTIONDICYCLOMINE HYDROCHLORIDE

AP		LUITPOLD PHARMS INC	10MG/ML	A208353	001	Feb 17, 2017	Feb NEWA
----	--	---------------------	---------	---------	-----	--------------	----------

DIFLORASONE DIACETATEOINTMENT; TOPICALDIFLORASONE DIACETATE

AB		RICONPHARMA LLC	0.05%	A207440	001	Feb 27, 2017	Feb NEWA
		PSORCON					
>D>		@ PHARMACIA AND UPJOHN	0.05%	N019260	001	Aug 28, 1985	Mar CRLD
>A>		+ @	0.05%	N019260	001	Aug 28, 1985	Mar CRLD

DIGOXIN

ELIXIR;ORAL

DIGOXIN

+! WEST-WARD PHARMS INT 0.05MG/ML

N021648 001 Aug 26, 2004 Jan CAHN

INJECTABLE;INJECTION

DIGOXIN

&gt;D&gt; AP SANDOZ 0.25MG/ML

A040481 001 Aug 21, 2003 Mar CAHN

&gt;A&gt; AP SANDOZ INC 0.25MG/ML

A040481 001 Aug 21, 2003 Mar CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

DIHYDROERGOTAMINE MESYLATE

AP WEST-WARD PHARMS INT 1MG/ML

A040453 001 Jun 09, 2003 Jan CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

&gt;D&gt; AP ! AMPHASTAR PHARMS INC 5MG/ML

A074617 001 Feb 28, 1996 Mar CAHN

&gt;A&gt; AP ! ATHENEX INC 5MG/ML

A074617 001 Feb 28, 1996 Mar CAHN

AP WEST-WARD PHARMS INT 5MG/ML

A078538 001 Dec 17, 2008 Jan CAHN

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

@ CHARTWELL MOLECULES 30MG

A074093 001 Nov 05, 1992 Feb CAHN

@ 60MG

A074093 002 Nov 05, 1992 Feb CAHN

@ 90MG

A074093 003 Nov 05, 1992 Feb CAHN

@ 120MG

A074093 004 Nov 05, 1992 Feb CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

&gt;D&gt; AP ! AMPHASTAR PHARMS INC 5MG/ML

A074939 001 Apr 13, 1998 Mar CAHN

&gt;A&gt; AP ! ATHENEX INC 5MG/ML

A074939 001 Apr 13, 1998 Mar CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB CHARTWELL MOLECULES 250MG

A091563 001 Dec 31, 2012 Jan CAHN

AB 500MG

A091563 002 Dec 31, 2012 Jan CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

AB PRINSTON INC EQ 125MG VALPROIC ACID

A090210 001 Nov 30, 2009 Feb CAHN

AB EQ 250MG VALPROIC ACID

A090210 002 Nov 30, 2009 Feb CAHN

AB EQ 500MG VALPROIC ACID

A090210 003 Nov 30, 2009 Feb CAHN

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP ACTAVIS LLC 20MG/ML (20MG/ML)

N203551 001 Apr 12, 2013 Feb CAHN

AP 80MG/4ML (20MG/ML)

N203551 002 Apr 12, 2013 Feb CAHN

140MG/7ML (20MG/ML)

N203551 003 Apr 12, 2013 Feb CAHN

AP DFB ONCOLOGY LTD 20MG/ML (20MG/ML)

A206177 001 Jan 20, 2017 Jan NEWA

AP 80MG/4ML (20MG/ML)

A206177 002 Jan 20, 2017 Jan NEWA

200MG/10ML (20MG/ML)

A206177 003 Jan 20, 2017 Jan NEWA

+ HOSPIRA INC 160MG/8ML (20MG/ML)

N022234 007 Jan 24, 2017 Jan NEWA

! JIANGSU HENGRUI MED 40MG/ML

A203170 001 Feb 15, 2017 Jan NEWA

@ PFIZER LABS 20MG/2ML (10MG/ML)

N202356 001 Mar 13, 2014 Jan DISC

@ 80MG/8ML (10MG/ML)

N202356 002 Mar 13, 2014 Jan DISC

@ 130MG/13ML (10MG/ML)

N202356 003 Mar 13, 2014 Jan DISC

@ 200MG/20ML (10MG/ML)

N202356 004 Mar 13, 2014 Jan DISC

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

AB MAYNE PHARMA INC 0.125MG

A207058 001 Jun 06, 2016 Feb CAHN

AB 0.25MG

A207058 002 Jun 06, 2016 Feb CAHN

AB 0.5MG

A207058 003 Jun 06, 2016 Feb CAHN

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	ALLIED PHARMA INC	5MG	A078662	001	May 31, 2011	Mar	CAHN
>A>	AB		10MG	A078662	002	May 31, 2011	Mar	CAHN
>D>	AB	ROXANE	5MG	A078662	001	May 31, 2011	Mar	CAHN
>D>	AB		10MG	A078662	002	May 31, 2011	Mar	CAHN
>A>	AB	ZHEJIANG HISUN PHARM	23MG	A202410	001	Mar 24, 2017	Mar	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB		AMNEAL PHARMS	10MG;14MG	A208328	001	Jan 27, 2017	Jan	NEWA
AB			10MG;28MG	A208328	002	Jan 27, 2017	Jan	NEWA
		NAMZARIC						
AB	+	FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Jan	CFTG
AB	+	!	10MG;28MG	N206439	002	Dec 23, 2014	Jan	CFTG

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

>D>	AT	SANDOZ	EQ 2% BASE	A078748	001	Nov 06, 2008	Mar	CAHN
>A>	AT	SANDOZ INC	EQ 2% BASE	A078748	001	Nov 06, 2008	Mar	CAHN
	AT		EQ 2% BASE	A078981	001	Apr 13, 2009	Feb	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>D>	AT	ALCON RES	EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	Mar	CAHN
>A>	AT	SANDOZ INC	EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	Mar	CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

>D>	AP	AMPHASTAR PHARMS INC	20MG/ML	A076266	001	Jan 10, 2003	Mar	CAHN
>A>	AP	ATHENEX INC	20MG/ML	A076266	001	Jan 10, 2003	Mar	CAHN

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

+	!	MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994	Jan	CAHN
---	---	------------------	----	---------	-----	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP		AMNEAL PHARMS CO	20MG/VIAL	A208888	001	Feb 17, 2017	Feb	NEWA
AP			50MG/VIAL	A208888	002	Feb 17, 2017	Feb	NEWA

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

VIBRAMYCIN

+	@	PFIZER	EQ 100MG BASE/VIAL	N050442	002		Jan	CRLD
+	@		EQ 200MG BASE/VIAL	N050442	001		Jan	CRLD

TABLET; ORAL

DOXYCYCLINE HYCLATE

>D>		@	CARIBE HOLDINGS	EQ 50MG BASE	A062269	003		Mar	CMFD
>A>				EQ 50MG BASE	A062269	003		Mar	CMFD
		@		EQ 50MG BASE	A062269	003		Jan	CAHN
	AB			EQ 100MG BASE	A062269	002	Nov 08, 1982	Jan	CAHN

DRONABINOL

>A>										
>A>										
>A>		+	!	INSYS DEV CO INC	5MG/ML	N205525	001	Mar 23, 2017	Mar	NEWA

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL  
DULOXETINE HYDROCHLORIDE

>A>	AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204815	001	Mar 23, 2017	Mar	NEWA
>A>	AB		EQ 30MG BASE	A204815	002	Mar 23, 2017	Mar	NEWA
>A>	AB		EQ 60MG BASE	A204815	003	Mar 23, 2017	Mar	NEWA

DUTASTERIDE

CAPSULE;ORAL  
DUTASTERIDE

>A>	AB	MARKSANS PHARMA	0.5MG	A204376	001	Apr 07, 2017	Mar	NEWA
-----	----	-----------------	-------	---------	-----	--------------	-----	------

DYPHYLLINE

TABLET;ORAL  
LUFYLLIN

>D>		@ MEDA PHARMS	200MG	A084566	001		Mar	CAHN
>D>		@	400MG	A084566	002		Mar	CAHN
>A>		@ MYLAN SPECIALITY LP	200MG	A084566	001		Mar	CAHN
>A>		@	400MG	A084566	002		Mar	CAHN

ECONAZOLE NITRATE

CREAM;TOPICAL  
SPECTAZOLE

>D>		@ ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Mar	CMS1
>A>		+ @	1%	N018751	001	Dec 23, 1982	Mar	CMS1

ENALAPRILAT

INJECTABLE;INJECTION  
ENALAPRILAT

>D>	AP	! AMPHASTAR PHARMS INC	1.25MG/ML	A075634	001	Aug 22, 2000	Mar	CAHN
>A>	AP	! ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Mar	CAHN
		VASOTEC						
>D>		@ BIOVAIL LABS INTL	1.25MG/ML	N019309	001	Feb 09, 1988	Mar	CRLD
>A>		+ @	1.25MG/ML	N019309	001	Feb 09, 1988	Mar	CRLD

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS  
AKOVAZ

>D>		+! FLAMEL IRELAND LTD	50MG/ML	N208289	001	Apr 29, 2016	Mar	CTEC
>A>	AP	+!	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Mar	CTEC
>A>		EPHEDRINE SULFATE						
>A>	AP	AKORN INC	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Mar	NEWA
		SOLUTION;IV (INFUSION)						
		CORPHEDRA						
		PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Jan	NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
EPINASTINE HYDROCHLORIDE

>D>	AT	ALCON RES LTD	0.05%	A203384	001	Dec 07, 2016	Mar	CAHN
>A>	AT	SANDOZ INC	0.05%	A203384	001	Dec 07, 2016	Mar	CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION  
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

		@ BELMORA LLC	0.01MG/ML;2%	A080504	004	Oct 19, 1983	Feb	CAHN
		@	0.02MG/ML;2%	A080504	005	Oct 19, 1983	Feb	CAHN
>D>		@ EUROHLTH INTL SARL	0.01MG/ML;1%	A080406	001		Mar	CAHN
>D>		@	0.01MG/ML;2%	A080406	002		Mar	CAHN
>A>		@ WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Mar	CAHN
>A>		@	0.01MG/ML;2%	A080406	002		Mar	CAHN

EPLERENONE

TABLET;ORAL  
EPLERENONE

AB		MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017	Jan	NEWA
AB			50MG	A203896	002	Feb 02, 2017	Jan	NEWA



ERYTHROMYCIN

	GEL;TOPICAL								
	E-GLADES								
	@ MYLAN PHARMS INC	2%		A065009	001	Mar 18, 2002	Jan	CAHN	
	ERYGEL								
AT	+! MYLAN PHARMS INC	2%		N050617	001	Oct 21, 1987	Jan	CAHN	
	SWAB;TOPICAL								
	ERYTHROMYCIN								
	@ MYLAN PHARMS INC	2%		A064128	001	Jul 03, 1996	Jan	CAHN	

ESOMEPRAZOLE SODIUM

	INJECTABLE;INTRAVENOUS								
	ESOMEPRAZOLE SODIUM								
AP	DEVA HOLDING AS	EQ 40MG BASE/VIAL		A207181	001	Mar 06, 2017	Feb	NEWA	

ESTRADIOL

	GEL, METERED;TRANSDERMAL								
	ELESTRIN								
>D>	+! MEDA PHARMS	0.06% (0.87GM/ACTIVATION)		N021813	001	Dec 15, 2006	Mar	CAHN	
>A>	+! MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)		N021813	001	Dec 15, 2006	Mar	CAHN	

ESTRADIOL; NORETHINDRONE ACETATE

	TABLET;ORAL								
	ESTRADIOL AND NORETHINDRONE ACETATE								
AB	MYLAN LABS LTD	0.5MG;0.1MG		A207261	001	Feb 10, 2017	Jan	NEWA	
AB		1MG;0.5MG		A207261	002	Feb 10, 2017	Jan	NEWA	

ESTROPIPATE

	TABLET;ORAL								
	ESTROPIPATE								
AB	WATSON LABS TEVA	3MG		A081215	001	Sep 23, 1993	Feb	CAHN	

ETELCALCETIDE

	SOLUTION;INTRAVENOUS								
	PARSABIV								
	+! KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)		N208325	001	Feb 07, 2017	Feb	NEWA	
	+!	5MG/ML (5MG/ML)		N208325	002	Feb 07, 2017	Feb	NEWA	
	+!	10MG/2ML (5MG/ML)		N208325	003	Feb 07, 2017	Feb	NEWA	

ETHACRYNIC ACID

	TABLET;ORAL								
	ETHACRYNIC ACID								
AB	WEST-WARD PHARMS INT	25MG		A207262	001	Feb 23, 2017	Feb	NEWA	

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

	TABLET;ORAL-21								
	ZOVIA 1/35E-21								
>D>	@ WATSON LABS	0.035MG;1MG		A072720	001	Dec 30, 1991	Mar	CAHN	
>A>	@ WATSON PHARMS TEVA	0.035MG;1MG		A072720	001	Dec 30, 1991	Mar	CAHN	

ETHINYL ESTRADIOL; LEVONORGESTREL

	TABLET;ORAL								
	SIMPESSE								
>A> AB	AUROBINDO PHARMA LTD	0.03MG,0.01MG;0.15MG,N/A		A206851	001	Apr 07, 2017	Mar	NEWA	
	TABLET;ORAL-28								
	ELIFEMME								
AB	LABS LEON FARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG		A202507	001	Dec 04, 2015	Feb	CAHN	

ETHINYL ESTRADIOL; NORELGESTROMIN

	FILM, EXTENDED RELEASE;TRANSDERMAL								
	XULANE								
>D> AB	! MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR		A200910	001	Apr 16, 2014	Mar	CAHN	
>A> AB	!	0.035MG/24HR;0.15MG/24HR		A200910	001	Apr 16, 2014	Mar	CAHN	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

>D>	@ WATSON LABS	0.035MG;1MG	A 071480	001	Apr 12, 1988	Mar	CAHN
>A>	@ WATSON PHARMS TEVA	0.035MG;1MG	A 071480	001	Apr 12, 1988	Mar	CAHN
	NORETHINDRONE AND ETHINYL ESTRADIOL						
>D>	@ WATSON LABS	0.035MG;1MG	A 070685	001	Jan 29, 1987	Mar	CAHN
>A>	@ WATSON PHARMS TEVA	0.035MG;1MG	A 070685	001	Jan 29, 1987	Mar	CAHN
	TABLET, CHEWABLE; ORAL						
	NEXESTA FE						
AB	AUROBINDO PHARMA LTD	0.035MG;0.4MG	A 207535	001	Feb 02, 2017	Jan	NEWA
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
>A>	AB	ACCORD HLTHCARE	A 207066	001	Mar 29, 2017	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	MYLAN LABS LTD	0.0025MG;0.5MG	A 207260	001	Feb 02, 2017	Jan	NEWA
----	----------------	----------------	----------	-----	--------------	-----	------

ETHOSUXIMIDE

SYRUP; ORAL

ZARONTIN

>D>	AA	!	PARKE DAVIS	250MG/5ML	A 080258	001	Mar	CAHN
>A>	AA	!	PARKE-DAVIS	250MG/5ML	A 080258	001	Mar	CAHN

ETODOLAC

CAPSULE; ORAL

ETODOLAC

>A>	@	CHARTWELL MOLECULES	200MG	A 074842	001	Jul 17, 1997	Mar	CAHN
>A>	@		300MG	A 074842	002	Jul 17, 1997	Mar	CAHN
>D>	@	CHARTWELL PHARMS LLC	200MG	A 074842	001	Jul 17, 1997	Mar	CAHN
	@		200MG	A 074842	001	Jul 17, 1997	Jan	CAHN
>D>	@		300MG	A 074842	002	Jul 17, 1997	Mar	CAHN
	@		300MG	A 074842	002	Jul 17, 1997	Jan	CAHN

TABLET; ORAL

ETODOLAC

	@	CHARTWELL MOLECULES	400MG	A 074841	001	Jun 27, 1997	Jan	CAHN
>D>	AB	MYLAN	400MG	A 075104	001	Feb 06, 1998	Mar	CAHN
>D>	AB		500MG	A 075104	002	Nov 20, 1998	Mar	CAHN
>A>	AB	MYLAN PHARMS INC	400MG	A 075104	001	Feb 06, 1998	Mar	CAHN
>A>	AB		500MG	A 075104	002	Nov 20, 1998	Mar	CAHN

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

AP	AUROBINDO PHARMA LTD	2MG/ML	A 206126	001	Feb 24, 2017	Feb	NEWA
AP	MYLAN LABS LTD	2MG/ML	A 201044	001	Feb 07, 2017	Jan	NEWA
AP	WEST-WARD PHARMS INT	2MG/ML	A 074593	001	Nov 04, 1996	Jan	CAHN

EXEMESTANE

TABLET; ORAL

EXEMESTANE

AB	MYLAN PHARMS INC	25MG	A 203315	001	Mar 10, 2017	Feb	NEWA
----	------------------	------	----------	-----	--------------	-----	------

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	!	TEVA PHARMS	500MG	A 077487	003	Aug 24, 2007	Jan	CHRS	
		FAMVIR							
	+	@	NOVARTIS	125MG	N 020363	003	Dec 11, 1995	Jan	DISC
	+	@		250MG	N 020363	001	Apr 26, 1996	Jan	DISC
	+	@		500MG	N 020363	002	Jun 29, 1994	Jan	DISC

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

>D>	AP	AMPHASTAR PHARMS INC	10MG/ML	A 075651	001	Apr 16, 2001	Mar	CAHN
>D>	AP		10MG/ML	A 075684	001	Apr 16, 2001	Mar	CAHN
>A>	AP	ATHENEX INC	10MG/ML	A 075651	001	Apr 16, 2001	Mar	CAHN
>A>	AP		10MG/ML	A 075684	001	Apr 16, 2001	Mar	CAHN

## INJECTABLE; INJECTION

## FAMOTIDINE PRESERVATIVE FREE

>D>	AP	AMPHASTAR PHARMS INC	10MG/ML	A075622	001	Apr 16, 2001	Mar	CAHN
>D>	AP		10MG/ML	A075825	001	Apr 17, 2001	Mar	CAHN
>A>	AP	ATHENEX INC	10MG/ML	A075622	001	Apr 16, 2001	Mar	CAHN
>A>	AP		10MG/ML	A075825	001	Apr 17, 2001	Mar	CAHN

FELBAMATE

## SUSPENSION; ORAL

## FELBATOL

>D>	AB	+! MEDA PHARMS	600MG/5ML	N020189	003	Jul 29, 1993	Mar	CAHN
>A>	AB	+! MYLAN SPECIALITY LP	600MG/5ML	N020189	003	Jul 29, 1993	Mar	CAHN

## TABLET; ORAL

## FELBAMATE

AB		IMPAX LABS INC	400MG	A202284	001	Nov 04, 2015	Feb	CAHN
AB			600MG	A202284	002	Nov 04, 2015	Feb	CAHN

## FELBATOL

>D>	AB	+ MEDA PHARMS	400MG	N020189	001	Jul 29, 1993	Mar	CAHN
>D>	AB	+!	600MG	N020189	002	Jul 29, 1993	Mar	CAHN
>A>	AB	+ MYLAN SPECIALITY LP	400MG	N020189	001	Jul 29, 1993	Mar	CAHN
>A>	AB	+!	600MG	N020189	002	Jul 29, 1993	Mar	CAHN

FENOFIBRATE

## CAPSULE; ORAL

## FENOFIBRATE (MICRONIZED)

>A>	AB	GLENMARK PHARMS LTD	67MG	A205566	001	Apr 07, 2017	Mar	NEWA
>A>	AB		134MG	A205566	002	Apr 07, 2017	Mar	NEWA
>A>	AB		200MG	A205566	003	Apr 07, 2017	Mar	NEWA
>A>	AB	INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar	NEWA
>A>	AB		134MG	A207378	002	Mar 28, 2017	Mar	NEWA
>A>	AB		200MG	A207378	003	Mar 28, 2017	Mar	NEWA

## TABLET; ORAL

## FENOFIBRATE

>D>	AB	IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar	CHRS
>A>	AB	!	160MG	A076509	002	Mar 26, 2008	Mar	CHRS
>D>	AB	! RHODES PHARMS	160MG	A076433	002	May 13, 2005	Mar	CHRS
>A>	AB		160MG	A076433	002	May 13, 2005	Mar	CHRS

FENOLDOPAM MESYLATE

## INJECTABLE; INJECTION

## FENOLDOPAM MESYLATE

>D>	AP	SANDOZ	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	Mar	CAHN
>A>	AP	SANDOZ INC	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	Mar	CAHN

FENTANYL

## FILM, EXTENDED RELEASE; TRANSDERMAL

## FENTANYL-100

>D>	AB	3M DRUG DELIVERY	100MCG/HR	A202097	005	Nov 04, 2016	Mar	CAHN
>A>	AB		100MCG/HR	A202097	005	Nov 04, 2016	Mar	CAHN
>D>	AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN
>A>	AB		100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN
>A>	AB	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Mar	CAHN
>D>	AB	PAR PHARM INC	100MCG/HR	A077062	004	Aug 20, 2007	Mar	CAHN

## FENTANYL-12

>D>	AB	3M DRUG DELIVERY	12.5MCG/HR	A202097	001	Nov 04, 2016	Mar	CAHN
>A>	AB		12.5MCG/HR	A202097	001	Nov 04, 2016	Mar	CAHN

## FENTANYL-25

>D>	AB	3M DRUG DELIVERY	25MCG/HR	A202097	002	Nov 04, 2016	Mar	CAHN
>A>	AB		25MCG/HR	A202097	002	Nov 04, 2016	Mar	CAHN
>D>	AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN
>A>	AB		25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN
>A>	AB	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007	Mar	CAHN
>D>	AB	PAR PHARM INC	25MCG/HR	A077062	001	Aug 20, 2007	Mar	CAHN

## FENTANYL-50

>D>	AB	3M DRUG DELIVERY	50MCG/HR	A202097	003	Nov 04, 2016	Mar	CAHN
>A>	AB		50MCG/HR	A202097	003	Nov 04, 2016	Mar	CAHN
>D>	AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN
>A>	AB		50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN
>A>	AB	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007	Mar	CAHN
>D>	AB	PAR PHARM INC	50MCG/HR	A077062	002	Aug 20, 2007	Mar	CAHN

## FENTANYL-75

>D>	AB	3M DRUG DELIVERY	75MCG/HR	A202097	004	Nov 04, 2016	Mar	CAHN
-----	----	------------------	----------	---------	-----	--------------	-----	------

FILM, EXTENDED RELEASE;TRANSDERMAL  
FENTANYL-75

>A>	AB		75MCG/HR	A202097	004	Nov 04, 2016	Mar	CAHN
>D>	AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN
>A>	AB		75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN
>A>	AB	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Mar	CAHN
>D>	AB	PAR PHARM INC	75MCG/HR	A077062	003	Aug 20, 2007	Mar	CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL  
FESOTERODINE FUMARATE

AB		AUROBINDO PHARMA LTD	4MG	A205007	001	Feb 17, 2017	Feb	NEWA
AB			8MG	A205007	002	Feb 17, 2017	Feb	NEWA

FINASTERIDE

TABLET;ORAL  
FINASTERIDE

>A>	AB	ACCORD HLTHCARE	1MG	A091643	001	Nov 05, 2013	Mar	CAHN
>D>	AB	ACCORD HLTHCARE INC	1MG	A091643	001	Nov 05, 2013	Mar	CAHN

FLUCONAZOLE

FOR SUSPENSION;ORAL  
FLUCONAZOLE

AB		AUROBINDO PHARMA LTD	50MG/5ML	A079150	001	Sep 18, 2009	Jan	CAHN
AB			200MG/5ML	A079150	002	Sep 18, 2009	Jan	CAHN

INJECTABLE;INJECTION

>D>			DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	+	PFIZER	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992	Mar	DISC
>A>		+	@	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992	Mar	DISC
>D>	AP	+	PFIZER	400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994	Mar	DISC
>A>		+	@	400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994	Mar	DISC
>D>			DIFLUCAN IN SODIUM CHLORIDE 0.9%						
>D>	AP	+	PFIZER	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990	Mar	DISC
>A>		+	@	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990	Mar	DISC
>D>	AP	+	PFIZER	400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990	Mar	DISC
>A>		+	@	400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990	Mar	DISC
>D>			DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>D>	AP	+	PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990	Mar	DISC
>A>		+	@	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990	Mar	DISC
>D>	AP	+	PFIZER	400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990	Mar	DISC
>A>		+	@	400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990	Mar	DISC

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP		HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar	CHRS
>A>	AP	!		200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar	CHRS
>D>	AP			400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar	CHRS
>A>	AP	!		400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar	CHRS

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

			WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan	CAHN
AP				200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Jan	CAHN
AP				400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Jan	CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP		ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar	CHRS
>A>	AP	!		200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar	CHRS
>D>	AP			400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar	CHRS
>A>	AP	!		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar	CHRS
	AP		WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jan	CAHN
	AP			400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jan	CAHN

TABLET;ORAL

FLUCONAZOLE

AB		UNIQUE PHARM LABS	150MG	A076957	004	Feb 27, 2017	Feb	NEWA
AB		ZYDUS PHARMS USA INC	50MG	A208963	001	Feb 16, 2017	Feb	NEWA
AB			100MG	A208963	002	Feb 16, 2017	Feb	NEWA
AB			150MG	A208963	003	Feb 16, 2017	Feb	NEWA
AB			200MG	A208963	004	Feb 16, 2017	Feb	NEWA

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION  
FLUDARABINE PHOSPHATE

AP		ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Feb	NEWA
----	--	-------------	--------------------	---------	-----	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION  
FLUMAZENIL

AP	WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Jan	CAHN
AP		0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jan	CAHN
AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Jan	CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION  
AEROSPAN HFA

>D>	+! MEDA PHARMS	0.078MG/INH	N021247	001	Jan 27, 2006	Mar	CAHN
>A>	+! MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Mar	CAHN

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL  
FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.01%	A088170	001	Dec 16, 1982	Jan	CAHN
AT		0.025%	A088169	001	Dec 16, 1982	Jan	CAHN

OINTMENT; TOPICAL  
FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.025%	A088168	001	Dec 16, 1982	Jan	CAHN
----	--------------------	--------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL  
FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.01%	A088167	001	Dec 16, 1982	Jan	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL  
FLUOCINONIDE

AB1	FOUGERA PHARMS INC	0.05%	A073030	001	Oct 17, 1994	Jan	CAHN
>D>	@ TARO	0.05%	A071500	001	Jun 10, 1987	Mar	CMFD
>A>	AB1	0.05%	A071500	001	Jun 10, 1987	Mar	CMFD

GEL; TOPICAL  
FLUOCINONIDE

AB	FOUGERA PHARMS INC	0.05%	A072933	001	Dec 30, 1994	Jan	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL  
LIDEX

>D>	AT	CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Mar	CRLD
>A>	AT	+	0.05%	N018849	001	Apr 06, 1984	Mar	CRLD

FLUOROURACIL

INJECTABLE; INJECTION  
FLUOROURACIL

	+ @ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan	CRLD
--	---------------------	----------------------	---------	-----	--	-----	------

SOLUTION; TOPICAL  
FLUOROURACIL

>D>	AT	TARO	2%	A076526	001	Nov 05, 2003	Mar	CAHN
>D>	AT		5%	A076526	002	Nov 05, 2003	Mar	CAHN
>A>	AT	TARO PHARM	2%	A076526	001	Nov 05, 2003	Mar	CAHN
>A>	AT		5%	A076526	002	Nov 05, 2003	Mar	CAHN

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL  
FLUOXETINE HYDROCHLORIDE

AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Jan	CAHN
----	----------------------	------------------	---------	-----	--------------	-----	------

TABLET; ORAL  
FLUOXETINE HYDROCHLORIDE

>A>	AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A208698	001	Apr 05, 2017	Mar	NEWA
>A>	AB		EQ 20MG BASE	A208698	002	Apr 05, 2017	Mar	NEWA
		+! ALVOGEN	EQ 60MG BASE	N202133	001	Oct 06, 2011	Jan	CAHN

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL  
FLUPHENAZINE HYDROCHLORIDE

	@ ANI PHARMS INC	5MG/ML	A073058	001	Aug 30, 1991	Jan	CAHN
--	------------------	--------	---------	-----	--------------	-----	------

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

@ AUROLIFE PHARMA LLC	15MG	A071717	002	Jul 31, 1991	Jan CMS1
-----------------------	------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

POWDER; INHALATION

ARMONAIR RESPICLICK

+ TEVA PHARM	0.055MG/INH	N208798	001	Jan 27, 2017	Jan NEWA
+	0.113MG/INH	N208798	002	Jan 27, 2017	Jan NEWA
+!	0.232MG/INH	N208798	003	Jan 27, 2017	Jan NEWA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

AIRDUO RESPICLICK

+ TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan NEWA
+	0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan NEWA
+!	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017	Jan NEWA

FOLIC ACID

TABLET;ORAL

FOLIC ACID

>D> AA	CONTRACT PHARMACAL	1MG	A085061	001		Mar DISC
>A>	@	1MG	A085061	001		Mar DISC

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

+ @ NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001	Feb DISC
--------------	-------------	---------	-----	--------------	----------

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

>A>	+! ASTRAZENECA PHARMS	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Mar CAHN
>D>	+! PEARL THERAPS INC	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Mar CAHN

FOSINOPRIL SODIUM

TABLET;ORAL

MONOPRIL

+ @ BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Jan CRLD
+ @	20MG	N019915	003	May 16, 1991	Jan CRLD
+ @	40MG	N019915	004	Mar 28, 1995	Jan CRLD

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

>D> AP	HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007	Mar DISC
>A>	@	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007	Mar DISC
AP	WEST-WARD PHARMS INT	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jan CAHN
AP		EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jan CAHN

FUROSEMIDE

TABLET;ORAL

FUROSEMIDE

AB	PRINSTON INC	20MG	A076796	001	Mar 26, 2004	Feb CAHN
AB		40MG	A076796	002	Mar 26, 2004	Feb CAHN
AB		80MG	A076796	003	Mar 26, 2004	Feb CAHN
AB	WEST-WARD PHARMS INT	20MG	N018823	001	Nov 10, 1983	Jan CAHN
AB		40MG	N018823	002	Nov 10, 1983	Jan CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB	AUROBINDO PHARMA LTD	100MG	A078787	001	Jan 31, 2008	Jan CAHN
AB		300MG	A078787	002	Jan 31, 2008	Jan CAHN
AB		400MG	A078787	003	Jan 31, 2008	Jan CAHN
>A> AB	EPIC PHARMA LLC	100MG	A207099	001	Mar 24, 2017	Mar NEWA
>A> AB		300MG	A207099	002	Mar 24, 2017	Mar NEWA
>A> AB		400MG	A207099	003	Mar 24, 2017	Mar NEWA

	TABLET;ORAL								
	GABAPENTIN								
AB	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Feb	NEWA		
AB		800MG	A205807	002	Mar 10, 2017	Feb	NEWA		
	<u>GANCICLOVIR</u>								
	SOLUTION;IV (INFUSION)								
	GANCICLOVIR								
	+!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Feb	NEWA	
	<u>GATIFLOXACIN</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	GATIFLOXACIN								
AT	SANDOZ INC	0.5%	A204227	001	Jul 11, 2016	Feb	CAHN		
	<u>GEMFIBROZIL</u>								
	TABLET;ORAL								
	GEMFIBROZIL								
AB	CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007	Jan	CAHN		
	<u>GEMIFLOXACIN MESYLATE</u>								
	TABLET;ORAL								
	FACTIVE								
>A>	AB	+!	LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Mar	CAHN
>D>	AB	+!	LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Mar	CAHN
	<u>GENTAMICIN SULFATE</u>								
	CREAM;TOPICAL								
	GENTAMICIN SULFATE								
AT	!	PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001		Jan	CHRS	
		@ TARO	EQ 0.1% BASE	A062427	001	May 26, 1983	Jan	DISC	
	OINTMENT;TOPICAL								
	GENTAMICIN SULFATE								
AT	FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan	CAHN		
	SOLUTION/DROPS;OPHTHALMIC								
	GENTAMICIN SULFATE								
>D>	AT	ALCON RES LTD	EQ 0.3% BASE	A062196	001		Mar	CAHN	
>A>	AT	SANDOZ INC	EQ 0.3% BASE	A062196	001		Mar	CAHN	
	<u>GLIMEPIRIDE</u>								
	TABLET;ORAL								
	GLIMEPIRIDE								
AB	PRINSTON INC	1MG	A077370	001	Dec 23, 2005	Feb	CAHN		
AB		2MG	A077370	002	Dec 23, 2005	Feb	CAHN		
AB		4MG	A077370	003	Dec 23, 2005	Feb	CAHN		
AB		8MG	A077370	004	Dec 23, 2005	Feb	CAHN		
	<u>GLIPIZIDE; METFORMIN HYDROCHLORIDE</u>								
	TABLET;ORAL								
	METAGLIP								
	+ @	BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002	Jan	CRLD	
	+ @		2.5MG;500MG	N021460	002	Oct 21, 2002	Jan	CRLD	
	+ @		5MG;500MG	N021460	003	Oct 21, 2002	Jan	CRLD	
	<u>GLYBURIDE</u>								
	TABLET;ORAL								
	GLYBURIDE								
AB2	IMPAX LABS INC	1.25MG	A206079	001	Sep 30, 2015	Feb	CAHN		
AB2		2.5MG	A206079	002	Sep 30, 2015	Feb	CAHN		
AB2		5MG	A206079	003	Sep 30, 2015	Feb	CAHN		
	<u>GLYBURIDE; METFORMIN HYDROCHLORIDE</u>								
	TABLET;ORAL								
	GLYBURIDE AND METFORMIN HYDROCHLORIDE								
	@	IMPAX LABS INC	1.25MG;250MG	A076731	001	Nov 19, 2004	Feb	CAHN	
	@		2.5MG;500MG	A076731	002	Nov 19, 2004	Feb	CAHN	
	@		5MG;500MG	A076731	003	Nov 19, 2004	Feb	CAHN	

GLYCINE

SOLUTION; IRRIGATION  
GLYCINE 1.5% IN PLASTIC CONTAINER

AT ICU MEDCL 1.5GM/100ML N018315 001 Feb CAHN

GLYCOPYRROLATE

POWDER; INHALATION  
SEEBRI

+! SUNOVION PHARMS INC 15.6MCG/INH N207923 001 Oct 29, 2015 Jan CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION  
UTIBRON

+! SUNOVION PHARMS INC 15.6MCG/INH; 27.5MCG/INH N207930 001 Oct 29, 2015 Jan CAHN

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION  
FACTREL

>D> @ HIKMA (MAPLE) EQ 0.1MG BASE/VIAL N018123 001 Sep 30, 1982 Mar CAHN  
>D> @ EQ 0.2MG BASE/VIAL N018123 002 Sep 30, 1982 Mar CAHN  
>D> @ EQ 0.5MG BASE/VIAL N018123 003 Sep 30, 1982 Mar CAHN  
>A> @ WEST-WARD PHARMS INT EQ 0.1MG BASE/VIAL N018123 001 Sep 30, 1982 Mar CAHN  
>A> @ EQ 0.2MG BASE/VIAL N018123 002 Sep 30, 1982 Mar CAHN  
>A> @ EQ 0.5MG BASE/VIAL N018123 003 Sep 30, 1982 Mar CAHN

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION  
CHORIONIC GONADOTROPIN

+! FERRING 5,000 UNITS/VIAL N017016 006 Jan CMFD

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC  
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

>A> AT AMRING PHARMS 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML A065187 001 Oct 28, 2005 Mar CAHN  
>D> AT LUITPOLD 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML A065187 001 Oct 28, 2005 Mar CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION  
GRANISETRON HYDROCHLORIDE

>A> AP MYLAN LABS LTD EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A203454 001 Apr 04, 2017 Mar NEWA  
>A> AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A203454 002 Apr 04, 2017 Mar NEWA  
AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A203453 001 Jan 31, 2017 Jan NEWA  
>D> AP SANDOZ EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078534 001 Apr 30, 2009 Mar CAHN  
>D> AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078531 001 Apr 30, 2009 Mar CAHN  
>D> AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078531 002 Apr 30, 2009 Mar CAHN  
>A> AP SANDOZ INC EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078534 001 Apr 30, 2009 Mar CAHN  
>A> AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078531 001 Apr 30, 2009 Mar CAHN  
>A> AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078531 002 Apr 30, 2009 Mar CAHN  
AP WEST-WARD PHARMS INT EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A077913 001 Jun 26, 2008 Jan CAHN  
AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A077186 001 Jun 30, 2008 Jan CAHN  
AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077187 001 Jun 30, 2008 Jan CAHN  
AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A077177 001 Dec 31, 2007 Jan CAHN

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

>D> AB TARO EQ 1MG BASE A090817 001 May 28, 2010 Mar CAHN  
>A> AB TARO PHARM EQ 1MG BASE A090817 001 May 28, 2010 Mar CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL  
ULTRAVATE

>D> AB +! RANBAXY 0.05% N019967 001 Dec 27, 1990 Mar CAHN  
>A> AB +! SUN PHARM INDS LTD 0.05% N019967 001 Dec 27, 1990 Mar CAHN



HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	@ FRONTIDA BIOPHARM	20MG	A071177	001	Jan 07, 1988	Feb CAHN
--	---------------------	------	---------	-----	--------------	----------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

>D>	@ SANDOZ	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005	Mar CAHN
>D>	@	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005	Mar CAHN
>A>	@ SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005	Mar CAHN
>A>	@	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005	Mar CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

>D>	@ SANDOZ	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Mar CAHN
>A>	@ SANDOZ INC	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Mar CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	GLAND PHARMA LTD	5,000 UNITS/ML	A205323	001	Feb 06, 2017	Jan NEWA
----	------------------	----------------	---------	-----	--------------	----------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Feb NEWA
AA	BIO-PHARM INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Feb NEWA
AA	NOVEL LABS INC	1.5MG/5ML; 5MG/5ML	A203535	001	Feb 13, 2017	Jan NEWA
AA	PADDOCK LLC	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Jan NEWA

TABLET; ORAL

TUSSIGON

AA	! KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Feb CAHN
----	---------------	------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG	A075907	001	Sep 17, 2002	Feb CAHN
----	--------------	--------	---------	-----	--------------	----------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Feb CAHN
AB		50MG	A040412	002	Mar 29, 2002	Feb CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	ATLAS PHARMS LLC	12.5MG; 150MG	A203036	001	Jan 15, 2016	Mar CAHN
>A>	AB		12.5MG; 300MG	A203036	002	Jan 15, 2016	Mar CAHN
>A>	AB		25MG; 300MG	A203036	003	Jan 15, 2016	Mar CAHN
>D>	AB	INTL SPECLT CHEMS	12.5MG; 150MG	A203036	001	Jan 15, 2016	Mar CAHN
>D>	AB		12.5MG; 300MG	A203036	002	Jan 15, 2016	Mar CAHN
>D>	AB		25MG; 300MG	A203036	003	Jan 15, 2016	Mar CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

PRINZIDE

	+ @ MERCK	12.5MG; 10MG	N019778	003	Nov 18, 1993	Jan CRLD
	+ @	12.5MG; 20MG	N019778	001	Feb 16, 1989	Jan CRLD

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	@ CHARTWELL RX	12.5MG; 7.5MG	A090096	001	Sep 25, 2008	Mar CAHN
>A>	@	12.5MG; 15MG	A090096	002	Sep 25, 2008	Mar CAHN
>A>	@	25MG; 15MG	A090096	003	Sep 25, 2008	Mar CAHN
AB	HERITAGE PHARMS INC	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Jan CMS1
AB		12.5MG; 15MG	A202150	002	Mar 07, 2014	Jan CMS1
AB		25MG; 15MG	A202150	003	Mar 07, 2014	Jan CMS1
>D>	@ PADDOCK LLC	12.5MG; 7.5MG	A090096	001	Sep 25, 2008	Mar CAHN
>D>	@	12.5MG; 15MG	A090096	002	Sep 25, 2008	Mar CAHN

<u>TABLET;ORAL</u>						
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
>D>	@	25MG;15MG	A090096	003	Sep 25, 2008	Mar CAHN
<u>HYDROCODONE BITARTRATE</u>						
TABLET, EXTENDED RELEASE;ORAL						
VANTRELA ER						
+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan NEWA
+		30MG	N207975	002	Jan 17, 2017	Jan NEWA
+		45MG	N207975	003	Jan 17, 2017	Jan NEWA
+		60MG	N207975	004	Jan 17, 2017	Jan NEWA
+		90MG	N207975	005	Jan 17, 2017	Jan NEWA
<u>HYDROCORTISONE</u>						
CREAM;TOPICAL						
HYDROCORTISONE						
AT	!	FOUGERA PHARMS INC	A080693	003		Jan CAHN
AT	!		A089414	001	Dec 16, 1986	Jan CAHN
OINTMENT;TOPICAL						
HYDROCORTISONE						
AT	!	FOUGERA PHARMS INC	A081203	001	May 28, 1993	Jan CAHN
<u>HYDROCORTISONE ACETATE</u>						
AEROSOL, METERED;RECTAL						
CORTIFOAM						
>D>	+	MEDA PHARMS	N017351	001	Feb 10, 1982	Mar CAHN
>A>	+	MYLAN SPECIALITY LP	N017351	001	Feb 10, 1982	Mar CAHN
<u>HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>						
CREAM;TOPICAL						
CORTISPORIN						
	+	MONARCH PHARMS	N050218	001	Aug 09, 1985	Feb CAHN
<u>HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE</u>						
AEROSOL, METERED;TOPICAL						
EPIFOAM						
>D>	BX	MEDA PHARMS	A086457	001		Mar CAHN
>A>	BX	MYLAN SPECIALITY LP	A086457	001		Mar CAHN
PROCTOFOAM HC						
>D>	BX	MEDA PHARMS	A086195	001		Mar CAHN
>A>	BX	MYLAN SPECIALITY LP	A086195	001		Mar CAHN
<u>HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>						
SOLUTION/DROPS;OTIC						
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
>A>	AT	AMRING PHARMS	A065216	001	Oct 31, 2005	Mar CAHN
>D>	AT	LUITPOLD	A065216	001	Oct 31, 2005	Mar CAHN
	AT	SANDOZ INC	A062423	001	Aug 25, 1983	Feb CAHN
SUSPENSION/DROPS;OPHTHALMIC						
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
	!	SANDOZ INC	A062874	001	May 11, 1988	Feb CAHN
SUSPENSION/DROPS;OTIC						
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
>A>	AT	AMRING PHARMS	A065219	001	May 01, 2006	Mar CAHN
>D>	AT	LUITPOLD	A065219	001	May 01, 2006	Mar CAHN
	AT	SANDOZ INC	A062488	001	Nov 06, 1985	Feb CAHN
<u>HYDROMORPHONE HYDROCHLORIDE</u>						
INJECTABLE;INJECTION						
DILAUDID						
AP	+	FRESENIUS KABI USA	N019034	003	Apr 30, 2009	Jan CAHN
AP	+		N019034	004	Apr 30, 2009	Jan CAHN
AP	+		N019034	005	Apr 30, 2009	Jan CAHN
DILAUDID-HP						
AP	+	FRESENIUS KABI USA	N019034	001	Jan 11, 1984	Jan CAHN

	INJECTABLE; INJECTION								
	DILAUDID-HP								
	@	250MG/VIAL			N019034	002	Aug 04, 1994	Jan	CAHN
	<u>HYDROXOCOBALAMIN</u>								
	INJECTABLE; INJECTION								
	HYDROXOCOBALAMIN								
	! ACTAVIS LLC	1MG/ML			A085998	001		Feb	CAHN
	<u>HYDROXYZINE HYDROCHLORIDE</u>								
	INJECTABLE; INJECTION								
	VISTARIL								
	+ @ PFIZER	25MG/ML			N011111	001		Jan	CRLD
	+ @	50MG/ML			N011111	002		Jan	CRLD
	TABLET; ORAL								
	HYDROXYZINE HYDROCHLORIDE								
	@ AUROLIFE PHARMA LLC	10MG			A087871	002	Dec 20, 1982	Jan	CMS1
	@	25MG			A087871	003	Dec 20, 1982	Jan	CMS1
>A>	AB NUVO PHARM INC	10MG			A207120	001	Mar 29, 2017	Mar	NEWA
>A>	AB	25MG			A207121	001	Mar 29, 2017	Mar	NEWA
>A>	AB	50MG			A207122	001	Mar 29, 2017	Mar	NEWA
	AB PRINSTON INC	10MG			A040579	001	May 27, 2005	Feb	CAHN
	AB	25MG			A040574	001	May 27, 2005	Feb	CAHN
	AB	50MG			A040580	001	May 27, 2005	Feb	CAHN
	<u>IBUPROFEN</u>								
	SUSPENSION; ORAL								
	MOTRIN								
	+ @ MCNEIL CONSUMER	100MG/5ML			N019842	001	Sep 19, 1989	Jan	CRLD
	TABLET; ORAL								
	IBUPROFEN								
>D>	@ MYLAN	400MG			A070045	001	Sep 24, 1985	Mar	CAHN
>A>	@ MYLAN PHARMS INC	400MG			A070045	001	Sep 24, 1985	Mar	CAHN
	<u>ICOSAPENT ETHYL</u>								
	CAPSULE; ORAL								
	VASCEPA								
>A>	+ AMARIN PHARMS	500MG			N202057	002	Feb 16, 2017	Mar	NEWA
	<u>IFOSFAMIDE; MESNA</u>								
	INJECTABLE; INTRAVENOUS								
>D>	IFOSFAMIDE/MESNA KIT								
>D>	! TEVA PHARMS USA	1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)			A075874	001	Feb 26, 2002	Mar	DISC
>A>	@	1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)			A075874	001	Feb 26, 2002	Mar	DISC
>D>	!	3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)			A075874	002	Feb 26, 2002	Mar	DISC
>A>	@	3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)			A075874	002	Feb 26, 2002	Mar	DISC
	<u>INDACATEROL MALEATE</u>								
	POWDER; INHALATION								
	ARCAPTA NEOHALER								
	+! SUNOVION PHARMS INC	EQ 75MCG BASE			N022383	001	Jul 01, 2011	Jan	CAHN
	<u>INDOMETHACIN</u>								
	CAPSULE; ORAL								
	INDOMETHACIN								
	@ CHARTWELL MOLECULES	25MG			N018829	002	Aug 06, 1984	Feb	CAHN
	@	50MG			N018829	001	Aug 06, 1984	Feb	CAHN
	CAPSULE, EXTENDED RELEASE; ORAL								
	INDOMETHACIN								
	@ WATSON LABS INC	75MG			A202572	001	Dec 09, 2013	Feb	DISC
	<u>IOPAMIDOL</u>								
	INJECTABLE; INJECTION								
	SCANLUX-300								
AP	MYLAN IRELAND LTD	61%			A090394	001	Jun 18, 2010	Jan	CAHN
AP	SANOCHEMIA CORP USA	61%			A090394	001	Jun 18, 2010	Feb	CAHN
	SCANLUX-370								
AP	MYLAN IRELAND LTD	76%			A090394	002	Jun 18, 2010	Jan	CAHN

	INJECTABLE; INJECTION							
	SCANLUX-370							
AP	SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Feb	CAHN	
	<u>IRINOTECAN HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	IRINOTECAN HYDROCHLORIDE							
AP	WEST-WARD PHARMS INT	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jan	CAHN	
AP		100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jan	CAHN	
	<u>ISONIAZID</u>							
	INJECTABLE; INJECTION							
	ISONIAZID							
>D>	!	SANDOZ	100MG/ML	A040648	001	Jul 05, 2005	Mar	CAHN
>A>	!	SANDOZ INC	100MG/ML	A040648	001	Jul 05, 2005	Mar	CAHN
	<u>ISOSORBIDE DINITRATE</u>							
	TABLET, EXTENDED RELEASE; ORAL							
	ISOSORBIDE DINITRATE							
	@	IMPAX LABS INC	40MG	A040723	001	Mar 17, 2008	Feb	CAHN
	<u>ITRACONAZOLE</u>							
	CAPSULE; ORAL							
	ITRACONAZOLE							
AB	JUBILANT GENERICS	100MG	A203445	001	Feb 23, 2017	Feb	NEWA	
	<u>KANAMYCIN SULFATE</u>							
	INJECTABLE; INJECTION							
	KANAMYCIN							
	@	WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A062324	001		Jan	CAHN
	@		EQ 500MG BASE/2ML	A062324	002		Jan	CAHN
	@		EQ 1GM BASE/3ML	A062324	003		Jan	CAHN
	<u>KETOCONAZOLE</u>							
	AEROSOL, FOAM; TOPICAL							
	EXTINA							
AT	+	MYLAN PHARMS INC	2%	N021738	001	Jun 12, 2007	Jan	CAHN
	<u>KETOPROFEN</u>							
	CAPSULE; ORAL							
	KETOPROFEN							
		HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993	Feb	CAHN
AB			50MG	A074014	002	Jan 29, 1993	Feb	CAHN
AB			75MG	A074014	003	Jan 29, 1993	Feb	CAHN
	<u>KETOROLAC TROMETHAMINE</u>							
	INJECTABLE; INJECTION							
	KETOROLAC TROMETHAMINE							
>D>	@	SANDOZ	15MG/ML	A076271	001	Oct 06, 2004	Mar	CAHN
>D>	AP		30MG/ML	A076271	002	Oct 06, 2004	Mar	CAHN
>A>	@	SANDOZ INC	15MG/ML	A076271	001	Oct 06, 2004	Mar	CAHN
>A>	AP		30MG/ML	A076271	002	Oct 06, 2004	Mar	CAHN
	SOLUTION/DROPS; OPHTHALMIC							
	KETOROLAC TROMETHAMINE							
AT		SANDOZ INC	0.5%	A076583	001	Nov 05, 2009	Feb	CAHN
	<u>LABETALOL HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	LABETALOL HYDROCHLORIDE							
AP	SAGENT AGILA	5MG/ML	A079134	001	Feb 03, 2010	Feb	CAHN	
	<u>LAMIVUDINE</u>							
	TABLET; ORAL							
	LAMIVUDINE							
AB	CIPLA LTD	150MG	A077221	001	Mar 03, 2017	Feb	NEWA	
AB		300MG	A077221	002	Mar 03, 2017	Feb	NEWA	

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

>A>	BX	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017	Mar	NEWA
-----	----	------------	-------------	---------	-----	--------------	-----	------

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

>D>		@ MATRIX LABS LTD	25MG	A078443	001	Feb 11, 2009	Mar	CAHN
>D>		@	100MG	A078443	002	Feb 11, 2009	Mar	CAHN
>D>		@	150MG	A078443	003	Feb 11, 2009	Mar	CAHN
>D>		@	200MG	A078443	004	Feb 11, 2009	Mar	CAHN
>A>		@ MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009	Mar	CAHN
>A>		@	100MG	A078443	002	Feb 11, 2009	Mar	CAHN
>A>		@	150MG	A078443	003	Feb 11, 2009	Mar	CAHN
>A>		@	200MG	A078443	004	Feb 11, 2009	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB		HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013	Jan	CAHN
AB			50MG	A202887	002	Jun 17, 2013	Jan	CAHN
AB			100MG	A202887	003	Jun 17, 2013	Jan	CAHN
AB			200MG	A202887	004	Jun 17, 2013	Jan	CAHN

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

>A>	AT	AMRING PHARMS	0.005%	A200925	001	Mar 22, 2011	Mar	CAHN
>D>	AT	LUITPOLD	0.005%	A200925	001	Mar 22, 2011	Mar	CAHN
	AT	SANDOZ INC	0.005%	A091449	001	Mar 22, 2011	Feb	CAHN

LEVAlBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVAlBUTEROL HYDROCHLORIDE

AN		AUROBINDO PHARMA LTD	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Jan	NEWA
----	--	----------------------	---------------	---------	-----	--------------	-----	------

LEVETIRACETAM

SOLUTION;ORAL

LEVETIRACETAM

>A>	AA	ALLIED PHARMA INC	100MG/ML	A078582	001	Jan 15, 2009	Mar	CAHN
	AA	AUROBINDO PHARMA LTD	100MG/ML	A079063	001	Jan 15, 2009	Jan	CAHN
>D>	AA	ROXANE	100MG/ML	A078582	001	Jan 15, 2009	Mar	CAHN

TABLET;ORAL

LEVETIRACETAM

>A>	AB	ALLIED PHARMA INC	250MG	A078042	001	Jan 15, 2009	Mar	CAHN
>A>	AB		500MG	A078042	002	Jan 15, 2009	Mar	CAHN
>A>	AB		750MG	A078042	003	Jan 15, 2009	Mar	CAHN
>A>	AB		1GM	A078042	004	Jan 15, 2009	Mar	CAHN
>D>	AB	ROXANE	250MG	A078042	001	Jan 15, 2009	Mar	CAHN
>D>	AB		500MG	A078042	002	Jan 15, 2009	Mar	CAHN
>D>	AB		750MG	A078042	003	Jan 15, 2009	Mar	CAHN
>D>	AB		1GM	A078042	004	Jan 15, 2009	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

>A>	AB	ECI PHARMS LLC	500MG	A204754	001	Aug 26, 2016	Mar	CAHN
>A>	AB		750MG	A204754	002	Aug 26, 2016	Mar	CAHN
>D>	AB	NOSTRUM LABS INC	500MG	A204754	001	Aug 26, 2016	Mar	CAHN
>D>	AB		750MG	A204754	002	Aug 26, 2016	Mar	CAHN
	AB	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Feb	CAHN
	AB		750MG	A202533	002	Jul 20, 2012	Feb	CAHN
	AB	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Feb	CAHN
	AB		750MG	A091291	002	Sep 12, 2011	Feb	CAHN

LEVObUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

LEVObUNOLOL HYDROCHLORIDE

		@ ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996	Feb	DISC
AT		SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	Feb	CAHN

LEVOCARNITINEINJECTABLE; INJECTION  
CARNITOR

>A>	AP	+	!	LEADIANT BIOSCI INC	200MG/ML	N020182	001	Dec 16, 1992	Mar	CAHN
>D>	AP	+	!	SIGMA TAU	200MG/ML	N020182	001	Dec 16, 1992	Mar	CAHN

SOLUTION; ORAL  
CARNITOR

>A>		@		LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988	Mar	CAHN
>A>	AA	+	!		1GM/10ML	N019257	001	Apr 10, 1986	Mar	CAHN
>D>		@		SIGMA TAU	1GM/10ML	N018948	002	Apr 27, 1988	Mar	CAHN
>D>	AA	+	!		1GM/10ML	N019257	001	Apr 10, 1986	Mar	CAHN

CARNITOR SF

>A>	AA	+		LEADIANT BIOSCI INC	1GM/10ML	N019257	002	Mar 28, 2007	Mar	CAHN
>D>	AA	+		SIGMA TAU	1GM/10ML	N019257	002	Mar 28, 2007	Mar	CAHN

TABLET; ORAL  
CARNITOR

>A>	AB	+	!	LEADIANT BIOSCI INC	330MG	N018948	001	Dec 27, 1985	Mar	CAHN
>D>	AB	+	!	SIGMA TAU	330MG	N018948	001	Dec 27, 1985	Mar	CAHN

LEVOCARNITINE

AB				IMPAX LABS INC	330MG	A076858	001	Sep 20, 2004	Feb	CAHN
----	--	--	--	----------------	-------	---------	-----	--------------	-----	------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	@	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan	CRLD
+	@		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan	CRLD
+	@		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan	CRLD

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT				WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011	Feb	CAHN
----	--	--	--	------------------	------	---------	-----	--------------	-----	------

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP				ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan	NEWA
AP				AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan	NEWA

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

@	BELMORA LLC	0.05MG/ML; 2%	A084850	002	Oct 21, 1983	Feb	CAHN
---	-------------	---------------	---------	-----	--------------	-----	------

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT				ALKEM LABS LTD	5%	A207810	001	Mar 10, 2017	Feb	NEWA
AT	!			FOUGERA PHARMS INC	5%	A080198	001		Jan	CAHN
				XYLOCAINE						
+	@	ASTRAZENECA	5%			N008048	001		Jan	CRLD

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

@	BELMORA LLC	2%	A080504	001		Feb	CAHN
---	-------------	----	---------	-----	--	-----	------

LINACLOTIDE

CAPSULE; ORAL

LINZESS

+		FOREST LABS LLC	72MCG	N202811	003	Jan 25, 2017	Jan	NEWA
---	--	-----------------	-------	---------	-----	--------------	-----	------

LINEZOLID

SOLUTION; IV (INFUSION)

LINEZOLID

AP				SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	Feb	NEWA
AP					600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	Feb	NEWA

TABLET; ORAL

LINEZOLID

AB				ZYDUS PHARMS USA INC	600MG	A206097	001	Feb 22, 2017	Feb	NEWA
----	--	--	--	----------------------	-------	---------	-----	--------------	-----	------

LIOETHYRONINE SODIUM

TABLET;ORAL

CYTOMEL

>A>	AB	+	KING PHARMS	EQ 0.005MG BASE	N010379	001		Mar	CAHN
>A>	AB	+		EQ 0.025MG BASE	N010379	002		Mar	CAHN
>A>	AB	+	!	EQ 0.05MG BASE	N010379	003		Mar	CAHN
>D>	AB	+	KING PHARMS R AND D	EQ 0.005MG BASE	N010379	001		Mar	CAHN
>D>	AB	+		EQ 0.025MG BASE	N010379	002		Mar	CAHN
>D>	AB	+	!	EQ 0.05MG BASE	N010379	003		Mar	CAHN

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE;ORAL

VYVANSE

+	SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017	Jan	NEWA
+		20MG	N208510	002	Jan 28, 2017	Jan	NEWA
+		30MG	N208510	003	Jan 28, 2017	Jan	NEWA
+		40MG	N208510	004	Jan 28, 2017	Jan	NEWA
+		50MG	N208510	005	Jan 28, 2017	Jan	NEWA
+		60MG	N208510	006	Jan 28, 2017	Jan	NEWA

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB	PRINSTON INC	2.5MG	A075743	001	Jul 01, 2002	Feb	CAHN
AB		5MG	A075743	002	Jul 01, 2002	Feb	CAHN
AB		10MG	A075743	003	Jul 01, 2002	Feb	CAHN
AB		20MG	A075743	004	Jul 01, 2002	Feb	CAHN
AB		30MG	A075743	005	Jul 01, 2002	Feb	CAHN
AB		40MG	A075743	006	Jul 01, 2002	Feb	CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB	MYLAN PHARMS INC	150MG	A076243	002	Feb 24, 2003	Jan	CAHN	
AB		300MG	A076243	001	Jun 27, 2002	Jan	CAHN	
AB		600MG	A078763	001	Apr 15, 2008	Jan	CAHN	
AB	+	WEST-WARD PHARMS INT	150MG	N017812	002	Jan 28, 1987	Jan	CAHN
AB	+		300MG	N017812	001		Jan	CAHN
AB	+	!	600MG	N017812	003	Jan 28, 1987	Jan	CAHN

TABLET;ORAL

LITHIUM CARBONATE

AB	+	!	WEST-WARD PHARMS INT	300MG	N018558	001	Jan 29, 1982	Jan	CAHN
----	---	---	----------------------	-------	---------	-----	--------------	-----	------

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	+	!	WEST-WARD PHARMS INT	EQ 300MG CARBONATE/5ML	N018421	001		Jan	CAHN
----	---	---	----------------------	------------------------	---------	-----	--	-----	------

LORAZEPAM

INJECTABLE;INJECTION

LORAZEPAM

>D>	@	EUROHLTH INTL SARL	2MG/ML	A074496	001	Sep 28, 1998	Mar	CAHN
>D>	@		4MG/ML	A074496	002	Sep 28, 1998	Mar	CAHN
>A>	AP	SAGENT AGILA	2MG/ML	A200217	001	Apr 04, 2017	Mar	NEWA
>A>	AP		4MG/ML	A200217	002	Apr 04, 2017	Mar	NEWA
>A>	@	WEST-WARD PHARMS INT	2MG/ML	A074496	001	Sep 28, 1998	Mar	CAHN
>A>	@		4MG/ML	A074496	002	Sep 28, 1998	Mar	CAHN

LOVASTATIN

TABLET;ORAL

LOVASTATIN

>D>	AB		MYLAN	10MG	A075935	001	Dec 17, 2001	Mar	DISC
>A>		@		10MG	A075935	001	Dec 17, 2001	Mar	DISC
>D>	AB			20MG	A075935	002	Dec 17, 2001	Mar	DISC
>A>		@		20MG	A075935	002	Dec 17, 2001	Mar	DISC
>D>	AB			40MG	A075935	003	Dec 17, 2001	Mar	DISC
>A>		@		40MG	A075935	003	Dec 17, 2001	Mar	DISC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

ICU MEDCL	30MG/100ML; 37MG/100ML; 222MG/100ML;	N017586	001			Feb	CAHN
	526MG/100ML; 502MG/100ML						

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

ICU MEDCL	30MG/100ML; 37MG/100ML; 222MG/100ML;	N017637	002	Jul 08, 1982		Feb	CAHN
	526MG/100ML; 502MG/100ML						

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA	NOVEL LABS INC	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	A202511	001	Feb 23, 2017	Feb	NEWA
	SUPREP BOWEL PREP KIT						

AA	+! BRAINTREE LABS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N022372	001	Aug 05, 2010	Feb	CFTG
----	-------------------	-----------------------------------	---------	-----	--------------	-----	------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP	ICU MEDCL	10GM/100ML	N019603	002	Jan 08, 1987	Feb	CAHN
----	-----------	------------	---------	-----	--------------	-----	------

MANNITOL 15% IN PLASTIC CONTAINER

AP	ICU MEDCL	15GM/100ML	N019603	003	Jan 08, 1990	Feb	CAHN
----	-----------	------------	---------	-----	--------------	-----	------

MANNITOL 20% IN PLASTIC CONTAINER

AP	ICU MEDCL	20GM/100ML	N019603	004	Jan 08, 1990	Feb	CAHN
----	-----------	------------	---------	-----	--------------	-----	------

MANNITOL 5% IN PLASTIC CONTAINER

AP	ICU MEDCL	5GM/100ML	N019603	001	Jan 08, 1987	Feb	CAHN
----	-----------	-----------	---------	-----	--------------	-----	------

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

ICU MEDCL	540MG/100ML; 2.7GM/100ML	N018316	001			Feb	CAHN
-----------	--------------------------	---------	-----	--	--	-----	------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

>D>	AB	SANDOZ	150MG/ML	A078711	001	May 20, 2009	Mar	CAHN
-----	----	--------	----------	---------	-----	--------------	-----	------

>A>	AB	SANDOZ INC	150MG/ML	A078711	001	May 20, 2009	Mar	CAHN
-----	----	------------	----------	---------	-----	--------------	-----	------

	AB	TEVA PHARMS USA	150MG/ML	A076553	001	Jul 28, 2004	Jan	CAHN
--	----	-----------------	----------	---------	-----	--------------	-----	------

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

+ @	BRISTOL MYERS SQUIBB	40MG/ML	N020264	001	Sep 10, 1993	Feb	DISC
-----	----------------------	---------	---------	-----	--------------	-----	------

MEGESTROL ACETATE

AB	! WEST-WARD PHARMS INT	40MG/ML	A075997	001	Feb 15, 2002	Feb	CHRS
----	------------------------	---------	---------	-----	--------------	-----	------

MELPHALAN

TABLET; ORAL

ALKERAN

>D>		+! APOTEX INC	2MG	N014691	002		Mar	CFTG
-----	--	---------------	-----	---------	-----	--	-----	------

>A>	AB	+!	2MG	N014691	002		Mar	CFTG
-----	----	----	-----	---------	-----	--	-----	------

>A>		MELPHALAN						
-----	--	-----------	--	--	--	--	--	--

>A>	AB	ALVOGEN MALTA	2MG	A207809	001	Mar 22, 2017	Mar	NEWA
-----	----	---------------	-----	---------	-----	--------------	-----	------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

AP	SAGENT PHARMS	EQ 50MG BASE/VIAL	A201379	001	Feb 28, 2017	Feb	NEWA
----	---------------	-------------------	---------	-----	--------------	-----	------

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	25MG/ML	A080445	001		Jan	CAHN
----	----------------------	---------	---------	-----	--	-----	------

AP		25MG/ML	A080455	007		Jan	CAHN
----	--	---------	---------	-----	--	-----	------

AP		50MG/ML	A080445	002		Jan	CAHN
----	--	---------	---------	-----	--	-----	------

AP		50MG/ML	A080455	008		Jan	CAHN
----	--	---------	---------	-----	--	-----	------

AP		75MG/ML	A080445	003		Jan	CAHN
----	--	---------	---------	-----	--	-----	------

AP		75MG/ML	A080455	009		Jan	CAHN
----	--	---------	---------	-----	--	-----	------

AP		100MG/ML	A080445	004		Jan	CAHN
----	--	----------	---------	-----	--	-----	------

AP		100MG/ML	A080455	010		Jan	CAHN
----	--	----------	---------	-----	--	-----	------



## INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

>D>	@ MALLINCKRODT	10MG/ML	A040163	001	May 12, 1997	Mar	CAHN
>A>	@ MALLINCKRODT INC	10MG/ML	A040163	001	May 12, 1997	Mar	CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPIVACAINE HYDROCHLORIDE

@ BELMORA LLC	3%	A083559	001			Feb	CAHN
---------------	----	---------	-----	--	--	-----	------

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

>A>	AP	AUROBINDO PHARMA LTD	500MG/VIAL	A205835	001	Mar 27, 2017	Mar	NEWA
>A>	AP		1GM/VIAL	A205835	002	Mar 27, 2017	Mar	NEWA

MESALAMINE

ENEMA; RECTAL

ROWASA

>D>	AB	+! MEDA PHARMS	4GM/60ML	N019618	001	Dec 24, 1987	Mar	CAHN
>A>	AB	+! MYLAN SPECIALITY LP	4GM/60ML	N019618	001	Dec 24, 1987	Mar	CAHN
		SFROWASA						
>D>	AB	+ MEDA PHARMS	4GM/60ML	N019618	002	Jun 20, 2008	Mar	CAHN
>A>	AB	+ MYLAN SPECIALITY LP	4GM/60ML	N019618	002	Jun 20, 2008	Mar	CAHN

METAXALONE

TABLET; ORAL

METAXALONE

IMPAX LABS INC	400MG	A040486	001	Feb 27, 2015	Feb	CAHN
----------------	-------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>D>	AB	WATSON LABS FLORIDA	500MG	A075961	001	Jan 25, 2002	Mar	DISC
>A>		@	500MG	A075961	001	Jan 25, 2002	Mar	DISC
>D>	AB		850MG	A075961	002	Jan 25, 2002	Mar	DISC
>A>		@	850MG	A075961	002	Jan 25, 2002	Mar	DISC
>D>	AB		1GM	A075961	003	Jan 25, 2002	Mar	DISC
>A>		@	1GM	A075961	003	Jan 25, 2002	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1	INTELLIPHARMACEUTICS	500MG	A202306	001	Feb 23, 2017	Feb	NEWA
AB		750MG	A202306	002	Feb 23, 2017	Feb	NEWA

METHADONE HYDROCHLORIDE

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE

@ WEST-WARD PHARMS INT	10MG/30ML	N006134	004			Jan	CAHN
------------------------	-----------	---------	-----	--	--	-----	------

TABLET; ORAL

DOLOPHINE HYDROCHLORIDE

AA	+! WEST-WARD PHARMS INT	5MG	N006134	002		Jan	CAHN
AA	+!	10MG	N006134	010		Jan	CAHN

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

AA	+! WEST-WARD PHARMS INT	40MG	N017058	001		Jan	CAHN
----	-------------------------	------	---------	-----	--	-----	------

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB	IMPAX LABS INC	1GM	A076411	001	Jun 20, 2003	Feb	CAHN
----	----------------	-----	---------	-----	--------------	-----	------

METHIMAZOLE

TABLET; ORAL

TAPAZOLE

AB	KING PHARMS LLC	5MG	A040320	001	Mar 31, 2000	Feb	CAHN
AB		10MG	A040320	002	Mar 31, 2000	Feb	CAHN

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

>D>	AP	RENAISSANCE PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Mar CAHN
	AP		1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jan NEWA
>A>	AP	RENAISSANCE SSA LLC	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Mar CAHN

TABLET;ORAL

METHOCARBAMOL

AA		ATLAS PHARMS LLC	500MG	A203550	001	Feb 08, 2017	Jan NEWA
AA			750MG	A203550	002	Feb 08, 2017	Jan NEWA

METHOTREXATE SODIUM

TABLET;ORAL

METHOTREXATE SODIUM

AB		ZYDUS PHARMS USA INC	EQ 2.5MG BASE	A207812	001	Jan 13, 2017	Jan NEWA
----	--	----------------------	---------------	---------	-----	--------------	----------

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION

METHYLDOPATE HYDROCHLORIDE

!		LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Jan CTEC
---	--	----------	---------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHERGINE

>D>		@ EDISON THERAPS LLC	0.2MG	N006035	003		Mar CRLD
>A>		+ @	0.2MG	N006035	003		Mar CRLD

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB2		IMPAX LABS INC	10MG	A205105	001	Jul 28, 2016	Feb CAHN
AB2			20MG	A205105	002	Jul 28, 2016	Feb CAHN
AB2			30MG	A205105	003	Jul 28, 2016	Feb CAHN
AB2			40MG	A205105	004	Jul 28, 2016	Feb CAHN
AB2			50MG	A205105	005	Jul 28, 2016	Feb CAHN
AB2			60MG	A205105	006	Jul 28, 2016	Feb CAHN
!		MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	Feb CHRS
		RITALIN LA					
		+ @ NOVARTIS	60MG	N021284	005	Oct 27, 2014	Feb DISC

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		IMPAX LABS INC	5MG	A091159	001	Mar 12, 2014	Feb CAHN
AB			10MG	A091159	002	Mar 12, 2014	Feb CAHN
AB			20MG	A091159	003	Mar 12, 2014	Feb CAHN
AB		NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017	Feb NEWA
AB			10MG	A207587	002	Mar 03, 2017	Feb NEWA
AB			20MG	A207587	003	Mar 03, 2017	Feb NEWA

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		NOSTRUM LABS INC	2.5MG	A204954	001	Jan 26, 2017	Jan NEWA
AB			5MG	A204954	002	Jan 26, 2017	Jan NEWA
AB			10MG	A204954	003	Jan 26, 2017	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

RITALIN-SR

AB		+ NOVARTIS	20MG	N018029	001	Mar 30, 1982	Feb CRLD
----	--	------------	------	---------	-----	--------------	----------

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

>D>	AB	SANDOZ	40MG/ML	A040719	001	Jan 29, 2009	Mar CAHN
>D>	AB		80MG/ML	A040719	002	Jan 29, 2009	Mar CAHN
>A>	AB	SANDOZ INC	40MG/ML	A040719	001	Jan 29, 2009	Mar CAHN
>A>	AB		80MG/ML	A040719	002	Jan 29, 2009	Mar CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

A-METHAPRED

@	HOSPIRA INC	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Jan DISC
@		EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Jan DISC

METIPRANOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
METIPRANOLOL

AT	SANDOZ INC	0.3%	A075720	001	Aug 06, 2001	Feb	CAHN
----	------------	------	---------	-----	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDETABLET;ORAL  
METOCLOPRAMIDE HYDROCHLORIDE

@	NORTHSTAR HLTHCARE	EQ 5MG BASE	A078374	001	Nov 30, 2007	Feb	DISC
@		EQ 10MG BASE	A078374	002	Nov 30, 2007	Feb	DISC

METOPROLOL SUCCINATETABLET, EXTENDED RELEASE;ORAL  
TOPROL-XL

AB	+	ARALEZ PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Jan	CAHN
AB	+	!	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Jan	CAHN
AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Jan	CAHN
AB	+	!	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Jan	CAHN

METOPROLOL TARTRATEINJECTABLE;INJECTION  
METOPROLOL TARTRATE

>D>	AP	SANDOZ	1MG/ML	A077360	001	Oct 02, 2007	Mar	CAHN
>A>	AP	SANDOZ INC	1MG/ML	A077360	001	Oct 02, 2007	Mar	CAHN
	AP	WEST-WARD PHARMS INT	1MG/ML	A076495	001	Jul 07, 2003	Jan	CAHN

METRONIDAZOLEGEL;TOPICAL  
METRONIDAZOLE

AB	TARO PHARM	1%	A204651	001	Mar 14, 2017	Feb	NEWA
----	------------	----	---------	-----	--------------	-----	------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDEOINTMENT;TOPICAL  
VUSION

+	!	MYLAN PHARMS INC	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jan	CAHN
---	---	------------------	------------------	---------	-----	--------------	-----	------

MIDAZOLAM HYDROCHLORIDEINJECTABLE;INJECTION  
MIDAZOLAM HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075324	001	Jun 20, 2000	Mar	CAHN
>D>	AP		EQ 5MG BASE/ML	A075324	002	Jun 20, 2000	Mar	CAHN
>A>		FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Mar	NEWA
	AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jan	CAHN
	AP		EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	Jan	CAHN
>A>	AP		EQ 1MG BASE/ML	A075324	001	Jun 20, 2000	Mar	CAHN
	AP		EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Jan	CAHN
	AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jan	CAHN
	AP		EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	Jan	CAHN
>A>	AP		EQ 5MG BASE/ML	A075324	002	Jun 20, 2000	Mar	CAHN
	AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Jan	CAHN

MIDODRINE HYDROCHLORIDETABLET;ORAL  
PROAMATINE

+	@	SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Feb	CRLD
+	@		5MG	N019815	002	Sep 06, 1996	Feb	CRLD
+	@		10MG	N019815	003	Mar 20, 2002	Feb	CRLD

MILNACIPRAN HYDROCHLORIDETABLET;ORAL  
SAVELLA

AB	+	ALLERGAN SALES LLC	12.5MG	N022256	001	Jan 14, 2009	Feb	CAHN
AB	+		25MG	N022256	002	Jan 14, 2009	Feb	CAHN
AB	+	!	50MG	N022256	003	Jan 14, 2009	Feb	CAHN
AB	+		100MG	N022256	004	Jan 14, 2009	Feb	CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

>D>	@ EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Mar	CAHN
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jan	CAHN
AP		EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan	CAHN
>A>	@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Mar	CAHN
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	@ EUROHLTH INTL SARL	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002	Mar	CAHN
>A>	@ WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002	Mar	CAHN
AP		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jan	CAHN
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jan	CAHN
	PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER						
+	@ SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan	CRLD
+	@	EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan	CRLD
+	@	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan	CRLD
+	@	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan	CRLD

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MYRBETRIQ

+	!	APGDI	25MG	N202611	001	Jun 28, 2012	Feb	CHRS
---	---	-------	------	---------	-----	--------------	-----	------

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB	AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan	CAHN
AB		30MG	A077376	003	Dec 08, 2005	Jan	CAHN
AB		45MG	A077376	004	Feb 28, 2006	Jan	CAHN

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan	CAHN	
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan	CAHN	
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan	CAHN	
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan	CAHN	
	MUTAMYCIN							
+	@	BRISTOL	5MG/VIAL	N050450	001		Jan	CRLD
+	@		20MG/VIAL	N050450	002		Jan	CRLD

MOMETASONE FUROATE

SPRAY, METERED; NASAL

MOMETASONE FUROATE

>A>	AB	AMNEAL PHARMS	EQ 0.05MG BASE/SPRAY	A207989	001	Apr 03, 2017	Mar	NEWA
-----	----	---------------	----------------------	---------	-----	--------------	-----	------

MORPHINE SULFATE

SOLUTION; ORAL

MORPHINE SULFATE

AA	+	WEST-WARD PHARMS INT	10MG/5ML	N022195	001	Mar 17, 2008	Jan	CAHN
AA	+		20MG/5ML	N022195	002	Mar 17, 2008	Jan	CAHN
AA	+	!	100MG/5ML	N022195	003	Jan 25, 2010	Jan	CAHN

TABLET; ORAL

MORPHINE SULFATE

+	WEST-WARD PHARMS INT	15MG	N022207	001	Mar 17, 2008	Jan	CAHN
+	!	30MG	N022207	002	Mar 17, 2008	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

ARYMO ER

+	EGALET	15MG	N208603	001	Jan 09, 2017	Jan	NEWA
+		30MG	N208603	002	Jan 09, 2017	Jan	NEWA
+		60MG	N208603	003	Jan 09, 2017	Jan	NEWA

MORPHABOND ER

+	DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Jan	CTNA
+		30MG	N206544	002	Oct 02, 2015	Jan	CTNA
+		60MG	N206544	003	Oct 02, 2015	Jan	CTNA
+	!	100MG	N206544	004	Oct 02, 2015	Jan	CTNA

TABLET, EXTENDED RELEASE;ORAL  
MORPHINE SULFATE

>A>	AB	SUN PHARM INDS	15MG	A205634	001	Aug 25, 2016	Mar CAHN
>A>	AB		30MG	A205634	002	Aug 25, 2016	Mar CAHN
>A>	AB		60MG	A205634	003	Aug 25, 2016	Mar CAHN
>A>	AB		100MG	A205634	004	Aug 25, 2016	Mar CAHN
>A>	AB		200MG	A205634	005	Aug 25, 2016	Mar CAHN
>D>	AB	SUN PHARM INDS LTD	15MG	A205634	001	Aug 25, 2016	Mar CAHN
>D>	AB		30MG	A205634	002	Aug 25, 2016	Mar CAHN
>D>	AB		60MG	A205634	003	Aug 25, 2016	Mar CAHN
>D>	AB		100MG	A205634	004	Aug 25, 2016	Mar CAHN
>D>	AB		200MG	A205634	005	Aug 25, 2016	Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL  
MOXIFLOXACIN HYDROCHLORIDE

AB		NOVEL LABS INC	EQ 400MG BASE	A207285	001	Feb 13, 2017	Jan NEWA
----	--	----------------	---------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION  
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		AKORN INC	500MG/VIAL	A204043	001	Feb 28, 2017	Feb NEWA
>A>	AP	MYLAN LABS LTD	500MG/VIAL	A203859	001	Mar 31, 2017	Mar NEWA

NABILONE

CAPSULE;ORAL  
CESAMET

>D>	+	MEDA PHARMS	1MG	N018677	001	Dec 26, 1985	Mar CAHN
>A>	+	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985	Mar CAHN

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL  
NAFTIFINE HYDROCHLORIDE

>A>	AB	TOLMAR	2%	A206960	001	Apr 10, 2017	Mar NEWA
-----	----	--------	----	---------	-----	--------------	----------

>A> NALDEMEDINE TOSYLATE

>A> TABLET;ORAL  
>A> SYMPROIC

>A>	+	SHIONOGI INC	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Mar NEWA
-----	---	--------------	---------------	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION  
NALOXONE  
@ WEST-WARD PHARMS INT 0.4MG/ML  
@ 0.4MG/ML  
NALOXONE HYDROCHLORIDE

AP		AKORN	0.4MG/ML	A208871	001	Feb 28, 2017	Feb NEWA
AP			0.4MG/ML	A208872	001	Mar 14, 2017	Feb NEWA

SPRAY, METERED;NASAL  
NARCAN

+ ADAPT 2MG/SPRAY

N208411	002	Jan 24, 2017	Jan NEWA
---------	-----	--------------	----------

NAPROXEN

TABLET;ORAL  
NAPROXEN

AB		AUROBINDO PHARMA LTD	250MG	A200429	001	Nov 08, 2011	Jan CAHN
AB			375MG	A200429	002	Nov 08, 2011	Jan CAHN
AB			500MG	A200429	003	Nov 08, 2011	Jan CAHN

NATAMYCIN

SUSPENSION;OPHTHALMIC  
NATACYN

+	!	NOVARTIS PHARMS CORP	5%	N050514	001		Jan CAHN
---	---	----------------------	----	---------	-----	--	----------

NELFINAVIR MESYLATE

POWDER;ORAL  
VIRACEPT  
@ AGOURON PHARMS EQ 50MG BASE/SCOOPFUL

N020778	001	Mar 14, 1997	Jan CAHN
---------	-----	--------------	----------

TABLET;ORAL  
VIRACEPT

+
 ! | AGOURON PHARMS | EQ 250MG BASE | N020779 | 001 | Mar 14, 1997 | Jan CAHN |

N021503	001	Apr 30, 2003	Jan CAHN
---------	-----	--------------	----------

NEOMYCIN SULFATE

SOLUTION;ORAL  
NEO-FRADIN  
@ X GEN PHARMS

EQ 87.5MG BASE/5ML

A065010 001 May 23, 2002 Feb DISC

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL  
NEVIRAPINE

>A>	AB	AUROBINDO PHARMA LTD	400MG	A207698	001	Feb 28, 2017	Mar	CAHN
>D>	AB	AUROBINDO PHARMA USA	400MG	A207698	001	Feb 28, 2017	Mar	CAHN
	AB		400MG	A207698	001	Feb 28, 2017	Feb	NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION  
NICARDIPINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	Jan	CAHN
----	--	----------------------	----------------------	---------	-----	--------------	-----	------

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

EXELA PHARMA SCIENCE 20MG/200ML (0.1MG/ML)

N022276 002 Apr 07, 2016 Feb NEWA

40MG/200ML (0.2MG/ML)

N022276 003 Apr 07, 2016 Feb NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL  
NIFEDIPINE

>D>	AB2	MATRIX LABS LTD	30MG	A090602	001	Sep 13, 2010	Mar	CAHN
>D>	AB2		60MG	A090602	002	Sep 13, 2010	Mar	CAHN
>D>	AB2		90MG	A090602	003	Sep 13, 2010	Mar	CAHN
>A>	AB2	MYLAN LABS LTD	30MG	A090602	001	Sep 13, 2010	Mar	CAHN
>A>	AB2		60MG	A090602	002	Sep 13, 2010	Mar	CAHN
>A>	AB2		90MG	A090602	003	Sep 13, 2010	Mar	CAHN

>A> NIRAPARIB TOSYLATE

>A> CAPSULE;ORAL  
>A> ZEJULA

>A>	+	TESARO INC	EQ 100MG BASE	N208447	001	Mar 27, 2017	Mar	NEWA
-----	---	------------	---------------	---------	-----	--------------	-----	------

NITROGLYCERIN

OINTMENT;TRANSDERMAL  
NITROGLYCERIN

! FOUGERA PHARMS INC 2%

A087355 001 Jul 08, 1988 Jan CAHN

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION  
NOREPINEPHRINE BITARTRATE

AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Jan	CAHN
----	--	----------------------	----------------	---------	-----	--------------	-----	------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL  
NORTRIPTYLINE HYDROCHLORIDE

>D>	AB	TARO	EQ 10MG BASE	A075520	004	May 08, 2000	Mar	CAHN
>D>	AB		EQ 25MG BASE	A075520	003	May 08, 2000	Mar	CAHN
>D>	AB		EQ 50MG BASE	A075520	001	May 08, 2000	Mar	CAHN
>D>	AB		EQ 75MG BASE	A075520	002	May 08, 2000	Mar	CAHN
>A>	AB	TARO PHARM	EQ 10MG BASE	A075520	004	May 08, 2000	Mar	CAHN
>A>	AB		EQ 25MG BASE	A075520	003	May 08, 2000	Mar	CAHN
>A>	AB		EQ 50MG BASE	A075520	001	May 08, 2000	Mar	CAHN
>A>	AB		EQ 75MG BASE	A075520	002	May 08, 2000	Mar	CAHN

NYSTATIN

SUSPENSION;ORAL  
NYSTATIN

AA		FOUGERA PHARMS INC	100,000 UNITS/ML	A062517	001	Jun 07, 1984	Jan	CAHN
----	--	--------------------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL  
MYCOLOG-II

@ MYLAN PHARMS INC 100,000 UNITS/GM;0.1%  
NYSTATIN AND TRIAMCINOLONE ACETONIDE

A062606 001 May 15, 1985 Jan CAHN

AT		FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062599	001	Oct 08, 1985	Jan	CAHN
----	--	--------------------	-----------------------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

## MYCOLOG-II

	@ MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985	Jan CAHN
	NYSTATIN AND TRIAMCINOLONE ACETONIDE					
AT	DR REDDYS LABS LTD	100,000 UNITS/GM;0.1%	A207741	001	Jan 31, 2017	Jan NEWA
AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062602	001	Oct 09, 1985	Jan CAHN

OFLOXACIN

## SOLUTION/DROPS;OPHTHALMIC

## OFLOXACIN

AT	SANDOZ INC	0.3%	A076231	001	May 14, 2004	Feb CAHN
----	------------	------	---------	-----	--------------	----------

## SOLUTION/DROPS;OTIC

## OFLOXACIN

AT	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Feb CAHN
----	------------	------	---------	-----	--------------	----------

OLANZAPINE

## TABLET;ORAL

## OLANZAPINE

>D>	AB	MYLAN	2.5MG	A076866	001	Apr 23, 2012	Mar CAHN
>D>	AB		5MG	A076866	002	Apr 23, 2012	Mar CAHN
>D>	AB		7.5MG	A076866	003	Apr 23, 2012	Mar CAHN
>D>	AB		10MG	A076866	004	Apr 23, 2012	Mar CAHN
>D>	AB		15MG	A076866	005	Apr 23, 2012	Mar CAHN
>D>	AB		20MG	A076866	006	Apr 23, 2012	Mar CAHN
>A>	AB	MYLAN PHARMS INC	2.5MG	A076866	001	Apr 23, 2012	Mar CAHN
>A>	AB		5MG	A076866	002	Apr 23, 2012	Mar CAHN
>A>	AB		7.5MG	A076866	003	Apr 23, 2012	Mar CAHN
>A>	AB		10MG	A076866	004	Apr 23, 2012	Mar CAHN
>A>	AB		15MG	A076866	005	Apr 23, 2012	Mar CAHN
>A>	AB		20MG	A076866	006	Apr 23, 2012	Mar CAHN

OLAPARIB

## CAPSULE;ORAL

## LYNPARZA

>D>		ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Mar CRLD
>A>		+	50MG	N206162	001	Dec 19, 2014	Mar CRLD

OLOPATADINE HYDROCHLORIDE

## SPRAY, METERED;NASAL

## OLOPATADINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	0.665MG/SPRAY	A202853	001	Jan 31, 2017	Jan NEWA
----	----------------	---------------	---------	-----	--------------	----------

OLSALAZINE SODIUM

## CAPSULE;ORAL

## DIPENTUM

>D>		+	MEDA PHARMS	250MG	N019715	001	Jul 31, 1990	Mar CAHN
>A>		+	MYLAN SPECIALITY LP	250MG	N019715	001	Jul 31, 1990	Mar CAHN

OMEPRAZOLE

## CAPSULE, DELAYED REL PELLETS;ORAL

## OMEPRAZOLE

AB	AUROBINDO PHARMA LTD	10MG	A203270	001	Aug 19, 2015	Jan CAHN
AB		20MG	A203270	002	Aug 19, 2015	Jan CAHN
AB		40MG	A203270	003	Aug 19, 2015	Jan CAHN

OMEPRAZOLE; SODIUM BICARBONATE

## FOR SUSPENSION;ORAL

## OMEPRAZOLE AND SODIUM BICARBONATE

AB	AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jan CTEC	
AB		40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jan CTEC	
AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jan CMFD	
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jan CMFD	
	ZEGERID						
AB	+	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jan CTEC
AB	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jan CTEC

ONDANSETRON

## TABLET, ORALLY DISINTEGRATING;ORAL

## ONDANSETRON

>A>		@ CHARTWELL MOLECULES	4MG	A076506	001	Dec 26, 2006	Mar CAHN
>A>		@	8MG	A076506	002	Dec 26, 2006	Mar CAHN
>A>		@	16MG	A077406	001	Dec 26, 2006	Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

## ONDANSETRON

>A>	@	24MG	A077406	002	Dec 26, 2006	Mar	CAHN
>D>	@ CHARTWELL PHARMS LLC	4MG	A076506	001	Dec 26, 2006	Mar	CAHN
>D>	@	8MG	A076506	002	Dec 26, 2006	Mar	CAHN
>D>	@	16MG	A077406	001	Dec 26, 2006	Mar	CAHN
>D>	@	24MG	A077406	002	Dec 26, 2006	Mar	CAHN

ONDANSETRON HYDROCHLORIDE

## INJECTABLE;INJECTION

## ONDANSETRON HYDROCHLORIDE

>D>	AP	SANDOZ	EQ 2MG BASE/ML	A077430	001	Jun 27, 2007	Mar	CAHN
>A>	AP	SANDOZ INC	EQ 2MG BASE/ML	A077430	001	Jun 27, 2007	Mar	CAHN
	AP	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Jan	CAHN
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
>D>	AP	SANDOZ	EQ 2MG BASE/ML	A077551	001	Jun 27, 2007	Mar	CAHN
>A>	AP	SANDOZ INC	EQ 2MG BASE/ML	A077551	001	Jun 27, 2007	Mar	CAHN
	AP	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan	CAHN
	AP		EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan	CAHN
		ZOFRAN						
>D>	@	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar	CRLD
>A>	+ @		EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar	CRLD
		ZOFRAN PRESERVATIVE FREE						
>D>	@	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar	CRLD
>A>	+ @		EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar	CRLD

OSELTAMIVIR PHOSPHATE

## CAPSULE;ORAL

## OSELTAMIVIR PHOSPHATE

AB		NESHER PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Feb	NEWA
AB			EQ 45MG BASE	A208578	002	Feb 24, 2017	Feb	NEWA
AB			EQ 75MG BASE	A208578	003	Feb 24, 2017	Feb	NEWA

OSPHEMIFENE

## TABLET;ORAL

## OSPHEMIFENE

>A>	+!	DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Mar	CAHN
>D>	+!	SHIONOGI INC	60MG	N203505	001	Feb 26, 2013	Mar	CAHN

OXALIPLATIN

## INJECTABLE;IV (INFUSION)

## ELOXATIN

	+ @	SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jan	CRLD
		OXALIPLATIN						
>A>	AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Mar	NEWA
>A>	AP		100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Mar	NEWA
>A>	AP		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Mar	NEWA
	AP	CIPLA LTD	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Jan	NEWA
	AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Jan	NEWA
	AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Jan	NEWA
	AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Jan	NEWA
	AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Jan	NEWA
	AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jan	NEWA
	AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jan	NEWA
	AP	! QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jan	CTEC

OXAZEPAM

## TABLET;ORAL

## OXAZEPAM

	@	SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jan	CAHN
--	---	----------------	------	---------	-----	--------------	-----	------

OXYBUTYNYN

## GEL, METERED;TRANSDERMAL

## GELNIQUE 3%

	+ @	ALLERGAN SALES LLC	3%	N202513	001	Dec 07, 2011	Feb	DISC
--	-----	--------------------	----	---------	-----	--------------	-----	------

OXYBUTYNYN CHLORIDE

## SYRUP;ORAL

## DITROPAN

	+ @	ORTHO MCNEIL JANSSEN	5MG/5ML	N018211	001		Jan	CRLD
--	-----	----------------------	---------	---------	-----	--	-----	------



OXYMETAZOLINE HYDROCHLORIDECREAM; TOPICAL  
RHOFAGE

+! ALLERGAN INC 1% N208552 001 Jan 18, 2017 Jan NEWA

OXYMETHOLONETABLET; ORAL  
ANADROL-50>D> +! MEDA PHARMS 50MG N016848 001 Mar CAHN  
>A> +! MYLAN SPECIALITY LP 50MG N016848 001 Mar CAHNPANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE; ORAL  
PANTOPRAZOLE SODIUM>A> AB SUN PHARM INDS LTD EQ 20MG BASE A077058 001 Sep 10, 2007 Mar CAHN  
>A> AB EQ 40MG BASE A077058 002 Sep 10, 2007 Mar CAHN  
>D> AB SUN PHARMA GLOBAL EQ 20MG BASE A077058 001 Sep 10, 2007 Mar CAHN  
>D> AB EQ 40MG BASE A077058 002 Sep 10, 2007 Mar CAHNPARICALCITOLSOLUTION; INTRAVENOUS  
PARICALCITOLAP AMNEAL PHARMS CO 0.002MG/ML (0.002MG/ML) A206699 001 Mar 09, 2017 Feb NEWA  
AP 0.005MG/ML (0.005MG/ML) A206699 002 Mar 09, 2017 Feb NEWA  
AP 0.01MG/2ML (0.005MG/ML) A206699 003 Mar 09, 2017 Feb NEWAPAROXETINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
PAROXETINE HYDROCHLORIDEAB LUPIN LTD EQ 12.5MG BASE A204134 001 Jan 20, 2017 Jan NEWA  
AB EQ 25MG BASE A204134 002 Jan 20, 2017 Jan NEWA  
AB EQ 37.5MG BASE A204134 003 Jan 20, 2017 Jan NEWAPENCICLOVIRCREAM; TOPICAL  
DENA VIR

+! MYLAN PHARMS INC 1% N020629 001 Sep 24, 1996 Jan CAHN

PENICILLAMINETABLET; ORAL  
DEPEN>D> +! MEDA PHARMS 250MG N019854 001 Mar CAHN  
>A> +! MYLAN SPECIALITY LP 250MG N019854 001 Mar CAHNPENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL  
TREN TAL

+ @ US PHARM HOLDINGS 400MG N018631 001 Aug 30, 1984 Jan CRLD

PERMETHRINCREAM; TOPICAL  
ELIMITE

AB +! MYLAN PHARMS INC 5% N019855 001 Aug 25, 1989 Jan CAHN

PERPHENAZINETABLET; ORAL  
PERPHENAZINE

@ ANI PHARMS INC 4MG A089708 001 Sep 10, 1987 Jan CAHN

PHENOXYBENZAMINE HYDROCHLORIDECAPSULE; ORAL  
PHENOXYBENZAMINE HYDROCHLORIDE

AB PAR PHARM INC 10MG A204522 001 Jan 24, 2017 Jan NEWA

PHENTERMINE HYDROCHLORIDETABLET; ORAL  
PHENTERMINE HYDROCHLORIDE>A> AA KVK TECH INC 8MG A203436 001 Mar 17, 2017 Mar NEWA  
AA PRINSTON INC 37.5MG A040377 001 Jan 04, 2002 Feb CAHN

PHENYLEPHRINE HYDROCHLORIDESOLUTION; IV (INFUSION)  
VAZCULEP

+	AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jan CAHN
+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jan CAHN
+	!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jan CAHN

PHENYTOINTABLET, CHEWABLE; ORAL  
DILANTIN

AB	!	PFIZER	50MG	A084427	001	Feb CAHN
----	---	--------	------	---------	-----	----------

PHENYTOIN SODIUMCAPSULE; ORAL  
DILANTIN

AB	!	PARKE-DAVIS	30MG EXTENDED	A084349	001	Feb CAHN
AB	!		100MG EXTENDED	A084349	002	Feb CAHN

INJECTABLE; INJECTION  
PHENYTOIN SODIUM

>D>	AP	HOSPIRA	50MG/ML	A089521	001	Mar 17, 1987	Mar DISC
>A>		@	50MG/ML	A089521	001	Mar 17, 1987	Mar DISC

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

>A>	AB	ALLIED PHARMA INC	5MG	A076963	001	Dec 22, 2004	Mar CAHN
>A>	AB		7.5MG	A076963	002	Feb 27, 2007	Mar CAHN
>D>	AB	ROXANE	5MG	A076963	001	Dec 22, 2004	Mar CAHN
>D>	AB		7.5MG	A076963	002	Feb 27, 2007	Mar CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		APOLLO PHARMS INC	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan NEWA
AP			EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan NEWA
AP			EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan NEWA
AP			EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan NEWA
>A>	AP	WOCKHARDT BIO AG	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Mar NEWA
>A>	AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Mar NEWA
>A>	AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Mar NEWA
>A>	AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A207146	001	Mar 17, 2017	Mar NEWA

PIRFENIDONE

TABLET; ORAL

ESBRIET

+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan NEWA
+	@	534MG	N208780	002	Jan 11, 2017	Jan DISC
+	!	801MG	N208780	003	Jan 11, 2017	Jan NEWA

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

AB		ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan NEWA
AB			EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan NEWA
AB			EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan NEWA
AB		SAWAI USA	EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan NEWA
AB			EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan NEWA
AB			EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan NEWA

PLECANATIDE

TABLET; ORAL

TRULANCE

+	!	SYNERGY PHARMS	3MG	N208745	001	Jan 19, 2017	Jan NEWA
---	---	----------------	-----	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

>A>	AA	BRECKENRIDGE PHARM	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017	Mar	CAHN
>D>	AA	BRECKENRIDGE PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017	Mar	CAHN
	AA		420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017	Feb	NEWA
		TRILYTE						
>D>	AA	MEDA PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A076491	001	Feb 05, 2004	Mar	CAHN
>A>	AA	MYLAN PHARMS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A076491	001	Feb 05, 2004	Mar	CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

>D>		© MEDA PHARMS	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Mar	CAHN
>D>		©	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Mar	CAHN
>D>		©	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Mar	CAHN
>D>		©	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Mar	CAHN
>D>		©	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Mar	CAHN
>A>		© MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Mar	CAHN
>A>		©	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Mar	CAHN
>A>		©	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Mar	CAHN
>A>		©	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Mar	CAHN
>A>		©	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Mar	CAHN
		COLYTE WITH FLAVOR PACKS						
>D>	AA	MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Mar	CAHN
>A>	AA	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Mar	CAHN
		COLYTE-FLAVORED						
>D>		© MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Mar	CAHN
>D>		©	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Mar	CAHN
>A>		© MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Mar	CAHN
>A>		©	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Mar	CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		SANDOZ INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb	CAHN
----	--	------------	--------------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

>A>	AB	ADARE PHARMS INC	8MEQ	A208864	001	Mar 17, 2017	Mar	NEWA
>A>	AB		10MEQ	A208864	002	Mar 17, 2017	Mar	NEWA

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	+	ICU MEDCL	14.9MG/ML	N020161	005	Nov 30, 1992	Feb	CAHN
AP	+		745MG/100ML	N020161	001	Nov 30, 1992	Feb	CAHN

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	+	ICU MEDCL	29.8MG/ML	N020161	006	Aug 11, 1998	Feb	CAHN
AP	+		1.49GM/100ML	N020161	002	Nov 30, 1992	Feb	CAHN

## INJECTABLE;INJECTION

		POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER						
AP	+!	ICU MEDCL	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb	CAHN
		POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER						
AP	+!	ICU MEDCL	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb	CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE;INJECTION

		POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		ICU MEDCL	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	Feb	CAHN
		POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ICU MEDCL	149MG/100ML;900MG/100ML	N019686	001	Oct 17, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ICU MEDCL	298MG/100ML;900MG/100ML	N019686	002	Oct 17, 1988	Feb	CAHN

POTASSIUM CITRATE

## TABLET, EXTENDED RELEASE;ORAL

		POTASSIUM CITRATE						
AB		IMPAX LABS INC	5MEQ	A077440	001	Jun 09, 2006	Feb	CAHN
AB			10MEQ	A077440	002	Jun 09, 2006	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

## TABLET;ORAL

		PRAMIPEXOLE DIHYDROCHLORIDE						
	@	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan	DISC
	@		0.25MG	A091254	002	Nov 30, 2010	Jan	DISC
	@		0.5MG	A091254	003	Nov 30, 2010	Jan	DISC
	@		0.75MG	A091254	004	Nov 30, 2010	Jan	DISC
	@		1MG	A091254	005	Nov 30, 2010	Jan	DISC
	@		1.5MG	A091254	006	Nov 30, 2010	Jan	DISC
	@	SANDOZ	0.125MG	A090190	001	Jul 06, 2010	Feb	DISC
	@		0.25MG	A090190	002	Jul 06, 2010	Feb	DISC
	@		0.5MG	A090190	003	Jul 06, 2010	Feb	DISC
	@		0.75MG	A090190	006	Oct 08, 2010	Feb	DISC
	@		1MG	A090190	004	Jul 06, 2010	Feb	DISC
	@		1.5MG	A090190	005	Jul 06, 2010	Feb	DISC
		TABLET, EXTENDED RELEASE;ORAL						
		PRAMIPEXOLE DIHYDROCHLORIDE						
AB		MACLEODS PHARMS LTD	3.75MG	A206156	007	Jan 23, 2017	Jan	NEWA

PRAVASTATIN SODIUM

## TABLET;ORAL

		PRAVASTATIN SODIUM						
AB		AUROBINDO PHARMA LTD	10MG	A203367	001	Feb 02, 2017	Jan	NEWA
AB			20MG	A203367	002	Feb 02, 2017	Jan	NEWA
AB			40MG	A203367	003	Feb 02, 2017	Jan	NEWA
AB			80MG	A203367	004	Feb 02, 2017	Jan	NEWA

PREDNISOLONE

## SYRUP;ORAL

		PREDNISOLONE						
>D>	AA	ALPHARMA	15MG/5ML	A040323	001	May 13, 1999	Mar	CAHN
>A>	AA	VISTAPHARM	15MG/5ML	A040323	001	May 13, 1999	Mar	CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

## SOLUTION/DROPS;OPHTHALMIC

		SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE						
AT	!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb	CAHN
AT		SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Feb	CAHN

PREDNISONE

## TABLET;ORAL

		METICORTEN						
>D>		@ SCHERING	1MG	N009766	002		Mar	CMS1
>A>	+	@	1MG	N009766	002		Mar	CMS1
>D>		@	5MG	N009766	001		Mar	CMS1
>A>	+	@	5MG	N009766	001		Mar	CMS1
		PREDNISONE						
>D>	AB	CONTRACT PHARMACAL	5MG	A080209	001		Mar	DISC
>A>		@	5MG	A080209	001		Mar	DISC
	AB	MYLAN PHARMS INC	5MG	A080292	001		Jan	CAHN
	AB		10MG	A088832	001	Dec 04, 1985	Jan	CAHN

	TABLET;ORAL								
	PREDNISONE								
AB		20MG		A 083677	001			Jan	CAHN
	<u>PROBENECID</u>								
	TABLET;ORAL								
	BENEMID								
	+ @ MERCK	500MG		N 007898	004			Jan	CRLD
	<u>PROCAINAMIDE HYDROCHLORIDE</u>								
	INJECTABLE; INJECTION								
	PROCAINAMIDE HYDROCHLORIDE								
>D>	@ EUROHLTH INTL SARL	500MG/ML		A 089030	001	Apr 17, 1986		Mar	CAHN
	@ WEST-WARD PHARMS INT	100MG/ML		A 089029	001	Apr 17, 1986		Jan	CAHN
>A>	@	500MG/ML		A 089030	001	Apr 17, 1986		Mar	CAHN
	<u>PROCARBAZINE HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	MATULANE								
	+! LEADIANT BIOSCI INC	EQ 50MG BASE		N 016785	001			Feb	CAHN
	<u>PROCHLORPERAZINE EDISYLATE</u>								
	INJECTABLE; INJECTION								
	COMPAZINE								
	+ @ GLAXOSMITHKLINE	EQ 5MG BASE/ML		N 010742	002			Feb	CRLD
	PROCHLORPERAZINE EDISYLATE								
>D>	@ AMPHASTAR PHARMS INC	EQ 5MG BASE/ML		A 040540	001	May 28, 2004		Mar	CAHN
>A>	@ ATHENEX INC	EQ 5MG BASE/ML		A 040540	001	May 28, 2004		Mar	CAHN
	@ WEST-WARD PHARMS INT	EQ 5MG BASE/ML		A 089523	001	May 03, 1988		Jan	CAHN
AP		EQ 5MG BASE/ML		A 089903	001	Aug 29, 1989		Jan	CAHN
	<u>PROGESTERONE</u>								
	CAPSULE;ORAL								
	PROGESTERONE								
AB	DR REDDYS LABS INC	100MG		A 208801	001	Feb 28, 2017		Feb	NEWA
AB		200MG		A 208801	002	Feb 28, 2017		Feb	NEWA
	INJECTABLE; INJECTION								
	PROGESTERONE								
AO	+! ACTAVIS LABS UT INC	50MG/ML		N 017362	002			Feb	CAHN
	<u>PROMETHAZINE HYDROCHLORIDE</u>								
	SUPPOSITORY;RECTAL								
	PHENERGAN								
	+ @ MYLAN PHARMS INC	50MG		N 011689	001			Jan	CAHN
	TABLET;ORAL								
	PROMETHAZINE HYDROCHLORIDE								
AB	PRINSTON INC	12.5MG		A 040622	001	Jul 18, 2006		Feb	CAHN
AB		25MG		A 040622	002	Jul 18, 2006		Feb	CAHN
AB		50MG		A 040622	003	Jul 18, 2006		Feb	CAHN
	<u>PROPIOMAZINE HYDROCHLORIDE</u>								
	INJECTABLE; INJECTION								
	LARGON								
	@ WEST-WARD PHARMS INT	20MG/ML		N 012382	002			Jan	CAHN
	<u>PROPRANOLOL HYDROCHLORIDE</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	INNOPRAN XL								
>A> BX	ANI PHARMS INC	80MG		N 021438	001	Mar 12, 2003		Mar	CAHN
>A> BX		120MG		N 021438	002	Mar 12, 2003		Mar	CAHN
>D> BX	GLAXOSMITHKLINE LLC	80MG		N 021438	001	Mar 12, 2003		Mar	CAHN
>D> BX		120MG		N 021438	002	Mar 12, 2003		Mar	CAHN
	PROPRANOLOL HYDROCHLORIDE								
	@ UPSHER SMITH	60MG		A 078311	001	Mar 06, 2009		Feb	DISC
	@	80MG		A 078311	002	Mar 06, 2009		Feb	DISC
	@	120MG		A 078311	003	Mar 06, 2009		Feb	DISC
	@	160MG		A 078311	004	Mar 06, 2009		Feb	DISC
	INJECTABLE; INJECTION								
	PROPRANOLOL HYDROCHLORIDE								
>D> AP	AMPHASTAR PHARMS INC	1MG/ML		A 075792	001	Aug 29, 2000		Mar	CAHN
>A> AP	ATHENEX INC	1MG/ML		A 075792	001	Aug 29, 2000		Mar	CAHN

		INJECTABLE; INJECTION							
		PROPRANOLOL HYDROCHLORIDE							
>D>		@ SANDOZ	1MG/ML	A076400	001	Feb 26, 2003	Mar	CAHN	
>A>		@ SANDOZ INC	1MG/ML	A076400	001	Feb 26, 2003	Mar	CAHN	
		TABLET; ORAL							
		INDERAL							
		+ @ WYETH PHARMS INC	40MG	N016418	002		Jan	CRLD	
		<u>PROTAMINE SULFATE</u>							
		INJECTABLE; INJECTION							
		PROTAMINE SULFATE							
>D>		@ EUROHLTH INTL SARL	10MG/ML	A089474	001	Nov 05, 1986	Mar	CAHN	
>A>		@ WEST-WARD PHARMS INT	10MG/ML	A089474	001	Nov 05, 1986	Mar	CAHN	
		@	10MG/ML	A089475	001	Nov 05, 1986	Jan	CAHN	
		<u>PYRIDOSTIGMINE BROMIDE</u>							
		TABLET; ORAL							
		PYRIDOSTIGMINE BROMIDE							
		@ IMPAX LABS INC	60MG	A040457	001	Dec 26, 2002	Feb	CAHN	
		<u>QUETIAPINE FUMARATE</u>							
		TABLET, EXTENDED RELEASE; ORAL							
		QUETIAPINE FUMARATE							
>A>	AB	ACCORD HLTHCARE	EQ 400MG BASE	A090681	004	Nov 01, 2016	Mar	CAHN	
>D>	AB	ACCORD HLTHCARE INC	EQ 400MG BASE	A090681	004	Nov 01, 2016	Mar	CAHN	
		<u>RABEPRAZOLE SODIUM</u>							
		TABLET, DELAYED RELEASE; ORAL							
		RABEPRAZOLE SODIUM							
	AB	AUROBINDO PHARMA LTD	20MG	A205761	001	Feb 17, 2017	Feb	NEWA	
	AB	KREMERS URBAN PHARMS	20MG	A090678	001	Nov 08, 2013	Jan	CAHN	
		<u>RAMIPRIL</u>							
		CAPSULE; ORAL							
		RAMIPRIL							
>A>	AB	ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	Mar	CAHN	
>A>	AB		2.5MG	A202392	002	Apr 15, 2014	Mar	CAHN	
>A>	AB		5MG	A202392	003	Apr 15, 2014	Mar	CAHN	
>A>	AB		10MG	A202392	004	Apr 15, 2014	Mar	CAHN	
>D>	AB	ACCORD HLTHCARE INC	1.25MG	A202392	001	Apr 15, 2014	Mar	CAHN	
>D>	AB		2.5MG	A202392	002	Apr 15, 2014	Mar	CAHN	
>D>	AB		5MG	A202392	003	Apr 15, 2014	Mar	CAHN	
>D>	AB		10MG	A202392	004	Apr 15, 2014	Mar	CAHN	
		<u>RANITIDINE HYDROCHLORIDE</u>							
		INJECTABLE; INJECTION							
		ZANTAC							
AP	+	TELIGENT PHARMA INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan	CAHN	
		SYRUP; ORAL							
		RANITIDINE HYDROCHLORIDE							
AA		AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010	Jan	CAHN	
		<u>RANOLAZINE</u>							
		TABLET, EXTENDED RELEASE; ORAL							
		RANEXA							
		+ GILEAD	500MG	N021526	002	Jan 27, 2006	Feb	CTEC	
		+	1GM	N021526	001	Feb 12, 2007	Feb	CTEC	
		RANOLAZINE							
		@ LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb	DISC	
		@	1GM	A201046	002	Jul 29, 2013	Feb	DISC	
		<u>REPAGLINIDE</u>							
		TABLET; ORAL							
		PRANDIN							
	AB	+ GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Feb	CAHN	
	AB	+	1MG	N020741	002	Dec 22, 1997	Feb	CAHN	
	AB	+	2MG	N020741	003	Dec 22, 1997	Feb	CAHN	

RIBAVIRINCAPSULE;ORAL  
RIBASPHERE

AB KADMON PHARMS LLC 200MG A076203 001 Apr 06, 2004 Jan CAHN

TABLET;ORAL  
RIBAVIRIN

AB KADMON PHARMS LLC 200MG A077456 001 Dec 05, 2005 Jan CAHN

AB 400MG A077456 002 Dec 05, 2005 Jan CAHN

AB ! 600MG A077456 003 Dec 05, 2005 Jan CAHN

>A> RIBOCICLIB SUCCINATE

&gt;A&gt; TABLET;ORAL

&gt;A&gt; KISQALI

&gt;A&gt; +! NOVARTIS PHARMS CORP EQ 200MG BASE N209092 001 Mar 13, 2017 Mar NEWA

RIFAMPININJECTABLE;INJECTION  
RIFAMPIN

AP WATSON PHARMS TEVA 600MG/VIAL A206736 001 Jan 19, 2016 Feb CAHN

AP WEST-WARD PHARMS INT 600MG/VIAL A064217 001 Oct 29, 1999 Jan CAHN

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

@ IMPAX LABS INC 100MG A075916 001 Nov 02, 2001 Feb CAHN

RISPERIDONE

TABLET;ORAL

RISPERIDONE

AB PRINSTON INC 0.25MG A078707 001 Dec 29, 2008 Feb CAHN

AB 0.5MG A078707 002 Dec 29, 2008 Feb CAHN

AB 1MG A078707 003 Dec 29, 2008 Feb CAHN

AB 2MG A078707 004 Dec 29, 2008 Feb CAHN

AB 3MG A078707 005 Dec 29, 2008 Feb CAHN

AB 4MG A078707 006 Dec 29, 2008 Feb CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB CADILA PHARMS LTD EQ 1.5MG BASE A203844 001 Feb 13, 2017 Jan NEWA

AB EQ 3MG BASE A203844 002 Feb 13, 2017 Jan NEWA

AB EQ 4.5MG BASE A203844 003 Feb 13, 2017 Jan NEWA

AB EQ 6MG BASE A203844 004 Feb 13, 2017 Jan NEWA

&gt;D&gt; AB SUN PHARM INDS EQ 1.5MG BASE A077131 001 Oct 22, 2007 Mar CAHN

&gt;D&gt; AB EQ 3MG BASE A077131 002 Oct 22, 2007 Mar CAHN

&gt;D&gt; AB EQ 4.5MG BASE A077131 003 Oct 22, 2007 Mar CAHN

&gt;D&gt; AB EQ 6MG BASE A077131 004 Oct 22, 2007 Mar CAHN

&gt;A&gt; AB SUN PHARM INDS LTD EQ 1.5MG BASE A077131 001 Oct 22, 2007 Mar CAHN

&gt;A&gt; AB EQ 3MG BASE A077131 002 Oct 22, 2007 Mar CAHN

&gt;A&gt; AB EQ 4.5MG BASE A077131 003 Oct 22, 2007 Mar CAHN

&gt;A&gt; AB EQ 6MG BASE A077131 004 Oct 22, 2007 Mar CAHN

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

&gt;A&gt; AB ECI PHARMS LLC EQ 5MG BASE A202047 001 Dec 31, 2012 Mar CAHN

&gt;A&gt; AB EQ 10MG BASE A202047 002 Dec 31, 2012 Mar CAHN

&gt;D&gt; AB NOSTRUM LABS INC EQ 5MG BASE A202047 001 Dec 31, 2012 Mar CAHN

&gt;D&gt; AB EQ 10MG BASE A202047 002 Dec 31, 2012 Mar CAHN

AB UNICHEM LABS LTD EQ 5MG BASE A207836 001 Mar 07, 2017 Feb NEWA

AB EQ 10MG BASE A207836 002 Mar 07, 2017 Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

AB PANACEA BIOTEC LTD EQ 5MG BASE A204722 001 Jan 11, 2017 Jan NEWA

AB EQ 10MG BASE A204722 002 Jan 11, 2017 Jan NEWA

AB UNICHEM LABS LTD EQ 5MG BASE A207835 001 Mar 07, 2017 Feb NEWA

AB EQ 10MG BASE A207835 002 Mar 07, 2017 Feb NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

>A>	AP	AUROBINDO PHARMA LTD	50MG/5ML (10MG/ML)	A206206	001	Apr 12, 2017	Mar	NEWA	
>A>	AP		100MG/10ML (10MG/ML)	A206206	002	Apr 12, 2017	Mar	NEWA	
>D>	AP	!	SANDOZ	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Mar	CAHN
>D>	AP	!		100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Mar	CAHN
>A>	AP	!	SANDOZ INC	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Mar	CAHN
>A>	AP	!		100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Mar	CAHN
	AP		WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A204679	001	Feb 28, 2017	Feb	NEWA
	AP			100MG/10ML (10MG/ML)	A204679	002	Feb 28, 2017	Feb	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB		ACCORD HLTHCARE INC	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Feb	NEWA
AB			EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Feb	NEWA
AB			EQ 1MG BASE	A204022	003	Feb 28, 2017	Feb	NEWA
AB			EQ 2MG BASE	A204022	004	Feb 28, 2017	Feb	NEWA
AB			EQ 3MG BASE	A204022	005	Feb 28, 2017	Feb	NEWA
AB			EQ 4MG BASE	A204022	006	Feb 28, 2017	Feb	NEWA
AB			EQ 5MG BASE	A204022	007	Feb 28, 2017	Feb	NEWA

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

>A>	AB	ACCORD HLTHCARE	5MG	A206434	001	Oct 31, 2016	Mar	CAHN
>A>	AB		10MG	A206434	002	Oct 31, 2016	Mar	CAHN
>A>	AB		20MG	A206434	003	Oct 31, 2016	Mar	CAHN
>A>	AB		40MG	A206434	004	Oct 31, 2016	Mar	CAHN
>D>	AB	ACCORD HLTHCARE INC	5MG	A206434	001	Oct 31, 2016	Mar	CAHN
>D>	AB		10MG	A206434	002	Oct 31, 2016	Mar	CAHN
>D>	AB		20MG	A206434	003	Oct 31, 2016	Mar	CAHN
>D>	AB		40MG	A206434	004	Oct 31, 2016	Mar	CAHN
>A>	AB	ALKEM LABS LTD	5MG	A206465	001	Mar 21, 2017	Mar	NEWA
>A>	AB		10MG	A206465	002	Mar 21, 2017	Mar	NEWA
>A>	AB		20MG	A206465	003	Mar 21, 2017	Mar	NEWA
>A>	AB		40MG	A206465	004	Mar 21, 2017	Mar	NEWA

SAFINAMIDE MESYLATE

TABLET; ORAL

XADAGO

>A>	+	NEWRON PHARMS US INC	50MG	N207145	001	Mar 21, 2017	Mar	NEWA
>A>	+	!	100MG	N207145	002	Mar 21, 2017	Mar	NEWA

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@	CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996	Jan	CAHN
@		5MG	A074641	001	Aug 02, 1996	Jan	CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

>A>	@	ALLIED PHARMA INC	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	CAHN
>D>	@	ROXANE	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	CAHN

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>A>	@	ALLIED PHARMA INC	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	CAHN
>A>	@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	CAHN
>A>	@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	CAHN
>D>	AB	MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007	Mar	DISC
>A>	@		EQ 25MG BASE	A076671	001	Feb 06, 2007	Mar	DISC
>D>	AB		EQ 50MG BASE	A076671	002	Feb 06, 2007	Mar	DISC
>A>	@		EQ 50MG BASE	A076671	002	Feb 06, 2007	Mar	DISC
>D>	AB		EQ 100MG BASE	A076671	003	Feb 06, 2007	Mar	DISC
>A>	@		EQ 100MG BASE	A076671	003	Feb 06, 2007	Mar	DISC
>D>	@	ROXANE	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	CAHN
>D>	@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	CAHN
>D>	@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	CAHN



SILODOSINCAPSULE;ORAL  
RAPAFLO

>D>	+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Mar	CFTG
>A>	AB	+	4MG	N022206	001	Oct 08, 2008	Mar	CFTG
>D>		+	8MG	N022206	002	Oct 08, 2008	Mar	CFTG
>A>	AB	+	8MG	N022206	002	Oct 08, 2008	Mar	CFTG
>A>		SILODOSIN						
>A>	AB	SANDOZ INC	4MG	A204726	001	Mar 31, 2017	Mar	NEWA
>A>	AB		8MG	A204726	002	Mar 31, 2017	Mar	NEWA

SIMVASTATINSUSPENSION;ORAL  
SIMVASTATIN

	+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Jan	CAHN
	+	!	40MG/5ML	N206679	002	Apr 21, 2016	Jan	CAHN

SODIUM BICARBONATEINJECTABLE;INJECTION  
SODIUM BICARBONATE

AP	!	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Feb	CTEC
AP	!		1MEQ/ML	A077394	002	Nov 09, 2005	Feb	CTEC
		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Feb	NEWA
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017	Feb	NEWA
			1MEQ/ML	A202495	001	Mar 06, 2017	Feb	NEWA
AP			1MEQ/ML	A202494	002	Mar 06, 2017	Feb	NEWA

SODIUM CHLORIDEINJECTABLE;INJECTION  
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	ICU MEDCL	450MG/100ML	N018090	001		Feb	CAHN
		SODIUM CHLORIDE 0.9%						
AP		WEST-WARD PHARMS INT	9MG/ML	A201850	001	Jan 20, 2012	Jan	CAHN
		SODIUM CHLORIDE 0.9%						
		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013	Jan	CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	+	ICU MEDCL	900MG/100ML	N016366	001		Feb	CAHN
		SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER						
	+	@ ABRAXIS PHARM	234MG/ML	N019329	001	Apr 22, 1987	Jan	CRLD
		SODIUM CHLORIDE IN PLASTIC CONTAINER						
>D>		HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Mar	CRLD
>A>	+		2.5MEQ/ML	N018897	001	Jul 20, 1984	Mar	CRLD
		SOLUTION;IRRIGATION						
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AT		ICU MEDCL	900MG/100ML	N017514	001		Feb	CAHN
AT			900MG/100ML	N018314	001		Feb	CAHN

SODIUM NITROPRUSSIDE

SOLUTION;IV (INFUSION)

>A>		NIPRIDE RTU IN SODIUM CHLORIDE 0.9%							
>A>	+	!	EXELA PHARMA SCS LLC	50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Mar	NEWA

SODIUM OXYBATESOLUTION;ORAL  
SODIUM OXYBATE

AA		WEST-WARD PHARMS INT	500MG/ML	A202090	001	Jan 17, 2017	Jan	NEWA	
		XYREM							
AA	+	!	JAZZ PHARMS	500MG/ML	N021196	001	Jul 17, 2002	Jan	CFTG

SODIUM POLYSTYRENE SULFONATEPOWDER;ORAL, RECTAL  
SODIUM POLYSTYRENE SULFONATE

>D>	AA	CEDAR PHARMS	453.6GM/BOT	A090313	001	Dec 21, 2011	Mar	CAHN
>A>	AA	ECI PHARMS LLC	453.6GM/BOT	A090313	001	Dec 21, 2011	Mar	CAHN

SONIDEGIB PHOSPHATECAPSULE;ORAL  
ODOMZO

>D>	+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N205266	001	Jul 24, 2015	Mar CAHN
>A>	+	SUN PHARM INDS INC	EQ 200MG BASE	N205266	001	Jul 24, 2015	Mar CAHN

SPIRONOLACTONETABLET;ORAL  
SPIRONOLACTONE

>A>	AB	ACCORD HLTHCARE	25MG	A203512	001	Sep 19, 2016	Mar CAHN
>A>	AB		50MG	A203512	002	Sep 19, 2016	Mar CAHN
>A>	AB		100MG	A203512	003	Sep 19, 2016	Mar CAHN
>D>	AB	ACCORD HLTHCARE INC	25MG	A203512	001	Sep 19, 2016	Mar CAHN
>D>	AB		50MG	A203512	002	Sep 19, 2016	Mar CAHN
>D>	AB		100MG	A203512	003	Sep 19, 2016	Mar CAHN

STAVUDINECAPSULE;ORAL  
STAVUDINE

>D>	AB	MATRIX LABS LTD	30MG	A078775	001	Jan 05, 2009	Mar CAHN
>D>	AB		40MG	A078775	002	Jan 05, 2009	Mar CAHN
>A>	AB	MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009	Mar CAHN
>A>	AB		40MG	A078775	002	Jan 05, 2009	Mar CAHN

STERILE WATER FOR INJECTIONLIQUID;N/A  
STERILE WATER FOR INJECTION

AP		WEST-WARD PHARMS INT	100%	A206369	001	Sep 02, 2015	Jan CAHN
AP	+	ICU MEDCL	100%	N018233	001		Feb CAHN

STERILE WATER FOR IRRIGATIONLIQUID;IRRIGATION  
STERILE WATER IN PLASTIC CONTAINER

AT		ICU MEDCL	100%	N017513	001		Feb CAHN
AT			100%	N018313	001		Feb CAHN

SULFACETAMIDE SODIUMSOLUTION/DROPS;OPHTHALMIC  
SULFACETAMIDE SODIUM

AT		SANDOZ INC	10%	A089560	001	Oct 18, 1988	Feb CAHN
----	--	------------	-----	---------	-----	--------------	----------

SULFAMETHOXAZOLE; TRIMETHOPRIMTABLET;ORAL  
SULFAMETHOXAZOLE AND TRIMETHOPRIM

>A>	AB	CHARTWELL MOLECULES	400MG;80MG	A078060	002	Jan 25, 2007	Mar CAHN
>A>	AB		800MG;160MG	A078060	001	Jan 25, 2007	Mar CAHN
>D>	AB	CHARTWELL PHARMS LLC	400MG;80MG	A078060	002	Jan 25, 2007	Mar CAHN
	AB		400MG;80MG	A078060	002	Jan 25, 2007	Jan CAHN
>D>	AB		800MG;160MG	A078060	001	Jan 25, 2007	Mar CAHN
	AB		800MG;160MG	A078060	001	Jan 25, 2007	Jan CAHN

SULFANILAMIDECREAM;VAGINAL  
AVC

>D>	+	MEDA PHARMS	15%	N006530	003	Jan 27, 1987	Mar CAHN
>A>	+	MYLAN SPECIALITY LP	15%	N006530	003	Jan 27, 1987	Mar CAHN

SUPPOSITORY;VAGINAL  
AVC

>D>	@	MEDA PHARMS	1.05GM	N006530	004	Jan 27, 1987	Mar CAHN
>A>	@	MYLAN SPECIALITY LP	1.05GM	N006530	004	Jan 27, 1987	Mar CAHN

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS  
SUMATRIPTAN SUCCINATE

>D>	@	SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067	002	Feb 06, 2009	Mar CAHN
>D>	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067	001	Feb 06, 2009	Mar CAHN
>A>	@	SANDOZ INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067	002	Feb 06, 2009	Mar CAHN
>A>	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067	001	Feb 06, 2009	Mar CAHN

INJECTABLE;SUBCUTANEOUS  
SUMATRIPTAN SUCCINATE

AP		WEST-WARD PHARMS INT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jan CAHN
----	--	----------------------	----------------------------------------	---------	-----	--------------	----------

SYSTEM;IONTOPHORESIS  
ZECUITY

	+	@ TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	Jan DISC
--	---	----------------------	-------------------	---------	-----	--------------	----------

SUNITINIB MALATECAPSULE;ORAL  
SUTENT

>D>	AB	+	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006	Mar CTEC
>A>			+	EQ 12.5MG BASE	N021938	001	Jan 26, 2006	Mar CTEC
>D>	AB	+		EQ 25MG BASE	N021938	002	Jan 26, 2006	Mar CTEC
>A>			+	EQ 25MG BASE	N021938	002	Jan 26, 2006	Mar CTEC
>D>	AB	+		EQ 37.5MG BASE	N021938	004	Mar 31, 2009	Mar CTEC
>A>			+	EQ 37.5MG BASE	N021938	004	Mar 31, 2009	Mar CTEC
>D>	AB	+	!	EQ 50MG BASE	N021938	003	Jan 26, 2006	Mar CTEC
>A>			+	EQ 50MG BASE	N021938	003	Jan 26, 2006	Mar CTEC

TAMSULOSIN HYDROCHLORIDECAPSULE;ORAL  
TAMSULOSIN HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	0.4MG	A204645	001	Jan 20, 2017	Jan NEWA
----	--	---------------------	-------	---------	-----	--------------	----------

TAZAROTENEAEROSOL, FOAM;TOPICAL  
FABIOR

	+	!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012	Jan CAHN
--	---	---	--------------	------	---------	-----	--------------	----------

CREAM;TOPICAL  
AVAGE

>D>		+	!	ALLERGAN	0.1%	N021184	003	Sep 30, 2002	Mar CFTG
>A>	AB	+	!		0.1%	N021184	003	Sep 30, 2002	Mar CFTG
>A>				TAZAROTENE					
>A>	AB			TARO	0.1%	A208258	001	Apr 03, 2017	Mar NEWA
				TAZORAC					
>D>		+	!	ALLERGAN	0.1%	N021184	002	Sep 29, 2000	Mar CFTG
>A>	AB	+	!		0.1%	N021184	002	Sep 29, 2000	Mar CFTG

TECHNETIUM TC-99M TILMANOCEPTINJECTABLE;INJECTION  
LYMPHOSEEK KIT

>A>		+	!	CARDINAL HLTH 414	N/A	N202207	001	Mar 13, 2013	Mar CAHN
>D>		+	!	NAVIDEA BIOPHARMS	N/A	N202207	001	Mar 13, 2013	Mar CAHN

TELOTRISTAT ETIPRATETABLET;ORAL  
XERMELO

	+	!	LEXICON PHARMS INC	EQ 250MG BASE	N208794	001	Feb 28, 2017	Feb NEWA
--	---	---	--------------------	---------------	---------	-----	--------------	----------

TEMAZEPAMCAPSULE;ORAL  
TEMAZEPAM

AB			PRINSTON INC	7.5MG	A201781	001	Jun 04, 2015	Feb CAHN
AB				15MG	A201781	002	Jun 04, 2015	Feb CAHN
AB				22.5MG	A201781	003	Jun 04, 2015	Feb CAHN
AB				30MG	A201781	004	Jun 04, 2015	Feb CAHN

TEMOZOLOMIDECAPSULE;ORAL  
TEMOZOLOMIDE

AB			ACCORD HLTHCARE	5MG	A201528	001	Feb 27, 2017	Feb NEWA
AB				20MG	A201528	002	Feb 27, 2017	Feb NEWA
AB				100MG	A201528	003	Feb 27, 2017	Feb NEWA
AB				140MG	A201528	004	Feb 27, 2017	Feb NEWA
AB				180MG	A201528	005	Feb 27, 2017	Feb NEWA
AB				250MG	A201528	006	Feb 27, 2017	Feb NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

>D>	AB	MYLAN	EQ 1MG BASE	A 075140	002	Feb 11, 2000	Mar	CAHN
>D>	AB		EQ 2MG BASE	A 075140	003	Feb 11, 2000	Mar	CAHN
>D>	AB		EQ 5MG BASE	A 075140	001	Feb 11, 2000	Mar	CAHN
>D>	AB		EQ 10MG BASE	A 075140	004	Feb 11, 2000	Mar	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 1MG BASE	A 075140	002	Feb 11, 2000	Mar	CAHN
>A>	AB		EQ 2MG BASE	A 075140	003	Feb 11, 2000	Mar	CAHN
>A>	AB		EQ 5MG BASE	A 075140	001	Feb 11, 2000	Mar	CAHN
>A>	AB		EQ 10MG BASE	A 075140	004	Feb 11, 2000	Mar	CAHN

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

>D>	AP	!	AMPHASTAR PHARMS INC	1MG/ML	A 076770	001	Apr 23, 2004	Mar	CAHN
>A>	AP	!	ATHENEX INC	1MG/ML	A 076770	001	Apr 23, 2004	Mar	CAHN

TABLET;ORAL

BRETHINE

+ @ ANI PHARMS INC

2.5MG

N 017849

001

Feb CAHN

+ @

5MG

N 017849

002

Feb CAHN

TERBUTALINE SULFATE

! LANNETT

5MG

A 077152

002

Mar 25, 2005

Jan CHRS

TESTOSTERONE

GEL, METERED;TRANSDERMAL

TESTOSTERONE

>D>	AB		ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A 204571	001	Aug 05, 2015	Mar	CAHN
>A>	AB			10MG/0.5GM ACTUATION	A 204571	001	Aug 05, 2015	Mar	CAHN

SOLUTION, METERED;TRANSDERMAL

AXIRON

AT +! ELI LILLY AND CO

30MG/1.5ML ACTUATION

N 022504

001

Nov 23, 2010

Feb CFTG

TESTOSTERONE

AT PERRIGO ISRAEL

30MG/1.5ML ACTUATION

A 204255

001

Feb 28, 2017

Feb NEWA

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

>D>	AO		SANDOZ	100MG/ML	A 040615	001	Aug 10, 2006	Mar	CAHN
>D>	AO			200MG/ML	A 040615	002	Aug 10, 2006	Mar	CAHN
>A>	AO		SANDOZ INC	100MG/ML	A 040615	001	Aug 10, 2006	Mar	CAHN
>A>	AO			200MG/ML	A 040615	002	Aug 10, 2006	Mar	CAHN
	AO		WATSON PHARMS INC	200MG/ML	A 086030	001		Feb	CAHN
	AO		WEST-WARD PHARMS INT	100MG/ML	A 090387	001	Jul 15, 2010	Jan	CAHN
	AO			200MG/ML	A 090387	002	Jul 15, 2010	Jan	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

TESTOSTERONE ENANTHATE

AO WATSON PHARMS INC

200MG/ML

A 085598

001

Feb CAHN

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB APICORE US

12.5MG

A 207682

001

Jan 31, 2017
 Jan | NEWA || AB |  |  |  | 25MG | A 207682 | 002 | Jan 31, 2017 | Jan | NEWA |
TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

AB + HERITAGE PHARMA

250MG

N 050278

003

Jan CAHN

AB +!

500MG

N 050278

001

Jan CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

@ WEST-WARD PHARMS INT

100MG/ML

A 080575

001

Jan CAHN

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THIORIDAZINE HYDROCHLORIDE

@ ANI PHARMS INC	30MG/ML	A089602	001	Nov 09, 1987	Jan CAHN
------------------	---------	---------	-----	--------------	----------

THIOTEPA

POWDER; IV (INFUSION)

TEPADINA

+! ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Jan NEWA
+!	100MG/VIAL	N208264	002	Jan 26, 2017	Jan NEWA

TICAGRELOR

TABLET; ORAL

BRILINTA

+ ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jan CAHN
+!	90MG	N022433	001	Jul 20, 2011	Jan CAHN

TIGECYCLINE

POWDER; IV (INFUSION)

TIGECYCLINE

AP	SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Feb CDFR
	TYGACIL					
AP	+! PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Feb CDFR

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AB	SANDOZ INC	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Feb CAHN
AB		EQ 0.5% BASE	N020963	002	Oct 21, 1998	Feb CAHN

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AT	! ALCON RES LTD	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Jan CHRS
AT1	!	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Jan CHRS
AT	! SANDOZ INC	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Feb CAHN
AT1	!	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Feb CAHN
	TIMOPTIC					
	+ @ ATON	EQ 0.25% BASE	N018086	001		Jan DISC
	+ @	EQ 0.5% BASE	N018086	002		Jan DISC

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

AB	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Jan CTEC
AB		500MG	A202489	002	Oct 09, 2013	Jan CTEC

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Feb NEWA
AB		EQ 4MG BASE	A207199	002	Mar 14, 2017	Feb NEWA
AB		EQ 6MG BASE	A207199	003	Mar 14, 2017	Feb NEWA
AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A208622	001	Mar 03, 2017	Feb NEWA
AB		EQ 4MG BASE	A208622	002	Mar 03, 2017	Feb NEWA
AB		EQ 6MG BASE	A208622	003	Mar 03, 2017	Feb NEWA

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Jan NEWA
AB		EQ 4MG BASE	A207170	002	Jan 26, 2017	Jan NEWA

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

>A>	AN	LUPIN ATLANTIS	300MG/5ML	A208964	001	Mar 22, 2017	Mar NEWA
-----	----	----------------	-----------	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC

TOBREX

AT	SANDOZ INC	0.3%	A062535	001	Dec 13, 1984	Feb CAHN
----	------------	------	---------	-----	--------------	----------

TOREMIFENE CITRATETABLET; ORAL  
FARESTON

+! KYOWA KIRIN EQ 60MG BASE N020497 001 May 29, 1997 Jan CAHN

TORSEMIDETABLET; ORAL  
DEMADEX

>D>	AB	+	MEDA PHARMS	5MG	N020136	001	Aug 23, 1993	Mar	CAHN
>D>	AB	+		10MG	N020136	002	Aug 23, 1993	Mar	CAHN
>D>	AB	+!		20MG	N020136	003	Aug 23, 1993	Mar	CAHN
>D>	AB	+		100MG	N020136	004	Aug 23, 1993	Mar	CAHN
>A>	AB	+	MYLAN SPECIALITY LP	5MG	N020136	001	Aug 23, 1993	Mar	CAHN
>A>	AB	+		10MG	N020136	002	Aug 23, 1993	Mar	CAHN
>A>	AB	+!		20MG	N020136	003	Aug 23, 1993	Mar	CAHN
>A>	AB	+		100MG	N020136	004	Aug 23, 1993	Mar	CAHN

TRAMADOL HYDROCHLORIDETABLET; ORAL  
TRAMADOL HYDROCHLORIDE

>A>	AB		ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013	Mar	CAHN
>D>	AB		ACCORD HLTHCARE INC	50MG	A202390	001	May 16, 2013	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL  
ULTRAM ER

>D>		@	VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar	CRLD
>A>		+ @		100MG	N021692	001	Sep 08, 2005	Mar	CRLD
>D>		@		200MG	N021692	002	Sep 08, 2005	Mar	CRLD
>A>		+ @		200MG	N021692	002	Sep 08, 2005	Mar	CRLD
>D>		@		300MG	N021692	003	Sep 08, 2005	Mar	CRLD
>A>		+ @		300MG	N021692	003	Sep 08, 2005	Mar	CRLD

TRANEXAMIC ACIDINJECTABLE; INJECTION  
TRANEXAMIC ACID

AP			AMNEAL PHARMS CO	100MG/ML	A208840	001	Feb 28, 2017	Feb	NEWA
AP			GLAND PHARMA LTD	100MG/ML	A207239	001	Feb 13, 2017	Jan	NEWA

TRETINOINCREAM; TOPICAL  
TRETINOIN

		@	ALLERGAN SALES LLC	0.0375%	A090098	001	Mar 22, 2010	Feb	DISC
		@		0.075%	A202209	001	Oct 11, 2012	Feb	DISC
AB2			ZO SKIN HEALTH	0.05%	A076498	001	Sep 15, 2005	Feb	CAHN

TRIAMCINOLONE ACETONIDECREAM; TOPICAL  
TRIAMCINOLONE ACETONIDE

AT			LUPIN ATLANTIS	0.025%	A208763	001	Feb 01, 2017	Jan	NEWA
AT				0.1%	A208763	002	Feb 01, 2017	Jan	NEWA
AT				0.5%	A208763	003	Feb 01, 2017	Jan	NEWA
AT		+	MYLAN PHARMS INC	0.025%	N011601	003		Jan	CAHN
AT		+		0.1%	N011601	006		Jan	CAHN
>D>	AT		TARO	0.1%	A040039	001	Nov 26, 1997	Mar	CAHN
>A>	AT			0.1%	A040039	001	Nov 26, 1997	Mar	CAHN

OINTMENT; TOPICAL  
KENALOG

AT			MYLAN PHARMS INC	0.025%	N011600	003		Jan	CAHN
AT				0.1%	N011600	001		Jan	CAHN

TRIAMCINOLONE ACETONIDE

AT			TELIGENT PHARMA INC	0.5%	A208590	001	Mar 03, 2017	Feb	NEWA
----	--	--	---------------------	------	---------	-----	--------------	-----	------

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

AT			G AND W LABS INC	0.1%	A205592	001	Jan 12, 2017	Jan	NEWA
----	--	--	------------------	------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL  
TRIAMCINOLONE ACETONIDE

		@	PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan	CAHN
--	--	---	----------------	---------------	---------	-----	--------------	-----	------

TRIFLURIDINESOLUTION/DROPS;OPHTHALMIC  
TRIFLURIDINE

AT		SANDOZ INC	1%	A074311	001	Oct 06, 1995	Feb	CAHN
		VIROPTIC						
AT	+	MONARCH PHARMS	1%	N018299	001		Feb	CAHN

TRIHEXYPHENIDYL HYDROCHLORIDETABLET;ORAL  
TRIHEXYPHENIDYL HYDROCHLORIDE

>D>	AA	VINTAGE PHARMS	2MG	A040254	001	Dec 24, 1998	Mar	CAHN
>D>	AA		5MG	A040254	002	Dec 24, 1998	Mar	CAHN
>A>	AA	VINTAGE PHARMS LLC	2MG	A040254	001	Dec 24, 1998	Mar	CAHN
>A>	AA		5MG	A040254	002	Dec 24, 1998	Mar	CAHN

TROPICAMIDESOLUTION/DROPS;OPHTHALMIC  
MYDRIACYL

AT	!	SANDOZ INC	0.5%	A084305	001		Feb	CAHN
----	---	------------	------	---------	-----	--	-----	------

ULIPRISTAL ACETATETABLET;ORAL  
ELLA

AB	+	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010	Jan	CFTG
		LOGILIA						
AB		TEVA PHARMS USA	30MG	A207952	001	Feb 13, 2017	Jan	NEWA

URSODIOLCAPSULE;ORAL  
URSODIOL

AB		IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006	Feb	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

VALPROATE SODIUMINJECTABLE;INJECTION  
VALPROATE SODIUM

>D>	AP	AMPHASTAR PHARMS INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Mar	CAHN
>A>	AP	ATHENEX INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Mar	CAHN

VALPROIC ACIDSYRUP;ORAL  
VALPROIC ACID

>A>	AA	ECI PHARMS LLC	250MG/5ML	A090517	001	May 28, 2010	Mar	CAHN
>D>	AA	NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar	CAHN
	AA	VISTAPHARM	250MG/5ML	A075782	001	Dec 22, 2000	Feb	CAHN

VALSARTANTABLET;ORAL  
VALSARTAN

AB		MYLAN PHARMS INC	40MG	A090866	001	Jan 05, 2015	Feb	CAHN
AB			80MG	A090866	002	Jan 05, 2015	Feb	CAHN
AB			160MG	A090866	003	Jan 05, 2015	Feb	CAHN
AB			320MG	A090866	004	Jan 05, 2015	Feb	CAHN

VECURONIUM BROMIDEINJECTABLE;INJECTION  
VECURONIUM BROMIDE

>D>		@ EUROHLTH INTL SARL	10MG/VIAL	A075218	001	Aug 23, 1999	Mar	CAHN
>D>		@	20MG/VIAL	A075218	002	Aug 23, 1999	Mar	CAHN
>A>		@ WEST-WARD PHARMS INT	10MG/VIAL	A075218	001	Aug 23, 1999	Mar	CAHN
	AP		10MG/VIAL	A075549	001	Jun 13, 2000	Jan	CAHN
>A>		@	20MG/VIAL	A075218	002	Aug 23, 1999	Mar	CAHN
	AP		20MG/VIAL	A075549	002	Jun 13, 2000	Jan	CAHN

VENLAFAXINE HYDROCHLORIDETABLET;ORAL  
VENLAFAXINE HYDROCHLORIDE

AB		PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Feb	CAHN
AB			EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Feb	CAHN
AB			EQ 50MG BASE	A090027	003	Aug 04, 2010	Feb	CAHN
AB			EQ 75MG BASE	A090027	004	Aug 04, 2010	Feb	CAHN
AB			EQ 100MG BASE	A090027	005	Aug 04, 2010	Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL  
VENLAFAXINE HYDROCHLORIDE

>A>	AB	NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017	Mar NEWA
>A>	AB		EQ 225MG BASE	A205468	003	Mar 24, 2017	Mar NEWA
>D>	+	OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008	Mar CFTG
>A>	AB	+	EQ 225MG BASE	N022104	004	May 20, 2008	Mar CFTG

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
CALAN SR

+	@	PFIZER	180MG	N019152	002	Dec 15, 1989	Jan CRLD
		COVERA-HS					
	@	GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996	Jan DISC
	@		240MG	N020552	002	Feb 26, 1996	Jan DISC

VIGABATRIN

FOR SOLUTION;ORAL  
SABRIL

+	!	LUNDBECK PHARMS LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Jan CAHN
		TABLET;ORAL					
		SABRIL					
+	!	LUNDBECK PHARMS LLC	500MG	N020427	001	Aug 21, 2009	Jan CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION  
VINORELBINE TARTRATE

>D>	AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Mar CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Mar CAHN
	AP		EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Jan CAHN

VORICONAZOLE

POWDER;IV (INFUSION)  
VORICONAZOLE

>A>		XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar NEWA
-----	--	-------------------	------------	---------	-----	--------------	----------

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL  
TRINTELLIX

>D>	+	TAKEDA PHARMS USA	EQ 15MG BASE	N204447	003	Sep 30, 2013	Mar DISC
>A>	+	@	EQ 15MG BASE	N204447	003	Sep 30, 2013	Mar DISC

WARFARIN SODIUM

TABLET;ORAL  
WARFARIN SODIUM

>D>	AB	TARO	1MG	A040301	002	Jul 15, 1999	Mar CAHN
>D>	AB		2MG	A040301	003	Jul 15, 1999	Mar CAHN
>D>	AB		2.5MG	A040301	004	Jul 15, 1999	Mar CAHN
>D>	AB		3MG	A040301	005	Jul 15, 1999	Mar CAHN
>D>	AB		4MG	A040301	006	Jul 15, 1999	Mar CAHN
>D>	AB		5MG	A040301	007	Jul 15, 1999	Mar CAHN
>D>	AB		6MG	A040301	008	Jul 15, 1999	Mar CAHN
>D>	AB		7.5MG	A040301	009	Jul 15, 1999	Mar CAHN
>D>	AB		10MG	A040301	001	Jul 15, 1999	Mar CAHN
>A>	AB	TARO PHARM	1MG	A040301	002	Jul 15, 1999	Mar CAHN
>A>	AB		2MG	A040301	003	Jul 15, 1999	Mar CAHN
>A>	AB		2.5MG	A040301	004	Jul 15, 1999	Mar CAHN
>A>	AB		3MG	A040301	005	Jul 15, 1999	Mar CAHN
>A>	AB		4MG	A040301	006	Jul 15, 1999	Mar CAHN
>A>	AB		5MG	A040301	007	Jul 15, 1999	Mar CAHN
>A>	AB		6MG	A040301	008	Jul 15, 1999	Mar CAHN
>A>	AB		7.5MG	A040301	009	Jul 15, 1999	Mar CAHN
>A>	AB		10MG	A040301	001	Jul 15, 1999	Mar CAHN

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL

>A>		ZILEUTON					
>A>	AB	PACK PHARMS LLC	600MG	A204929	001	Mar 17, 2017	Mar NEWA
>A>	AB	RISING PHARMS INC	600MG	A204929	001	Mar 17, 2017	Mar CAHN
		ZYFLO CR					
>D>	+	CHIESI USA INC	600MG	N022052	001	May 30, 2007	Mar CFTG
>A>	AB	+	600MG	N022052	001	May 30, 2007	Mar CFTG



ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204375	001	Feb 17, 2017	Feb NEWA
AB		EQ 40MG BASE	A204375	002	Feb 17, 2017	Feb NEWA
AB		EQ 60MG BASE	A204375	003	Feb 17, 2017	Feb NEWA
AB		EQ 80MG BASE	A204375	004	Feb 17, 2017	Feb NEWA

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan NEWA
----	----------------	-------------------	---------	-----	--------------	----------

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB	PLD ACQUISITIONS LLC	2.5MG	A207867	001	Feb 27, 2017	Feb NEWA
AB		5MG	A207867	002	Feb 27, 2017	Feb NEWA

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

>A>	AB	ALLIED PHARMA INC	5MG	A077214	001	Apr 23, 2007	Mar CAHN
>A>	AB		10MG	A077214	002	Apr 23, 2007	Mar CAHN
>D>	AB	ROXANE	5MG	A077214	001	Apr 23, 2007	Mar CAHN
>D>	AB		10MG	A077214	002	Apr 23, 2007	Mar CAHN

TABLET;SUBLINGUAL

EDLUAR

>D>	AB	+ MEDA PHARMS	5MG	N021997	001	Mar 13, 2009	Mar CAHN
>D>	AB	+!	10MG	N021997	002	Mar 13, 2009	Mar CAHN
>A>	AB	+ MYLAN SPECIALITY LP	5MG	N021997	001	Mar 13, 2009	Mar CAHN
>A>	AB	+!	10MG	N021997	002	Mar 13, 2009	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

AB	SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan NEWA
AB		12.5MG	A204170	002	Jan 24, 2017	Jan NEWA

CIMETIDINE

TABLET;ORAL  
CIMETIDINE

>D>	@ LEK PHARMS	100MG	A 075122	001	Jun 19, 1998	Mar	CAHN
>D>	@	200MG	A 075122	002	Jun 19, 1998	Mar	CAHN
>A>	@ SANDOZ INC	100MG	A 075122	001	Jun 19, 1998	Mar	CAHN
>A>	@	200MG	A 075122	002	Jun 19, 1998	Mar	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL  
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

>A>	ACTAVIS LABS FL	30MG;600MG	A 091070	001	Aug 31, 2015	Mar	CAHN
>A>		60MG;1.2GM	A 091070	002	Aug 31, 2015	Mar	CAHN
>D>	ACTAVIS LABS FL INC	30MG;600MG	A 091070	001	Aug 31, 2015	Mar	CAHN
>D>		60MG;1.2GM	A 091070	002	Aug 31, 2015	Mar	CAHN
>A>	AUROBINDO PHARMA LTD	30MG;600MG	A 206941	001	Mar 17, 2017	Mar	NEWA
>A>		60MG;1.2GM	A 206941	002	Mar 17, 2017	Mar	NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL  
GUAIFENESIN

>A>	ACTAVIS LABS FL	1.2GM	A 091009	002	Sep 03, 2015	Mar	CAHN
>D>	ACTAVIS LABS FL INC	1.2GM	A 091009	002	Sep 03, 2015	Mar	CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A>	ACTAVIS LABS FL	600MG;60MG	A 091071	001	May 27, 2015	Mar	CAHN
>A>		1.2GM;120MG	A 091071	002	May 27, 2015	Mar	CAHN
>D>	ACTAVIS LABS FL INC	600MG;60MG	A 091071	001	May 27, 2015	Mar	CAHN
>D>		1.2GM;120MG	A 091071	002	May 27, 2015	Mar	CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC  
ZADITOR

>D>	@ ALCON PHARMA	EQ 0.025% BASE	N 021066	002	Oct 19, 2006	Mar	CRLD
>A>	+ @	EQ 0.025% BASE	N 021066	002	Oct 19, 2006	Mar	CRLD

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL  
XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 2.5MG/5ML (0.5MG/ML)  
+ UCB INC 2.5MG/5ML (0.5MG/ML)

N 209090	001	Jan 31, 2017	Feb	CAHN
N 209090	001	Jan 31, 2017	Jan	NEWA

TABLET;ORAL  
XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 5MG  
+ UCB INC 5MG

N 209089	001	Jan 31, 2017	Feb	CAHN
N 209089	001	Jan 31, 2017	Jan	NEWA

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL  
LOPERAMIDE HYDROCHLORIDE

>A>	ALLIED PHARMA INC	1MG/5ML	A 073079	001	Apr 30, 1992	Mar	CAHN
>D>	ROXANE	1MG/5ML	A 073079	001	Apr 30, 1992	Mar	CAHN

TABLET, CHEWABLE;ORAL  
IMODIUM A-D EZ CHEWS

+ @ J AND J CONSUMER INC 2MG

N 020448	001	Jul 24, 1997	Jan	DISC
----------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL  
IMODIUM MULTI-SYMPTOM RELIEF

+ @ J AND J CONSUMER INC 2MG;125MG  
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE  
! PERRIGO 2MG;125MG

N 020606	001	Jun 26, 1996	Jan	DISC
A 076029	001	Aug 30, 2002	Jan	CHRS

LORATADINESYRUP;ORAL  
LORATADINE

>D>	TARO	1MG/ML	A201865	001	Jul 31, 2015	Mar	CAHN
>A>	TARO PHARM	1MG/ML	A201865	001	Jul 31, 2015	Mar	CAHN

MINOXIDILAEROSOL, FOAM;TOPICAL  
MINOXIDIL (FOR MEN)  
WATSON LABS INC

5%

A208092 001 Feb 17, 2017 Feb NEWA

NAPROXEN SODIUMTABLET;ORAL  
NAPROXEN SODIUM  
LNK INTL INC

EQ 200MG BASE

A204872 001 Jan 23, 2017 Jan NEWA

RANITIDINE HYDROCHLORIDETABLET;ORAL  
RANITIDINE HYDROCHLORIDE  
STRIDES PHARMA  
ZANTAC 150

EQ 150MG BASE

A200536 001 Jun 28, 2011 Jan CAHN

>D>	+!	BOEHRINGER INGELHEIM	EQ 150MG BASE	N021698	001	Aug 31, 2004	Mar	CAHN
>D>	+		EQ 150MG BASE	N021698	002	Mar 13, 2007	Mar	CAHN
>A>	+!	SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004	Mar	CAHN
>A>	+		EQ 150MG BASE	N021698	002	Mar 13, 2007	Mar	CAHN

ZANTAC 75

>D>		BOEHRINGER INGELHEIM	EQ 75MG BASE	N020520	001	Dec 19, 1995	Mar	CAHN
>A>		SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995	Mar	CAHN

TABLET, EFFERVESCENT;ORAL  
ZANTAC 75

>D>	+ @	BOEHRINGER INGELHEIM	EQ 75MG BASE	N020745	001	Feb 26, 1998	Mar	CAHN
>A>	+ @	SANOFI US	EQ 75MG BASE	N020745	001	Feb 26, 1998	Mar	CAHN

TRIAMCINOLONE ACETONIDESPRAY, METERED;NASAL  
TRIAMCINOLONE ACETONIDE  
PERRIGO ISRAEL

0.055MG/SPRAY

A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2017**

NO MARCH 2017 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2017 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001					M-196 PED	Jan 27, 2020 Jul 27, 2020
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 001	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003	9539258	Nov 09, 2026	U-1950			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8173663 8697125	Dec 02, 2025 Jun 16, 2029	U-1338 DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663 8697125	Dec 02, 2025 Jun 16, 2029	U-1338 DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8173663 8697125	Dec 02, 2025 Jun 16, 2029	U-1338 DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6329404	Jun 19, 2021	DP U-1334			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	9549926	Oct 14, 2031	U-1965			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	9549926	Oct 14, 2031	U-1965			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 003					NP	Jan 21, 2018
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9526726	Mar 19, 2035	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9539214	Mar 13, 2033	U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	9539214	Mar 13, 2033	U-1902			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	9284314	Jun 15, 2032	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	>A> 9597397	Mar 15, 2033	U-1971			
	>A> 9597397	Mar 15, 2033	U-1972			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	>A> 9597398	Mar 15, 2033	U-1971			
	>A> 9597399	Mar 15, 2033	U-1971			
	>A> 9597399	Mar 15, 2033	U-1972			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	9561208	Jun 03, 2029	DP U-916			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	>A> 9579270	Jan 31, 2021	U-1975			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9522117	Apr 30, 2032	DP U-976			
	9522117	Apr 30, 2032	DP U-1939			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9532954	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	6123924	Sep 26, 2017	DP		NPP	Jan 27, 2020
	6123924*PED	Mar 26, 2018			PED	Jul 27, 2020
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-1073			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-1073			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-1073			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	6123924	Sep 26, 2017	DP			
	6123924*PED	Mar 26, 2018				
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-1073			
	7759328*PED	Jul 29, 2023				
	7897646	Sep 09, 2018	U-1118			
	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-1073			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8461211	Sep 09, 2018	U-1118			
	8461211*PED	Mar 09, 2019				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-1073			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001 >A>	9585838	Dec 24, 2021	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002 >A>	9585838	Dec 24, 2021	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					M-197	Feb 01, 2020
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	9493582	Feb 27, 2033	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	9533046	Dec 26, 2028	DP U-219			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	9493582	Feb 27, 2033	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	9493582	Feb 27, 2033	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001					NPP	Jan 27, 2020

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9555029	Aug 22, 2033	U-1020			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8168614	Jan 20, 2030	U-1932			
	8501712	Feb 16, 2027	U-1932			
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	>A> 6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
	>A> 6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
	>A> 6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
	>A> 6515117	Oct 04, 2020	DS DP U-1977			
	>A> 6936590	Oct 04, 2020	U-1976			
	>A> 6936590	Oct 04, 2020	U-1977			
	>A> 7919598	Dec 16, 2029	DS			
	>A> 8221786	Mar 21, 2028	DP			
	>A> 8361972	Mar 21, 2028	U-1976			
	>A> 8361972	Mar 21, 2028	U-1977			
	>A> 8501698	Jun 20, 2027	DP U-1976			
	>A> 8501698	Jun 20, 2027	DP U-1977			
	>A> 8628799	Jul 13, 2025	DP			
	>A> 8716251	Mar 21, 2028	DP			
	>A> 9198925	Oct 04, 2020	U-1976			
	>A> 9198925	Oct 04, 2020	U-1977			
	>A> RE44186	Jul 31, 2023	DS DP U-1976			
	>A> RE44186	Jul 31, 2023	DS DP U-1977			
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001				>A>	NCE	Feb 09, 2022
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002				>A>	NCE	Feb 09, 2022
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003				>A>	NCE	Feb 09, 2022
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004				>A>	NCE	Feb 09, 2022
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001				>A>	NCE	Feb 09, 2022
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	>A> 9579359	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	>A> 9579359	Feb 10, 2029	U-1978			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9522155	Feb 21, 2028	DP U-1940			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	>A> 7405203	May 06, 2023	U-1980	>A>	NP	Mar 03, 2020
	>A> 7579321	May 06, 2023	U-1980			
	>A> 7799761	Sep 26, 2024	DP			
	>A> 9539302	Jun 15, 2030	DP			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	>A> 7405203	May 06, 2023	U-1980	>A>	NP	Mar 03, 2020
	>A> 7579321	May 06, 2023	U-1980			
	>A> 7799761	Sep 26, 2024	DP			
	>A> 9539302	Jun 15, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	>A> 7405203	May 06, 2023	U-1980		>A> NP	Mar 03, 2020
	>A> 7579321	May 06, 2023	U-1980			
	>A> 7799761	Sep 26, 2024	DP			
	>A> 9539302	Jun 15, 2030	DP			
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204082 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204083 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 002					PC	Aug 28, 2017
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	9561200	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9539335	Oct 17, 2027	U-1614			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9532971	Jun 01, 2029	DP			
	>A> 9572814	Jul 20, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9532971	Jun 01, 2029	DP			
	>A> 9572814	Jul 20, 2027	U-620			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	>A> 9345771	Aug 06, 2028	DS DP			
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9545414	Jun 13, 2026	DP U-750			
	9545414	Jun 13, 2026	DP U-1170			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9566272	Jan 03, 2028	U-1969			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	8772325	Mar 14, 2025	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8772325	Mar 14, 2025	U-1709			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	>A> 6642245	Nov 04, 2020	U-248			
	>A> 6642245	Nov 04, 2020	U-541			
	>A> 6642245	Nov 04, 2020	U-1170			
	>A> 6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	>A> 6642245	Nov 04, 2020	U-248			
	>A> 6642245	Nov 04, 2020	U-541			
	>A> 6642245	Nov 04, 2020	U-1170			
	>A> 6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	>A> 6642245	Nov 04, 2020	U-248			
	>A> 6642245	Nov 04, 2020	U-541			
	>A> 6642245	Nov 04, 2020	U-1170			
	>A> 6642245*PED	May 04, 2021				
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	>A> 9566244	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	>A> 9566244	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	>A> 9566244	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	>A> 9566244	Oct 23, 2028	DP			
<u>ETELALCETIDE - PARSABIV</u>						
N 208325 001					NCE	Feb 07, 2022
<u>ETELALCETIDE - PARSABIV</u>						
N 208325 002					NCE	Feb 07, 2022
<u>ETELALCETIDE - PARSABIV</u>						
N 208325 003					NCE	Feb 07, 2022
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE</u>						
A 206287 001				>A> PC		Sep 11, 2017
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	>A> 9579288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	>A> 9579288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	>A> 9579288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	>A> 9579288	Jul 23, 2027	DP U-767			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005 >A>	9579288	Jul 23, 2027	DP U-767			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP	U-645		
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP	U-645		
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>GANCICLOVIR - GANCICLOVIR</u>						
N 209347 001	>A> 9486530	Sep 02, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9486451	Sep 12, 2034	U-55			
	>A> 9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9486451	Sep 12, 2034	U-55			
	>A> 9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9486451	Sep 12, 2034	U-55			
	>A> 9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9486451	Sep 12, 2034	U-55			
	>A> 9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
	>A> 9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9486451	Sep 12, 2034	U-55			
	>A> 9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	>A> 9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	>A> 9572804	Oct 30, 2021	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
>A>	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
>A>	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
>A>	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
>A>	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
>A>	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
>A>	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9540382	Aug 18, 2033	U-1456		I-741	Jan 18, 2020
	9540382	Aug 18, 2033	U-1650		ODE	Jan 18, 2024
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9561331	Aug 28, 2024	DP			
	>A> 9604008	Mar 02, 2024	DP			
	>A> 9604009	Aug 16, 2024	DP			
	>A> 9610409	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	>A> 9604008	Mar 02, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9526764	Oct 09, 2029	DP			
	9561331	Aug 28, 2024	DP			
	>A> 9604008	Mar 02, 2024	DP			
	>A> 9604009	Aug 16, 2024	DP			
	>A> 9610409	Mar 02, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9561331	Aug 28, 2024	DP			
	>A> 9604008	Mar 02, 2024	DP			
	>A> 9610409	Mar 02, 2024	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7973038	Nov 08, 2026	U-1973			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7973038	Nov 08, 2026	U-1973			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	>A> 5635517	Oct 04, 2019	DS		>A> ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	>A> 5635517	Oct 04, 2019	DS		>A> ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	>A> 5635517	Oct 04, 2019	DS		>A> ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	>A> 5635517	Oct 04, 2019	DS		>A> ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	>A> 5635517	Oct 04, 2019	DS		>A> ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	>A> 5635517	Oct 04, 2019	DS		>A> ODE	Feb 22, 2024
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	9254307	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP	U-621		
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP	U-621		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001 >A>	8633194	Oct 16, 2027	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	7304036	Aug 30, 2026	DS DP U-1516		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS		NS	Jan 25, 2020
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1516			
	8933030	Feb 17, 2031	DP U-1516			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9555027	May 26, 2026	DP U-543		NPP PED	Jan 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9555027	May 26, 2026	DP U-543			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001					NP	Nov 04, 2019
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	9493582	Feb 27, 2033	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					>A> M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					>A> M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					>A> M-198	Feb 27, 2020
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	9533102	Jan 24, 2026	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9545399	Aug 14, 2033	DP U-1827			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	>A> 8084460	Jan 11, 2028	DS DP		>A> NCE	Mar 23, 2022
	>A> 8536192	Oct 05, 2026	DS DP U-1185			
	>A> 9108975	Nov 11, 2031	DS DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9561177	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9555000	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9555000	Apr 04, 2023	DP U-1556			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001					>A> NCE	Mar 27, 2022
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	6166197	Dec 26, 2017	DS		ODE	Dec 23, 2023
	6210892	Oct 07, 2018		U-1942		
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025		U-1942		
	8110560	Dec 05, 2025		U-1943		
	8110560	Dec 05, 2025		U-1944		
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030		U-1941		
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	9533053	May 19, 2032	DP			
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001					I-743	Jul 24, 2018
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	>A> 9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	>A> 9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	>A> 9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	>A> 9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	>A> 9592200	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	9492443	May 26, 2024	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	7812049	May 02, 2028		U-1959	NP	Jan 18, 2020
	8420688	Aug 02, 2024		U-1959		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	8883838	Dec 01, 2031	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9511046	Jan 12, 2034	U-1434			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	9545457	Jan 13, 2019	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9566271	Jan 15, 2024	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022	U-1964			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	>A> 8114874	Dec 22, 2026	DS DP			
	>A> 9493470	Dec 12, 2033	DS DP U-1700			
	>A> 9493470	Dec 12, 2033	DS DP U-1948			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9504699	Aug 03, 2027	U-1362			
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 001					PC	Jul 01, 2017

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823	002				PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950	001				PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950	002				PC	Jul 01, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001				M-194	Jan 17, 2020
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092	001	>A> 8324225	Jun 17, 2028	DS DP	>A> NCE	Mar 13, 2022
		>A> 8415355	Feb 19, 2031	DS DP		
		>A> 8685980	May 25, 2030	DS DP		
		>A> 8962630	Dec 09, 2029	U-1981		
		>A> 9193732	Nov 09, 2031	DS DP		
		>A> 9416136	Aug 20, 2029	U-1981		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	001	9539218	Feb 17, 2034	U-1953		
		9539218	Feb 17, 2034	U-1954		
		9539218	Feb 17, 2034	U-1955		
		9539218	Feb 17, 2034	U-1956		
		9539218	Feb 17, 2034	U-1957		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	002	9539218	Feb 17, 2034	U-1953		
		9539218	Feb 17, 2034	U-1954		
		9539218	Feb 17, 2034	U-1955		
		9539218	Feb 17, 2034	U-1956		
		9539218	Feb 17, 2034	U-1957		
<u>RIVAROXABAN - XARELTO</u>						
N 022406	003	9539218	Feb 17, 2034	U-1953		
		9539218	Feb 17, 2034	U-1954		
		9539218	Feb 17, 2034	U-1955		
		9539218	Feb 17, 2034	U-1956		
		9539218	Feb 17, 2034	U-1957		
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500	001	>A> 8404702	Apr 04, 2027	U-1741		
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	001				ODE	Dec 19, 2023
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	002				ODE	Dec 19, 2023
<u>SACROSIDASE - SUCRAID</u>						
N 020772	001	9469847	Feb 07, 2034	DS DP		
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145	001				>A> NCE	Mar 21, 2022
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145	002				>A> NCE	Mar 21, 2022
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	001				>A> M-198	Feb 27, 2020



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	002				>A> M-198	Feb 27, 2020
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995	001	7459428	Feb 02, 2019	U-1945		
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995	002	7459428	Feb 02, 2019	U-1945		
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995	003	7459428	Feb 02, 2019	U-1945		
<u>SODIUM OXYBATE - XYREM</u>						
N 021196	001	9539330	Dec 22, 2019	DP		
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671	001	9549941	Mar 26, 2029	U-1958		
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109	001	9561251	Jan 23, 2030	DP U-1468		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	9539234	Jan 25, 2033	U-1934		
		9549913	Jan 25, 2033	U-1486		
<u>TAVABOROLE - KERYDIN</u>						
N 204427	001	9549938	Feb 16, 2026	U-1951		
		9566289	Feb 16, 2026	DP		
		9566290	Feb 16, 2026	U-1970		
	>A>	9572823	Feb 16, 2026	U-1970		
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441	001	9539310	Nov 01, 2025	U-1320		
		9545434	Nov 01, 2025	U-1320		
		9545435	Nov 01, 2025	U-1320		
		9555079	Nov 01, 2025	U-1320		
		9572867	Nov 01, 2025	U-1320		
	>A>	9592273	Nov 01, 2025	U-1320		
	>A>	9592274	Nov 01, 2025	U-1320		
<u>TELOTRIPTAT ETIPRATE - XERMELO</u>						
N 208794	001	>A> 7553840	Dec 11, 2027	DS	NCE	Feb 28, 2022
		>A> 7709493	Dec 11, 2027	DS	ODE	Feb 28, 2024
		>A> 7968559	Dec 11, 2027	U-1979		
		>A> 8193204	Feb 27, 2031	DS		
		>A> 8653094	Dec 19, 2028	U-1979		
<u>THIOTEPA - TEPADINA</u>						
N 208264	001				ODE	Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264	002				ODE	Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433	001	6525060	Dec 02, 2019	DS DP U-1171	Y	
		6525060	Dec 02, 2019	DS DP U-1860	Y	
		6525060	Dec 02, 2019	DS DP U-1862	Y	
		6525060	Dec 02, 2019	DS DP U-1863	Y	
		RE46276	Dec 02, 2019	DS DP U-1935		
		RE46276	Dec 02, 2019	DS DP U-1936		
		RE46276	Dec 02, 2019	DS DP U-1937		
		RE46276	Dec 02, 2019	DS DP U-1938		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Dec 02, 2019	DS DP U-1935			
	RE46276	Dec 02, 2019	DS DP U-1936			
	RE46276	Dec 02, 2019	DS DP U-1937			
	RE46276	Dec 02, 2019	DS DP U-1938			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Dec 02, 2019	DS DP U-1935			
	RE46276	Dec 02, 2019	DS DP U-1936			
	RE46276	Dec 02, 2019	DS DP U-1937			
	RE46276	Dec 02, 2019	DS DP U-1938			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS DP U-566			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	5964416*PED	Apr 04, 2017			PED	Aug 15, 2020
	6149054	Dec 16, 2016	DP			
	6149054*PED	Jun 16, 2017				
	6176442*PED	Dec 01, 2016				
	6453795	Dec 05, 2016	DP			
	6453795*PED	Jun 05, 2017				
	6726124	Oct 04, 2016	DP			
	6726124*PED	Apr 04, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7104470*PED	Apr 04, 2017				
	7246615*PED	Dec 01, 2016				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	RE39820	Jan 30, 2018	DS DP	U-1593		
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	6149054	Dec 16, 2016	DP		NPP	Feb 15, 2020
	6846413	Aug 28, 2018	DP		PED	Aug 15, 2020
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Dec 16, 2029	DP			
	8733341*PED	Jun 16, 2030				
	RE39820	Jan 30, 2018	DS DP			
	RE39820*PED	Jul 30, 2018				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026		U-1751		
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026		U-1751		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	9549940	Nov 16, 2027	DP	U-1675		
	9555004	Nov 16, 2027	DP	U-1675		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	9549940	Nov 16, 2027	DP	U-1675		
	9555004	Nov 16, 2027	DP	U-1675		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	9549940	Nov 16, 2027	DP	U-1675		
	9555004	Nov 16, 2027	DP	U-1675		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	9549940	Nov 16, 2027	DP	U-1675		
	9555004	Nov 16, 2027	DP	U-1675		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9555005	Mar 19, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9555005	Mar 19, 2033	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005 >A>	9604901	Dec 15, 2028	DS			

## Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)